| Code | Reagent Title | Description |
|---|
| 0001 | H9 | Cloned cell line derived from HUT78 cell line; Widely used for the propagation of HIV. |
| 0002 | HUT78 | Human cutaneous T-cell lymphoma. Secretes IL-2 and migration inhibition factor. |
| 0005 | CEM-CCRF (CAMR) | Human T-lymphoblastoid cell line. |
| 0006 | CEM4 | High level of cell surface CD4 expression. Closely related to CEM-CCRF by fingerprint analysis. CEM derived clone |
| 0010 | Molt 3 | From the peripheral blood of a 19 year old male with acute lymphoblastic leukeamia. |
| 0011 | Molt 4 | From the peripheral blood of a 19 year old male with acute lymphoblastic leukeamia. |
| 0012 | U937 | Suitable for the growth of macrophage-tropic strains of HIV (CD14+, CD15+) |
| 0013 | C8166 | Human T-lymphoblastoid cell. Reported to carry but not express HTLV-1; expresses tat sequence. |
| 0014 | MT2 | Human T-cell transformed by co-cultivating with leukaemia lymphocytes harbouring HTLV-1. Sheds HTLV-1 in culture |
| 0016 | MT4(P) | May shed HTLV-1 in culture. Stable sub-population of MT4 suitable for plaque assays |
| 0017 | MT4(S) | Human T-cell transformed co-cultivating with leukaemia lymphocytes harbouring HTLV-1. May shed HTLV-1 in culture. Sub population of MT4 that are suitable for the induction of syncytia |
| 0018 | C91-PL | Human cord-blood T-cells infected with co-cultivation with HTLV-positive T-cell lines. Sheds HTLV-1 in culture |
| 0019 | HeLa T4+ | Transfected with CD4 cDNA. Supports infection with HIV and induction of syncytia. |
| 0020 | HeLa T8+ | Transfected with CD8 cDNA. Does not support infection by HIV |
| 0021 | HeLa CD4 (HT4-C6) | HeLa cells infected with a retrovirus vector expressing CD4. Support infection by HIV and induction of syncytia. Cells contain amphotropic MuLV and when co-infected with HIV may give rise to pseudotype virus particle formation. |
| 0024 | Sup-T1 | Cells are TdT positive, CALLA negative and DR negative. They express pan T antigens, high levels of surface CD4 and lack sheep erythrocyte receptors. Morphology - Native lymphocyte. |
| 0025 | Jurkat tat III | Jurkat cell line expressing the HIV-1 tat protein. Useful for growth of poorly replicating strains of HIV. Related to JM cells by DNA fingerprint analysis. |
| 0026 | LC5 | HIV susceptible clone of Human embryonic lung fibroblasts. Used for neutralisation assays and for screening anti-viral compounds. |
| 0027 | Jurkat Clone E6-1 | Clone of jurkat-FHCRC producing large amounts of IL-2 after stimulation. Cells may be induced to secrete gamma interferon and are CD4+. Related to JM cells (008) by DNA fingerprint analysis. |
| 0028 | U138MG | Human glioblastoma cell line. Adherent cells growing as a monolayer with polygonal morphology |
| 0029 | U373MG | Human glioblastoma/astrocytoma cell line. Epithelial-like cells growing as a monolayer. |
| 0030 | HL60 | Human myeloid leukaemia cell line. From macrophage lineage (CD15+) |
| 0031 | THP1 | Human acute monocytic leukaemia cell line. From macrophage lineage (CD14+, CD15+) |
| 0032 | Kas 45 T-cell line | Human T-cell leukaemia cell line. Susceptible to infection with HIV-1/2 and can be used for the detection of antibodies to HIV. |
| 0033 | M8166 | Human T-lymphoblastoid cell. Cloned from C8166 by K Mulder for increased susceptibility to SIV syncytium formation. |
| 0034 | HeLa-T4 pBK-LTRLac | Transfected with LTR-LacZ. Supports infection by HIV with production of blue foci. |
| 0035 | HeLa env C | Produces HIV-1 env, tat and presumably also rev gene products. |
| 0036 | HL2/3 | Human Epithelial cells. Stably integrated copies of HXB2/3gpt. High level production of gag, env, tat, rev and nef but no RT or infectious virus produced. |
| 0037 | HLCD4-CAT | HeLa Epithelial-like cells.. Contains integrated copies of HIV-1 LTR promotor linked to CAT gene (HeLa T4+) |
| 0039 | U38 | U937 Monocyte-like cells. Contains integrated copies of HIV-1 LTR promotor linked to CAT gene. |
| 0040 | H938 | H9 Lymphocyte-like cells. Contains integrated copies of HIV-1 LTR promotor linked to CAT gene (H938). When infected by HIV-1, H938 produces high levels of CAT. |
| 0041 | MV-1-lu | Original CD4-negative mink lung cell line. (CCL64) |
| 0042 | MV-1-lu/CD4 | Infected with an amphotropic retrovirus encoding the cDNA of the CD4 message downstream from the MoMLV LTR promoter as well as a neomycin resistance-selectable marker. Cells bind gp120 but are resistant to infection with HIV. |
| 0043 | U87.MG | Original CD4-negative human glioma cells |
| 0044 | U87.MG/CD4 | Human glioma cells expressing human CD4, infected with an amphotropic retrovirus encoding the cDNA of the CD4 message. Cells bind gp120, are resistant to infection by HIV-1 but sensitive to infection by HIV-2 and SIV. |
| 0045 | TE671/RD | Human rhabdomyosarcoma cell line. Original CD4-negative cell line |
| 0046 | TE671/RD/CD4 | Rhabdomyosarcoma cells were infected with an amphotropic retrovirus encoding the cDNA of the CD4 message downstream from the MoMLV LTR promoter as well as a neomycin resistance-selectable marker. Cells bind gp120 and are sensitive to infection with HIV-1 |
| 0047 | HeLa CD4 + Clone 1022 | HeLa cells were infected with a retroviral vector expressing CD4 and Neo resistance. Clone 1022 cells ezpress human CD4 protein on the cell surface and can be infected by most isolates of HIV. |
| 0048 | CEM SS | Human T4-lymphoblastoid cell line. These cells have been cloned for both poly-L-lysine induced adherence to microtitre plates and viral-induced syncytial fusigenic sensitivity following infection with either cell-free or cell-associated HIV-1 and HIV-2. |
| 0049 | 174 x CEM | Fusion product of human B cell line 721.174 and human T cell line CEM. Found to be particularly useful for studies with SIV as it can be easily infected. |
| 0050 | CEM-A | Fusion product of CEM-A and normal PBMC. Highly susceptible to HIV infection, 69% CD4+, 18% CD3+ and 1% CD20+ |
| 0052 | Molt4 Clone8 | High susceptibility to HIV-1 infection. Can be used to isolate and produce SIVagm |
| 0053 | HL tat | Contains stably integrated copies of the HIV-1 LTR promoter linked tp a synthetic one-exon tat gene. This cell line was generated by co-transfection of HeLa cells with pSV2neo and with pL3tat, which contains the HIV-1 LTR promoter, synthetic first tat exo |
| 0054 | AA-2 | Lymphoblastoid-like. AK- dCK- subclone of AA cells. Highly permissive to HIV-1 infection, useful for producing high titre virus stocks. |
| 0055 | HeLa/CD4-LTR-Beta-gal | Express high levels of CD4 and contain one integrated copy of the HIV-1 LTR linked to the B-galactosidase gene. |
| 0056 | 1A2 | Secretes HIV-1 rev and tat proteins. Suited to viability endpoint assays for determining anti-HIV activity with the replication defective HIV-1 strain HIV-1 MC99Dtat-rev |
| 0057 | PM1 | Permissive for growth of macrophage and t-tropic viruses |
| 0058 | FC36 cl.22 | Adherent cells. Secretes HIV suppressive factors RANTES, MIP-1 alpha and beta after IL-2 stimulation. |
| 0059 | HSC-F | H. Saimiri immortalised T-cell line from foetal Cynomolgus monkey. Consists of CD4+ and CD4+/CD8+ double positive cells |
| 0063 | HSR-1 | Consists of CD4+ single positive and CD4+CD8+ double positive sub-populations. These cells can be productively infected with both SIVmac and SIVagm. |
| 0064 | HOS.CD4 | Adherent cells. CD4 control cell, low level expression of CXCR4. |
| 0065 | HOS.CD4 (Chemokine Receptor Transfectants) | Adherant cells expressing chemokine receptors on the cell surface. |
| 0066 | HOS.CD4-pBABE-puro | HOS-CD4 cells stably transformed with pBABE-puro. Can be used as a negative control for other p-BABE-puro derived HOS CD4 cell lines. |
| 0067 | A3.01/CCR5-A5 | Clones of A3.01(A5) , expressing CCR5. Resistant to 2mg/ml G418 and is infectable by different NSI viruses. Also fuses in the presence of different NSI envelope |
| 0068 | A3.01/CCR5-F7 | Clones of A3.01 (F7) expressing CCR5.Resistant to 2mg/ml G418 and is infectable by different NSI viruses. Also fuses in the presence of different NSI envelope |
| 0069 | U87/CD4 or CCR1 | Adherent cells expressing human CD4 (0069c) or CCR1 (0069) on cell surface. |
| 0070 | U87.CD4/CCR2b | Adherent cells expressing CCR2b on cell surface |
| 0071 | U87.CD4.CCR3 | Adherent cells expressing CCR3 on cell surface |
| 0072 | U87.CD4.CCR5 | Adherent cells expressing CCR5 on cell surface |
| 0073 | U87.CD4.CXCR4 | Adherent cells expressing CXCR4 on cell surface |
| 0074 | GHOST cell CCR1 | Express CCR1 , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0075 | GHOST cell CCR2 | Express CCR2 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0076 | GHOST cell CCR3 | Express CCR3 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0077 | GHOST cell CCR4 | Express CCR4 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0078 | GHOST cell CCR5 | Express CCR5 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0079 | GHOST cell CXCR4 | Express CXCR4 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0080 | GHOST cell BOB/GPR15 | Express chemokines on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0081 | GHOST cell BONZO/STRL33 | Express chemokines on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0082 | GHOST Parental cells | Parental CD4 + cell line |
| 0083 | GHOST cell CCR8 | Express CCR8 , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0084 | GHOST cell X4/R5 | Express CXCR4 and CCR5 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0085 | GHOST cell R3/X4/R5 | Express CCR3, CXCR4 and CCR5 on surface , also contain an HIV-2 ltr linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0086 | GHOST cell Hi5 | Express high levels of CCR5 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0087 | GHOST cell V28 CXCR1 | Express CX3CR1 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection. |
| 0088 | Hos.CD4.CXCR4 | Human CD4 cell expressing Simian CXCR4. HOS.CD4 cells have been stably transfected with pTARGET and cynomolgus macaque CXCR4. Co-receptor selected with G418. |
| 0089 | Hos.CD4.CCR5 | Human CD4 cell expressing Simian CCR5. HOS.CD4 cells have been stably transfected with pTARGET and cynomolgus macaque CCR5. Co-receptor selected with G418. |
| 0090 | A2.01 | Clonally selected natural CD4 negative mutant and resistant to HIV infection. May serve as a CD4 negative control. |
| 0091 | A2.01-CCR5 | Clonally selected natural CD4 negative mutant, transfected to stably express CCR5. May be used in conjunction with 090 and 067/068 |
| 0092 | HPBALL.CD4-CCR5 | CD4+ T cell line with endogenous CXCR4 and stably transfected to express human CCR5. Susceptible to infection by R5, X4 & R5X4 using HIV-1 isolates. |
| 0094 | Jurkat-CD4.CCR5 | CD4+ T cell line with endogenous CXCR4 and stably transfected to express human CCR5. Susceptible to infection by R5, X4 & R5X4 using HIV-1 isolates. |
| 0097 | RAW N5 & N7 | Raw - N5 (0097.1) and - N7 (0097.2) Transfection with pSC NEF 51. Transfected to express low levels of NEF that are inducible by exposure of cells to cadmium chloride. |
| 0098 | A3.01 | HAT sensitive derivative of CEM, a human T-cell line derived from the peripheral blood buffy coat of a four -year old Caucasian female with acute lymphoblastic leaukemia. Morphology is mature lymphocytic. |
| 0099 | CEM-NKR-CCR5 | CEM-NKR cells were transduced with a retroviral vector to express
human CCR5. Cells do not secrete infectious virus. Suitable for infection with primary HIV isolates and for neutralization assays. |
| 0101 | IIIB | Original isolate of HIV-1 from Dr Robert Gallo's lab. Grows to high titre. |
| 0102 | MN | Early isolate of HIV-1 from Dr Robet Gallo's lab |
| 0103 | RF | Early isolate of HIV-1 from Dr Gallo laboratory |
| 0104 | LAI (BRU) | First strain of HIV-1 to be isolated in 1983 |
| 0109 | CBL-4 | Tanzania, 1985, African isolate of HIV-1 originally called RUT. |
| 0110 | 8E5/LAV | Subclone of A3.01, a CD4+ CEM derived human T-cell line. Each cell contains a single integrated copy of LAV proviral DNA directing synthesis of defective virus particles. |
| 0111 | u455 | Rapid virus production leading to syncytia and high levels
of RT activity. Genome is divergent from other HIV-1
isolates including those from neighbouring Zaire. |
| 0112 | SF2 | Early isolate from San Francico, easily neutralised |
| 0113 | SF162 | Macrophage tropic strain |
| 0114 | SF2 mc | Molecular clone of SF2 |
| 0115 | A012B/D (AZT Resistant) | Pair of sequential virus isolates from a patient with ARC/AIDS taken at 2 and 26 months after commencing AZT chemotherapy. Peripheral blood lymphocytes from the patient were co-cultivated with MT2 cells and drug sensitivity was examined using HeLa CD4+ ce |
| 0116 | A018A/C (AZT Resistant) | Pair of sequential virus isolates from a patient with ARC/AIDS taken at 0 (A018A) and 14 (A018C) months after commencing AZT chemotherapy. Peripheral blood lymphocytes from the patient were co-cultivated with MT2 cells and drug sensitivity was examined us |
| 0117 | HIV-1 ELI | Early African isolate, Zaire 1983. |
| 0118 | Ba-L | Macrophage-monocyte-tropic strain, orginally identified as HTLVIII Ba-L in 1986. |
| 0119 | Ada-M | Macrophage-monocyte-tropic strain. Drived from seropositive AIDS patient in 1986 |
| 0120 | C-HIV-1 | Original cambridege isolate isolated in 1984. Lacks Xhol, BamH1 and EcoR1 restriction sites. |
| 0121 | HIV-2 ROD | ROD was one of the first reported isolates of HIV-2 |
| 0122 | HIV-2 CBL-20 | Rapid growing, produces syncytia in primary culture.
Isolated from a patient with AIDS.
Grows rapidly in culture producing high levels of RT.
Produces syncytia in primary culture. |
| 0123 | HIV-2 CBL-21 | Rapid growing, produces syncytia in primary culture.
Isolated from a patient with AIDS.
Grows rapidly in culture producing high levels of RT.
Produces syncytia in primary culture. |
| 0124 | HIV-2 CBL-22 | Isolated from a patient with ARC. Sensitive to neutralisation by antibodiesin HIV-2 positive sera and some cross reactivity with HIV-1 positive sera.. Slow growing , produces syncytia. |
| 0125 | HIV-2 CBL-23 | Isolated from a patient without symptoms of HIV-related disease. Grows slowly and produces syncytia in primary cultures. |
| 0126 | HIV-2 CAM2 | Full length lambda clone of HIV-2CAM2 is available (0225) as are a number of plasmid sub-clones (0212-0218) |
| 0127 | HIV-2 MIR | One of the first reported isolates of HIV-2 |
| 0128 | EHC91 | Virus isolate from the Edinburgh heamophiliac cohort. |
| 0129 | EHC98 | Isolate from the edinburgh heamophiliac cohort. |
| 0131 | GB8 | Four sequential isolates. Produce distict syncytial morphologies in JM cells. Supplid as infected JM cells |
| 0132 | HIV-2 EHO | Diverse strain of HIV-2 markedly different from HIV-2 ROD. |
| 0135 | Z129 | Isolate from Zaire. |
| 0136 | HIV-1 MAL | Isolated from a 7 year old boy with ARC from Zaire. |
| 0137 | 105A-F (AZT Resistant) | Series of 6 sequential isolates from a patient in Amsterdam. First isolate taken before commencement on AZT, then at 24, 60, 86, 115 and 136 weeks of therapy. Patient progressed to AIDS at week 80. |
| 0138 | ACH-2 | Subclone of A3.01 producing low levels of RT and p24. Can be induced with phorbol myristate acetate or TNF-a to secrete high levels of HIV-1. |
| 0139 | U1/HIV-1 | Sub-clone of the U937 chronically infected with HIV-1 with minimal constitutive expression of virus. U937 is a promonocyte obtained from a pleural effusion of a two year old Caucasian male with diffuse histiocytic lymphoma. Large semi-granular cells. |
| 0140 | OM-10.1 | Cloned from HL60 infected with HIV-1. Each cell contains single integrated provirus. Expression can be induced. OM-10.1 cells show minimum, constitutive HIV-1 production and remain CD4+ under normal conditions. |
| 0141 | RTMC (AZT Resistant) | In HeLa CD4+ cell assay, this virus has an IC50 value for AZT around 100 fold that of the wild type parental virus, HXB2. |
| 0142 | RTMF (AZT Resistant) | In HeLa CD4+ cell assay, this virus has an IC50 value for AZT around 15-20-fold that of the wild type parental virus, HXB2. |
| 0143 | RTMN (AZT Resistant) | In HeLa CD4+ cell assay this virus has an IC50 value for AZT around 60-70 fold that of the wild type parental virus HXB2. |
| 0144 | 74V (DDI Resistant) | In HeLa CD4+ cell assay this virus has an IC50 value for ddI and ddC around 6-10 fold that of the wild type parental virus HXB2. Derived by co-transfection of MT-2 cells with M13 RT clone containing 74V plus RT deleted proviral clone pHIVdRTBstEII |
| 0145 | 184V (3TC/FTC Resistant) | In HeLa CD4+ cell assay this virus has an IC50 value for 3TC and FTC around 1000 fold that of the wild type parental virus HXB2. Derived by co-transfection of MT-2 cells with M13 RT clone containing 184V plus RT deleted proviral clone pHIVdRTBstEII |
| 0146 | RTMDR1 (Triple Drug Resistant) | In HeLa CD4+ cell assay this virus displays co-resistance to AZT, ddI and nevirapine. Derived by co-transfection of MT-2 cells with M13 RT clone containing 4IL, 74V, 106A, 215Y plus RT deleted proviral clone pHIVdRTBstEII |
| 0147 | JR-CSF | Infects human brain primary glioma explant cells, producing persistant low levels of virus. The virus is non-cytopathic. |
| 0148 | JR-FL | This virus was isolated from the same patient as JR-CSF ( 0147), but has been found to be phenotypically distinct.Will not replicate in Jurkat , HUT78 or U937. Weekly cytopathic in PBL |
| 0149 | Primary isolates South Africa | Clade C, NSI isolate SA/93/454 and Clade B, SI isolate SA/93/506. |
| 0151 | SIVmac251 (32H Isolate) | Isolated from rhesus macaque given SIVmac251. |
| 0156 | FIV E77 | Capable of inducing clinical signs of typical acute syndrome in 12 week old kittens, FeSFV has not been isolated from this stock. |
| 0157 | Purified SIVmac251 (32H isolate) | SIVmac251 grown on C8166 cells for 3 days. Virus recovered by ultracentrifugation and purified.. Virus was 8-9 passages on from the 11/88 challenge stock. Reacts with Mab's to p26 (KK33) and gp120 (KK8) in western blot. |
| 0158 | Euro HIV-1 Field isolate - Han2 | Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones. |
| 0159 | Euro HIV-1 Field isolate - 4830 | Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones. |
| 0160 | Euro HIV-1 Field isolate - ACH168 (Q17BC) | Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones. |
| 0161 | Euro HIV-1 Field isolate - Ach320 (W6BC) | Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones. |
| 0163 | Euro HIV-1 Field isolate - 4803cll2mc | Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones. |
| 0165 | Euro HIV-1 Field isolate - ACH320.3.1.mc | Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones. |
| 0166 | SAQr (Saquinvir Resistant) | HIV-1 GB8 sequentially passaged in the presence of Saquinvir produced this double mutant which has reduced sensitivity to the , Saquinvir (Roche proteinase inhibitor, Ro 31-8959) in vitro. |
| 0167 | MVP-5180 (Subtype O) | A prototype HIV-1 subtype O virus, induces syncytia. Supplied as cell free supernatant from H9's or infected H9 cells. |
| 0168 | Ca-9 (Subtype O) | Replicates in human PBMCs and CEMSS, but not in MT2, MOLT, U937,THP or Jurkat. NSI phenotype. |
| 0169 | HIV-1 primary isolates (env Subtypes A-F) | Isolates of env subtypes A-F from HIV-1 seropositive, asymptomatic individuals in Brazil, Rwanda, Thailand and Uganda. Both SI and NSI viruses are provided. Genetic clones of the env regions are available for some of these viruses. |
| 0170 | MC99IIIBTat-Rev | was generated by transfection of the proviral plasmid IIIB, an HXB-3 derivative. Oligonucleotidedirected mutagenesis with the bacteriophage M13 system (Amersham) was used to introduce five point mutations into the coding regions of tat and rev. Alows stud |
| 0171 | xxHIV-1LAI/ xxHIV-1 LAI M184V (3TC Resistant) | 3TC-sensitive virus. Produced by electroporation of MT-2 cells with pxxHIV-1Lai proviral DNA. The virus was expanded once in MT-2 cells, harvested , aliquoted, and stored at -80°C. |
| 0173 | RU570 (Subtype G) | env subtype G, slow growimg |
| 0174 | R132 (Subtype G) | env subtype G, slow growing |
| 0175 | VI557 (Subtype H) | env subtype H |
| 0176 | VI525 (Subtype G/H) | subtype G (env)/subtype H (gag) |
| 0177 | HIV-1 primary isolates Uganda | Isolated from seropositive individuals from Uganda. For known Genotype and Phenotype see datasheet . |
| 0178 | HIV-1 Primary isolates Rwanda | Isolated from seropositive individuals from Rwanda. For known Genotype and Phenotype see datasheet . |
| 0179 | HIV-1 Primary isolates Brazil | Isolated from seropositive individuals from Brazil. For known Genotype and Phenotype see datasheet |
| 0180 | HIV-1 primary isolates Thailand | Isolated from seropositive individuals from Thialand. For known Genotype and Phenotype see datasheet. |
| 0182 | SHIV W61D | Constructed by the replacement of gp120-Δgp41 region of SHIV-4 with the equivalent region of the HIV-1 clone ACH320.3.1. Infectious virus recovered by transfection into CEMx174 cells. |
| 0183 | SHIV HAN2 | Constructed by the replacement of gp120-Δgp41 region of SHIV-4 with the equivalent region of the HIV-1 clone HAN2. Infectious virus recovered by transfection into human PBMC's |
| 0187 | SHIV-33 (CL18) | DNA fragment encoding tat,rev,env (gp160) and vpu of HIV-1sf33 inserted into SIVmac239 to produce chimaeric recombinant SHIVsf33 |
| 0188 | SHIV-162 (CL28) | DNA fragment encoding tat,rev,env (gp160) and vpu of HIV-1sf162 inserted into SIVmac239 to produce chimaeric recombinant SHIVsf162. |
| 0189 | 89.6 | Replicates to high titres in primary human lymphocytes, macrophages, CEMx174 and MT4 cells; syncytium forming and extremely cytopathic. Uses chemokine co-receptors CCR1, CCR2, CCR3, CXCR4 & CCR5. |
| 0190 | YBF30 (Subtype N) | Representative group N isolate. Shows genetic divergence, which suggests strain lies equidistant between HIV-1 group M and SIVcpz-gab. NSI, CCR5 using. |
| 0191 | BCF01 (Subtype O) | Representative group O isolate. NSI, CCR5 using. |
| 0192 | BCF02 (Subtype O) | Representative group O isolate. NSI, CCR5 using |
| 0193 | BCF06 (Subtype O) | Representative group O isolate. SI, CXCR4, MT2 using. |
| 0194 | BCF07 (Subtype O) | Representative group O isolate. NSI, CCR5 using |
| 0195 | BCF011 (Subtype O) | Representative group O isolate. NSI, CCR5 using. |
| 0196 | Nucleoside RT Inhibitor Resistant Virus | Sequential NNRTI & NRTI resistant isolates taken from a single patient. |
| 0197 | SE12808 & SE14784 | Sub-type C isolates, SI, MT2 positive. Will infect U87.CD4-CXCR4. |
| 0198 | B117 | Replicates on U87.CD4 cells expressing CCR1, CCR2b, CCR3, CXCR4 & CCR5. |
| 0201 | pNIBSC (SIV p26) | pNIBSCI is dsM13mp18 containing a 744 base pair insert composed of the last 60 bases of p17 and the full length p27 gene from SIVmac251 (32H isolate). |
| 0202 | pLAI2 | Full length insert of HIV-1 LAI. Produces infectious virus in PBL's, CD4+ t-cell lines and U937's |
| 0204 | pBK28-SIV | Full length SIV infectious clone. Derived from SIVmac251 |
| 0205 | pBH10 | 9Kb insert of BH-10 (III B), with 150bp deletion in both LTR's, subcloned into Sst1 site of SP64 |
| 0206 | pHXB2D | 12.5 Kb Xba I fragment of lambda HXB2 (HIV-1 IIIB). Complete provirus with flanking cellular sequences. Infectious when transfected into approprate cell line. |
| 0207 | pNIBSC2 (SIV gp32) | Contains the full length gp32 env transmembrane protein from SIVmac251 (32H isolate). Fully sequenced. |
| 0210 | pGB8.C4 | Full length insert of env gp160 from GB8.C4 |
| 0211 | pGB8B.C9 | Full length insert of env gp160 from GB8B.C9 |
| 0219 | pNIBSC8 (SIV gp120) | pNIBSC8 is dsM13 mp18 bacteriophage containing the entire env gene of SIVmac251 (32H isolate). The genomic DNA was extracted from C8166 cells infected with SIVmac251 (32H) and digested with Sal1. Primers were used to insert RE sites SalI and EcoRV at the |
| 0220 | pNIBSC7 (SIV gag) | pNIBSC7 is dsM13 mp19 containing the entire gag gene of SIVmac251 (32H isolate). The genomic DNA was extracted from C8166 cells infected with SIVmac251 (32H) and digested with EcoR1. Primers were used to insert RE sites EcoR1 and Sma1 at the 5’ end and Hi |
| 0221 | pKA 27 (replaces pOGS247) | pNIBSC1 was subcloned into pUC19 inframe with lacZ gene. Permits IPTG inducilble expression of SIV p27 (plus 20aa of p17) in a suitable E.coli host. |
| 0222 | pNIBSC9 (SIV rev) | Contains a 343 bp insert of full length rev gene of SIVmac251 (32H isolate). |
| 0223 | pNIBSC4 (SIV pol) | Spans the 3' end of gag and 5' end of pol including the entire proteinase gene. |
| 0229 | pJ5 del T-KS- (SIVmac32H) | Full length infectious clone. Xhol sites at both ends of provirus. These clones are derivatives from the original SIVmac32H (pJ5) and SIVmac32H (pC8) clones. BamH1 to Xhol sites removed, BamH1, EcoR1, Xhol linker added. Sac1 site eliminated after cloni |
| 0230 | pC8 Del T-KS (SIVmac32H) | Full length infectious clone with a 4 aa deletion in nef. xhoI sites at both ends of the virus. Derived from original C8 clones. |
| 0231 | pHIVdRTBstE11 | Complete provirus except for a 1.4 Kb deletion at the RT region and the introduction of a BstEII restriction enzyme site at the deletion junction. |
| 0232 | pROD 10 | Complete proviral sequence of HIV-2 ROD constructed from λROD27,
λROD35 and pSPE2. Flanked by 200bp of cellular DNA at the 5’ end and 10bp at the 3’ end. Insert 10.5Kb; Vector 2Kb.Ampicillin Resistance Marker.
232.1 has SV40 ori inserted to assist trans |
| 0233 | pLTR/CAT | Contains 5' LTR from HIV-1, Sub-clone of pNL4 |
| 0235 | pC63.4.1 (tat) | Retroviral vector for the expression of tat in mammalian cells |
| 0237 | ACH320 molecular clones | 4 full length infectious clones with distinct biological phenotypes derived from a single individual infected with HIV. |
| 0238 | HIV-gpt | Contains intact HIV-1HXB2 rev and tat genes. Deletion of sequences encoding gp160 has rendered HIV-gpt replication -defective. The pvuII-Dra1 SV2gpt fragment contains the SV40 origin of replication and coding sequences for the gpt gene. |
| 0239 | HIV-1 160 and 120 clones | Envelope genes (gp160 and gp120) were PCR amplified from PBMC grown HIV-1 obtained from asymptomatic individuals within 2 years of sero-conversion. Amplification products were cloned by T/A overhang. These clones represent HIV-1 sequence subtypes A-E. |
| 0240 | CHO-pEE6HCMVgp120 GS | Secretes rec HIV-1 IIIB gp120 into culture medium. |
| 0242 | CHO ST4.2 | Secreates soluble CD4 (mycoplasma positve) |
| 0243 | CHO-6.2 (SIV gp120) | Transfected with pSIV1 (SIV gp120) derived fron pNIBSC8 supplied by Dr N Almond. Secretes SIVmac251 (32H) rgp120 |
| 0244 | CHO-P5 (SIV sgp160 cleavable) | CHO cells transfected with pSIV3 (SIV gp160 with primary and secondary cleavage sites retained). Secretes SIVmac251 (32H) soluble gp160 |
| 0245 | CHO -M5 (SIV sgp160 uncleavable) | CHO cells transfected with pSIV3 (SIV gp160 with primary and secondary cleavage sites abolished). Secretes SIVmac251 (32H) soluble gp160 (uncleavable) |
| 0246 | CHO-4.4 (HIV-1 GB8 gp120) | Secretes HIV-1 GB8 gp120 . Contains glutamine synthetase gene as a selectable marker. |
| 0253 | Vaccinia gag-vac | Contains the HIV-1 gag-gene of pHIII 5.5 under the the control of the 7.5K early late promoter. Cells infected with this virus express the p55 gag protein. |
| 0254 | Vaccinia gag p17 vac | Contains the HIV-1 gag p17 fragment of pHIII 5.5 under the control of the 7.5K early late promoter. Cells infected with this virus express the p17 gag protein |
| 0255 | Vaccinia env 2 | Contains the env gene from HIV-1 IIIB. Cells infected with this virus express gp160 |
| 0256 | Vaccinia v120 | Contains the env gp120 from HIV-1 BRU.Cells infected with this virus express gp120 |
| 0257 | Vaccinia v gag 1 | Contains the gag p55 from hIV-1 IIIB. Cells infected with this virus express HIV-1 gag p55 |
| 0258 | Vaccinia v gag 2 | Contains the gag p57 gene from HIV-1 BRU. Cells infected with this virus express HIV-1 gag p57 |
| 0259 | Vaccinia v gag F1 | Contains the gag p40 gene fragment of HIV-1 IIIB. Cells infected with this virus express HIV-1 gag p40 |
| 0260 | Vaccinia vp27 | Infected cells express SIV gag p27 |
| 0261 | Vaccinia vv SIV gag | Contains gag of SIVmac (BK28). The myristylated p57 gag is expressed and targeted to the plasma membrane where budding occurs. |
| 0262 | Vaccinia vv SIV env | Contains env gene of SIVmac (BK28). Gp 160 will be inserted into the plasma membrane. Will form syncytia with CD4+ cells |
| 0263 | Vaccinia vv SIV pol | Express RT and integrase (Fused) protein approx. 90Kd |
| 0264 | HIV-1 env specific Riboprobe | Complementary to highly conserved regions of HIV-1 |
| 0265 | HIV-1 gag-specific Riboprobe | Complementary to highly conserved regions of HIV-1 |
| 0266 | HIV-1 pol-specific Riboprobe | Complementary to highly conserved regions of HIV-1 |
| 0267 | Vaccinia vRF222 | Full length HIV-1 RF env gene expressed under the control of the vaccinia virus 7.5k promoter. Env gp160 is expressed in infected cells and syncitium formation may be observed. |
| 0268 | Vaccinia vMN462 | Full length HIV-1 MN env gene expressed under the control of the 7.5 promoter. Env gp160 is expressed in infected cells , cleavage to gp120 and pg41 does not occur and syncitium formation not observed. |
| 0269 | Vaccinia vv 9001 (SIVmac vpx) | vpx gene from SIVmac32H (pJ5 clone). Expression confirmed by immunoblot. |
| 0270 | Vaccinia vv 9002 (SIVmac env gp160) | env gene from SIVmac32H (pJ5 clone) not PCR derived . Expression confirmed by immunoblot. |
| 0271 | Vaccinia vv 9003 (SIVmac vif) | vif gene from SIVmac32H (pJ5 clone). Expression confirmed by immunoblot. |
| 0272 | Vaccinia vv 9001 (SIVmac vpr) | vpr gene from SIVmac32H (pJ5 clone). Expression confirmed by immunoblot. |
| 0273 | Vaccinia vv 9001 (SIVmac rev) | rev gene from SIVmac32H (pJ5 clone). |
| 0274 | Vaccinia vv9011 (SIVmac nef pJ5) | nef gene from SIVmac32H (pJ5) clone. Expression confirmed by T-cell reactivity of infected mice to nef peptides |
| 0275 | Vaccinia vv9012 (SIVmac nef pC8) | nef gene from SIVmac32H (pC8) clone. Expression confirmed by T-cell reactivity of infected mice to nef peptides |
| 0276 | Vaccinia vv9013 (SIVmac RT) | RT PCR amplified from SIVmac32H (pJ5). Added EEF motif for purification. RT activity, Immunoblot reactive, IFA |
| 0277 | Vaccinia vv9015 (SIVmac tat) | tat gene from SIVmac32H (pJ5) clone. tat gene product active on HIV LTR |
| 0278 | Vaccinia vv9019 (SIVmac gag/pol) | gag/pol gene from SIVmac32H (pJ5) clone. Not PCR amplified. Genes active in a HERPES virus construct. |
| 0279 | Baculovirus- HIV-1 nef GST | Baculovirus expressing HIV-1 nef |
| 0280 | Baculovirus-p17-GST | GST with myristoylation sequence of HIV-1 p17 gag at the N-terminus MGARAS-GST. |
| 0281 | Baculovirus- human CD4 | Baculovirus expressing CD4. 281.1 Full length human CD4. 281.2 Human CD4 with deletion of cytoplasmic domain, produces CD4 molecule truncated at aa394. |
| 0282 | GST-SIV-Pk expression vectors | Contain various SIV genes derived from pBK28-SIV. The combination of two tags (GST or HIS and Pk) permits the purification of expressed proteins by a two step procedure or their assembly onto a solid matrix for immunisation. |
| 0283 | His-SIV-Pk Expression vectors | Contain various SIV genes derived from pBK28-SIV. Genes encoding rev and tat were derived from SIVmac 32H (pJ5).The combination of two tags (GST or HIS and Pk) permits the purification of expressed proteins by a two step procedure or their assembly onto a |
| 0284 | HIV HXB2-env | Contains HXB2 env fragment from pHXB2 gpt. HIV-1 gp160 is expressed, though no other viral products. Provides high levels of gp160 in COS cells. |
| 0285 | CHO-SIVmac 239 gp130 Clone 3 | Cells secrete SIVmac 239 gp130. |
| 0288 | Baculovirus- SIV J5 nef GST | Baculovirus expressing SIV J5 nef GST. |
| 0289 | Vaccinia HIV-1 env | Envelope genes ( 239.1,2,3 and 11) pcr amplified by Dr B Hahn from primary isolates. Expression confirmed by immunoblot. |
| 0290 | MVA SIV recombinants | Env, gag-pol, tat, rev, and nef genes from SIVmac J5. Expression confirmed by immunoblot. |
| 0297 | CHO pEE14/tpa/HIV-1 env PR1-16 | Three sets of gp120 or gp160 inserts :-
a) N Terminal truncates
b) Loop deletions starting at aa93. Do not bind sCD4 or IIIB mabs recognising conformation dependant epitopes.
c)As b) but bind sCD4 and confirmation dependant Mabs.
Secreation of env dir |
| 0298 | CHO pEE14/tpa/HIV-2 env ROD | CHO cells stably transfected with pEE14/tpa/HIV-2 ROD. Signal sequence of env replaced by tpa to direct secreation of rgp105 into culture medium |
| 0299 | Vaccinia p55 gag A clade | p55 DNA from a Ugandan patient was PCR amplified and cloned into a modified plasmid (supplied by Dr P Balfe, UCLMS) expression is regulated by the vaccinia virus P7.5 promoter |
| 0301 | HIV-1 gp160/gp120 | Binds to native gp120 weakly. Binds to denatured gp120 (SDS-DTT treated) more strongly.
Mapped to peptide 740.45 at gp120 carboxy terminus. |
| 0302 | CD4 | Suitable for Immunoabsorption and as a diagnostic antibody for suspension and tissue culture work |
| 0304 | HIV-1 gp160/gp41 | Mapped to peptide 740.14 with some overlap with peptide 740.13 |
| 0305 | HIV-1 gp160/gp41 | Specific to HIV-1 gp160/gp41 |
| 0306 | HIV-1 gp160/gp41 | Specific to HIV-1 gp160/gp41 by Immunoblot / ELISA. |
| 0307 | HIV-1 p24 | Mapped to aa 284-289 and aa 351-356 |
| 0308 | HIV-1 p55 | Mapped to aa 357-362 |
| 0309 | HIV-1 p24 | mapped to aa288-295 and aa 351-356. reacts with peptide 788.22 |
| 0310 | CD4 | Blocked by sCD4, inhibits syncitium formation (IIIB) |
| 0311 | CD4 | Weakly inhibits syncitia (IIIB). Mapped to V3 domain |
| 0313 | HIV-1 p55/24 | Reacts with peptides 788 .7,.8,.13. Broadly reactive. Also availble conjugated to a/p or Biotinylated. |
| 0314 | HIV-1 p55/24 | HIV-1 p55/p24 by immunoblot. Mapped to 177-182 (HIV-1 LAI). Reacts with peptide 788.5 |
| 0315 | HIV-1 p55/p18 | HIV-1 p55/p18 by immunoblot. Mapped to 121-134 (HIV-1 SF2) |
| 0316 | HIV-1 p18 | HIV-1 p18 by immunoblot. Mapped to 121-134 (HIV-1 SF2). |
| 0317 | HIV-1 gp41 | Neutralises range of HIV-1 isolates. |
| 0318 | CD4 | Blocked by sCD4; inhibits syncitia (IIIB) formation. Mapped to V1 domain of CD4 |
| 0319 | HIV-1 p55/p24 | Mapped to aa 275-280. reacts with peptide 788.17 |
| 0320 | HIV-1 p55/p24 | Mapped to aa 363-368 |
| 0321 | HIV-1 p24 | Mapped to aa 358-363. reacts with peptide 788.22 |
| 0322 | HIV-1 p24 | Mapped to aa281-286 |
| 0323 | HIV-1 gp160/120 (CRA1) | Recognises the 50K but not the 70K cleavage product of CHO gp120. Binds weakley to native gp120 (IIIB), but strongley to denatured gp120 |
| 0324 | HIV-1 gp120 (CRA3) | Does not immunoblot, binds native not denatured gp120. Neutralises HIV-1 (IIIB) |
| 0325 | HIV-1 gp120 (CRA4) | Does not immunoblot, binds native not denatured gp120. Neutralises HIV-1 (IIIB) |
| 0326 | HIV-1 gp120 (CRA5) | Does not immunoblot. Blocks CD4 binding. Binds native but not denatured gp120. Optimal binding in the presence of non-ionic detergent. |
| 0327 | HIV-1 gp120/gp160 (37.1.1) | Binds native gp120 (IIIB) weakly, but denatured strongly. |
| 0328 | HIV-1 gp160/gp41 (60.1.1) | Binds to denatured but not native gp120 |
| 0329 | HIV-1 gp160/gp120 (136.1) | Binds to denatured but not native gp120 |
| 0330 | HIV-1 gp160/gp120 (140.1.1.1) | Specific to HIV-1 gp160/gp41 by RIPA/Immunoblot/ELISA |
| 0331 | HIV-1 gp160/gp120 (178.1.1.1) | Strongly binds to native gp120 (IIIB), but not to HXB2 gp120 (KRIRI sequence) |
| 0332 | HIV-1 gp160/gp120 (187.2.1) | Moderate binding to native gp120, strong binding to denatured gp120 |
| 0333 | HIV-1 gp160/gp120 (190.1.1) | Specific to HIV-1 gp160/gp120 by RIPA/Immunoblot/ELISA |
| 0334 | HIV-1 gp160/gp120 (213.1) | Weak binding to native gp120, but strong to denatured gp120. |
| 0335 | HIV-1 gp160/gp120 (H339.1.1) | SPECIFICITY: HIV-1 gp160/gp120 by RIPA/ELISA; HOST: BALB/C mouse; IMMUNOGEN: HIV-1 IIIB; MYELOMA: Sp2 |
| 0337 | CD4 | High functional affinity equivalent to a Leu3a. Blocks gp120/CD4 binding and inhibits syncitia formation. Cross competes with 386, 351, 357, a Leu3a, OKT4D or MT151. Similar to OKT4A.
1ml culture supernatant, 100ul ascitic fluid. |
| 0338 | HIV-1 gp120 (CRA2) | Specific to HIV-1 gp120 by IRMA. Does not immunoblot. |
| 0339 | HIV-1 gp120 (CRA6) | Specific to HIV-1 gp120 by IRMA. Does not immunoblot. |
| 0340 | HIV-1 gp120 (CRA7) | Specific to HIV-1 gp120 by IRMA. Does not immunoblot. |
| 0342 | HIV-1 p18 | HIV-1 p18 by immunoblot. Mapped to 121-134 (HIV-1 SF2) |
| 0343 | HIV-1 p18 | HIV-1 p18. Mapped to 121-134 (HIV-1 SF2) |
| 0344 | HIV-1 p55/p18 | HIV-1 p55/p18. Mapped to 101-115 (HIV-1 SF2). |
| 0345 | HIV-1 p55/p24 | HIV-1 p55/p24. Mapped to 253-267 (HIV-1 LAI).. Reacts with peptide 788.13 |
| 0346 | HIV-1 p55/p24 | HIV-1 p55/p24. Mapped to 303-317 (HIV-1 LAI) |
| 0347 | HIV-1 p55/p24 | |
| 0348 | HIV-1 p55/p24 | HIV-1 p55/p24. Mapped to 143-157 (HIV-1 LAI). Reacts with peptide 788.2 |
| 0350 | HIV-1 p55/p24 | HIV-1 p55/p24 by immunoblot (weak reactivity). Mapped to 133-147 (HIV-1 LAI).Reported to react with. Reacts with peptrides 788.1,7 and 14 |
| 0351 | CD4 | Blocks gp120 binding. |
| 0352 | HIV-1 tat | Immunoprecipitates and Immunoblots HIV-1 tat. mAb to N-terminal peptide. |
| 0355 | HIV-1 rev | Reacts with HIV-1 rev in an immunoblot |
| 0356 | CD4 | Does not block syncitium formation or rgp120 binding. Probably binds to V2 domain. |
| 0357 | CD4 | Strongly blocks syncitium formation and blocks gp120 binding. |
| 0359 | CD4 | V4 domain of human CD4. Suitable for use in ELISA's of gp120-CD4 binding. Cross blocks OKT4 and DK4003 (372) |
| 0364 | CD4 | Reacts with sCD4 and inhibits HIV- induced fusion. |
| 0365 | HIV-1 p24 | Mapped to HIV-1 HXB2 aa 253-282 |
| 0366 | HIV-1 p24 | Mapped to HIV-1 HXB2 gag aa273-302 |
| 0367 | HIV-1 p24 | Mapped to HIV-1 HXB2 gag aa 273-302 |
| 0368 | HIV-1 p24 | Mapped to HIV-1 HXB2 gag aa 308-322. Reacts with peptides 788.18 and 19 |
| 0369 | HIV-1 p24 | Mapped to HIV-1 HXB2 gag aa308-322 |
| 0370 | HIV-1 p24 | Mapped to HIV-1 HXB2 gag aa 331-354. Reacts with peptide 788.21 |
| 0372 | CD4 | Fails to inhibit gp120 binding and HIV- induced fusion. Cross-blocks L120 and MT429. Binds strongly to sCD4 |
| 0373 | SIV env gp120 (KK8) | SIV env gp160/gp120. Maps to V1/V2 region.. Suitable for ELISA, immunoblotting , RIPA and IF |
| 0380 | HIV-1 RT | Reacts with p66/p51 in Immunoblots, confirmational epitope. |
| 0381 | HIV-1 RT | Reacts with p66/p51 in immunoblots and inhibits the reaction of RT enzyme in a Biological assay. Confirmational epitope possibly reacting with central region of RT aa231-430 |
| 0384 | HIV-1 RT | Reacts with p66/p51 in immunoblot. Mapped to C-terminus (aa 431-531) |
| 0385 | HIV-1 nef | Recognises aa 179-195 of HIV-1 IIIB nef. Suitable for ELISA/immunoblotting |
| 0386 | HIV-1 nef | Recognises aa 179-195 of HIV-1 IIIB nef. Suitable for ELISA/immunoblotting |
| 0387 | HIV-1 nef | Recognises aa 179-195 of HIV-1 IIIB nef. Suitable for ELISA/immunoblotting |
| 0388 | HIV-1 gp120 (ICR 38.1a) | Blocks CD4 binding. Neutralises HIV-1 IIIB/RF/MN/ at high concentrations. Suitable for ELISA |
| 0389 | HIV-1 gp120 (ICR 38.8f) | Blocks CD4 binding. Neutralises HIV-1 IIIB/RF/MN/ at high concentrations. Suitable for ELISA |
| 0390 | HIV-1 gp120 (ICR 39.13g) | Blocks CD4 binding. Neutralises HIV-1 IIIB/RF/MN/ at high concentrations. Suitable for ELISA |
| 0391 | HIV-1 gp120 (ICR 39.3b) | Blocks CD4 binding. Neutralises HIV-1 IIIB/RF/MN/ at high concentrations. Suitable for ELISA |
| 0392 | SIV p27 | Reacts in Immunoblot with SIV lysate |
| 0393 | SIV p27 | Reacts in Immunoblot with SIV lysate |
| 0394 | SIV p27 | Reacts in Immunoblot with SIV lysate |
| 0395 | SIV p27 | Reacts in Immunoblot with SIV lysate |
| 0396 | SIV p27 | Reacts in Immunoblot with SIV lysate |
| 0397 | SIV p27 | Reacts in Immunoblot with SIV lysate |
| 0398 | SIV p27 | Reacts in Immunoblot with SIV lysate |
| 0401 | Antiserum to HIV-1 rgp120 (CHO) | Type specific to HIV-1 IIIB. The antiserum reacts strongly in a Western blot with native viral gp160 and gp120 and with both uncleaved and cleaved CH derived gp120.It has a type specific (HIV-I strain IIIB) virus-neutralisation titre of 1:80. |
| 0403 | Antiserum to HIV-1 rgp120 (CHO) | Does not neutralise HIV-1 strain IIIB |
| 0404 | Antiserum to sCD4 (CHO) | |
| 0405 | Antiserum to sCD4 (Baculovirus) | |
| 0406 | Antisrum to HIV-1 rp24 (baculovirus) | |
| 0407 | Antiserum to HIV-1 rgp160 (Baculovirus) | Neutralising antobody titre of 1:20 against HIV-1 IIIB |
| 0408 | Antiserum to HIV-1 gp160 (Vaccinia) | |
| 0409 | Antiserum to HIV-1 rgp160 (Vaccinia) | |
| 0410 | Antiserum to HIV-1 p24 peptides | For use in twin site ELISA for p24. |
| 0411 | Antiserum to HIV-1 rgp120 (Baculovirus) | |
| 0412 | Antiserum to HIV-1 rgp120 (Baculovirus) | |
| 0413 | Antiserum to HIV-1 protease | |
| 0414 | Antiserum to SIV p27 | |
| 0415 | Antiserum to SIV env C-terminal peptide | |
| 0416 | Antiserum to SIVmac251 (32H) | Pooled antiserum from monkeys infected with live SIV. Antibodies to env, gag and pol are seen in an immunoblot |
| 0418 | Antiserum to HIV-2 gp105 (baculovirus) | |
| 0419 | Antiserum to HIV-1 integrase peptide 1 | |
| 0420 | Antiserum to HIV-1 integrase peptide 2 | |
| 0421 | Antiserum to HIV-1 gp120 #20 (CHO) | Neutralises IIIB at a titre of 1:20 |
| 0422 | Antiserum to HIV-1 gp120#42 (CHO) | Neutralises IIIB at a titre of 1:320 |
| 0423 | Antiserum to HIV-1 gp120 #52 (CHO) | Neutralises IIIB at a titre of 1:20 |
| 0424 | Antiserum to SIV gp140 | Neutralises SIVmac251 at a titre of 1:240 |
| 0425 | Antiserum to HIV-1 gp120 #52 (CHO) | |
| 0426 | Antiserum toHIV-2 gp105 #12 | |
| 0427 | Antiserum to NFk beta | The cellular transcription factor NF-kB consists of two DNA-binding subunits of 50K and 65K and is believed to play an important role in stimulating transcriptional activation of HIV-1 in latently infected T-cells |
| 0428 | Antiserum to HIV-1 RT | |
| 0429 | Antiserum to HIV-1 SF2 gp120 | Neutralises SF2 at a titre of 1:10,000 |
| 0430 | Antiserum to SIV gp140 | |
| 0431 | Antiserum to HIV-1 p17 | |
| 0432 | Antiserum to HIV-1 p24 | |
| 0433 | Antiserum to HIV-1 LAI V3 loop | |
| 0434 | Antiserum to HIV-1 V3 Consensus group A | |
| 0435 | Antiserum to HIV-1 V3 Consensus group B | |
| 0436 | Antiserum to HIV-1 V3 Consensus group C | |
| 0437 | Antiserum to HIV-1 V3 Consensus group D | |
| 0438 | Antiserum to HIV-1 V3 Consensus group A_E | |
| 0439 | Antiserum to HIV-1 MN gp120 | Inhibits syncitium formation of IIIB and 4 clinical isolates |
| 0440 | Antiserum to HIV-1 GB8 gp120 (CHO) | ELISA titre >10,000, neutralises GB8- titre 1:460 and R336 neutralises SF2 at a titre of 1:40 |
| 0441 | Antiserum to SIV gp120 (CHO) | Reacts with SIV gp120 in ELISA and Immunoblots |
| 0443 | Antiserum to HIV-1 GB8 rgp120 | Reacts in ELISA (titre >10,000), immunoblot and neutralises HIV-1-see cat. |
| 0444 | Antiserum to HIV-1 nef-GST | Reacts in ELISA, western blot and immunofluorescence. Will immunoprecipitate from in vitro translation assays but not from cell lysates. |
| 0446 | Antiserum to HIV-2 ST gp120 | ELISA titre 1:250,000, western blots 1:2000 or 1:5000 with enhanced chemi-luminescence detection. |
| 0452 | Alkaline Phosphatase conjugated anti p24 | Suitable for use in twin site ELISA's for p24 as a detection antibody |
| 0453 | AP conjugated anti-p18 | Suitable for use in Immunoblots for p18 as a detection antibody. |
| 0454 | Biotinylated anti-p24 | Suitable for use in ELISA's for p24 as a detection antibody. |
| 0501 | Panel of HIV-2 Positive sera | Sera have been characterised in a collaborative study. |
| 0509 | HIV-1 neutralising serum #1 | Sample is pooled serum of three separate bleeds from the same
patient. An international collaborative study between six laboratories
each using their own neutralisation assays demonstrated crossreactivity
with other HIV-1 strains. |
| 0510 | HIV-1 neutralising serum #2 | Sample is pooled serum of three separate bleeds from the same
patient. An international collaborative study between six
laboratories each using their own neutralization assays demonstrated
cross-reactivity with other HIV-1 strains. |
| 0512 | Panel of HIV-1 (genotypes A-F) positive plasma | WHO panel G. Panel of 8 plasma samples (8 x 100μl), with at least one ffrom each subtype A - F. |
| 0513 | HIVIG 1031 | Purified HIV Immunoglobulin (HIVIG). HIVIG was prepared from discarded HIV-positive units of blood collected from the National Blood Bank in Kampala, Uganda. The pooled plasma was inactivated using solvent/detergent and the IgG fraction purified using ion |
| 0514 | Inactivated HIV Plasma Pool | This reagent was prepared from discarded HIV-positive units of blood collected from the National Blood Bank in Kampala, Uganda. The pooled plasma was inactivated using solvent/detergent. |
| 0515 | HIV Positive Sera | HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522) |
| 0516 | HIV Positive Sera | HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522) |
| 0517 | HIV Positive Sera | HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522) |
| 0518 | HIV Positive Sera | HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522) |
| 0519 | HIV Positive Sera | HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522) |
| 0520 | HIV Positive Sera | HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522) |
| 0522 | HIV Positive Sera | HIV+ plasma, subtype F. Part of Neut Net Panel (515-522) |
| 0523 | HIV Negative Plasma | Negative control plasma |
| 0526 | HIV-1 Plasma (C) | Subtype C plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0527 | HIV-1 Plasma (BBR) | Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0528 | HIV-1 Plasma (BBR) | Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0529 | HIV-1 Plasma (F) | Subtype F plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0530 | HIV-1 Plasma (F) | Subtype F plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0531 | HIV-1 Plasma (BBR) | Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0532 | HIV-1 Plasma (C) | Subtype C plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0533 | HIV-1 Plasma (E) | Subtype E plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0534 | HIV-1 Plasma (BBR) | Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0535 | HIV-1 Plasma (BBR) | Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0536 | HIV-1 Plasma (B) | Subtype B plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0537 | HIV-1 Plasma (BBR) | Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0538 | HIV-1 Plasma (F) | Subtype F plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0539 | HIV-1 Plasma (B) | Subtype B plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0540 | HIV-1 Plasma (BBR) | Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0541 | HIV-1 Plasma (B) | Subtype B plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0542 | HIV-1 Plasma (BBR) | Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil. |
| 0543 | HIV-1 Plasma (F) | Subtype F plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil |
| 0544 | HIV-1 Plasma (C) | Subtype C plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil |
| 0545 | HIV-1 Plasma (C) | Subtype C plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil |
| 0547 | Subtype B Positive Plasma (12033) | |
| 0548 | Subtype B Positive Plasma (12033) | |
| 0549 | Subtype B Positive Plasma (13975) | |
| 0550 | Subtype B Positive Plasma (10875) | |
| 0551 | Subtype B Positive Plasma (14997) | |
| 0552 | Subtype B Positive Plasma (11704) | |
| 0553 | Subtype F Positive Plasma (14812) | |
| 0554 | Subtype CR47BF Positive Plasma (13767) | |
| 0555 | Subtype B Positive Plasma (14622) | |
| 0556 | Subtype BF1 Positive Plasma (15368) | |
| 0557 | Subtype B Positive Plasma (14532) | |
| 0558 | Subtype B Positive Plasma (14745) | |
| 0559 | Subtype F1 Positive Plasma (14934) | |
| 0560 | Subtype CR47BF Positive Plasma (13718) | |
| 0561 | Subtype B Positive Plasma (15354) | |
| 0562 | Subtype B Positive Plasma (14295) | |
| 0563 | Subtype B Positive Plasma (13162) | |
| 0564 | HIV-1 (URF CRF02_AG/B) EUR001 | Plasma from HIV-1 infected patient, SUBTYPE: URF CRF02_AG/B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0565 | HIV-1 (G) EUR002 | Plasma from HIV-1 infected patient, SUBTYPE: Subtype G (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0566 | HIV-1 (CRF02_AG) EUR003 | Plasma from HIV-1 infected patient, SUBTYPE: CRF02_AG (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0567 | HIV-1 (C) EUR004 | Plasma from HIV-1 infected patient, SUBTYPE: C (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0568 | HIV-1 (C) EUR005 | Plasma from HIV-1 infected patient, SUBTYPE: C (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0569 | HIV-1 (B) EUR006 | Plasma from HIV-1 infected patient, SUBTYPE: B (pol).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0570 | HIV-1 (B) EUR007 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0571 | HIV-1 (B) EUR008 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0572 | HIV-1 (G) EUR009 | Plasma from HIV-1 infected patient, SUBTYPE: G (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0573 | HIV-1 (F1) EUR010 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0574 | HIV-1 (C) EUR011 | Plasma from HIV-1 infected patient, SUBTYPE: C (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0575 | HIV-1 (B) EUR012 | Plasma from HIV-1 infected patient, SUBTYPE:B (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0576 | HIV-1 (URF_BF1) EUR013 | Plasma from HIV-1 infected patient, SUBTYPE:URF BF1 (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0577 | HIV-1 (F1) EUR014 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0578 | HIV-1 (CRF26_AU) EUR015 | Plasma from HIV-1 infected patient, SUBTYPE: CRF26_AU (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0579 | HIV-1 (G) EUR016 | Plasma from HIV-1 infected patient, SUBTYPE: G (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0580 | HIV-1 (B) EUR017 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0581 | HIV-1 (D) EUR018 | Plasma from HIV-1 infected patient, SUBTYPE: D (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0582 | HIV-1 (A1) | Plasma from HIV-1 infected patient, SUBTYPE: A1 (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0583 | HIV-1 (F1) EUR020 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0584 | HIV-1 (A1) EUR021 | Plasma from HIV-1 infected patient, SUBTYPE: A1 (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0585 | HIV-1 (B) EUR022 | Plasma from HIV-1 infected patient, SUBTYPE: B (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0586 | HIV-1 (B) EUR023 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0587 | HIV-1 (B) EUR024 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0588 | HIV-1 (URF_02_AG/A1) | Plasma from HIV-1 infected patient, SUBTYPE: URF_02_AG/A1.
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0589 | HIV-1 (B) EUR026 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0590 | HIV-1 (B) EUR027 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0591 | HIV-1 (B) EUR028 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0592 | HIV-1 (URF_BF1) EUR029 | Plasma from HIV-1 infected patient, SUBTYPE: URF BF1 (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0593 | HIV-1 (CRF20_BG) EUR030 | Plasma from HIV-1 infected patient, SUBTYPE: CRF20_BG (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0594 | HIV-1 (B) EUR031 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0595 | HIV-1 (URF_BF1) EUR032 | Plasma from HIV-1 infected patient, SUBTYPE: URF BF1 (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0596 | HIV-1 (G) EUR033 | Plasma from HIV-1 infected patient, SUBTYPE: G (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0597 | HIV-1 (F1) EUR034 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0598 | HIV-1 (B) EUR035 | Plasma from HIV-1 infected patient, SUBTYPE: B (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0599 | HIV-1 (CRF02_AG) EUR036 | Plasma from HIV-1 infected patient, SUBTYPE: CRF02_AG (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 0607 | HIV-1 IIIB gp120 (Baculo.) | Full Length Recombinant HIV-1 IIIB gp120 produced in the Baculovirus Expression System. Binds to sCD4. |
| 0609 | Human sCD4 | Full-length recombinant Human T-Cell Receptor sCD4, produced in Baculovirus expression system. This protein binds to native and recombinant HIV-1 gp120 and HIV-2 gp105 and neutralises HIV-1 infectivity in CD4- bearing, HIV-1 infected cell cultures and HIV |
| 0620 | Rec HIV-1 LAI p24 | Rec HIV-1 IIIB p24 produced in the Baculovirus expression system. |
| 0621 | HIV-2 gp105 (Baculo.) | Migrates as a 105Kd protein on SDS-PAGE |
| 0630 | HIV-1 Proteinase (E.coli) | Recombinant HIV-1 proteinase produced in E.coli. |
| 0635 | FIV p17 | Recombinant FIV GLASGOW8 p17-GST fusion protein produced in E.coli |
| 0636 | FIV p24 | Recombinant FIV GLASGOW8 p24-GST fusion protein produced in E.coli |
| 0643 | SIV p27 | Expressed by pGEX-3X as a GST fusion protein. Reacts in Immunoblot with monkey antiserum to SIV and with Mabs to SIV p27 |
| 0646 | HIV-1 MN gp120 (Baculo.) | Full length recombinant envelope gp120 from T-cell-tropic HIV-1 MN strain, produced in the Baculovirus Expression System. |
| 0648 | HIV-1 W61D gp120 (CHO) | HIV-1 rgp120 from the molecular clone W61D derived from a Dutch field isolate of HIV-1, produced in CHO cells. |
| 0651 | HIV-1 integrase (E.coli) | Recombinant HIV-1 Integrase from (LAV/BRU) strain. Produced in E.Coli. Active in 3' end processing and strand transfer of HIV-1 LTR substrates. |
| 0657 | HIV-1 gp120 (CHO) | This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti gp120 mAb-peroxidase capture ELISA. This protein activates human T-Lymphocytes (CD4+, CD4 -), in vitro, as measured by RNA synthesis during G0 to G1 |
| 0659 | HIV-1 vif | Recombinant HIV-1 vif from IIIB strain, expressed in E.coli |
| 0660 | SIV p17 | SIVmac 251 gag p17 (His p17-Pk fusion Protein). Produced in E.coli. |
| 0661 | HIV-2 p26 | Recombinant HIV-2 p26 with GST fusion protein. |
| 0667 | HIV-1 gp120 from 93TH975 (Baculo.) | Can be detected in Western blot using sheep or goat antibodies to HIV-1 gp120. Production: The env gene from HIV-1 93TH975.15 (GenBank Accession #U08457, construct donated by Dr. Beatrice Hahn) was cloned into a baculovirus vector. The protein was purifie |
| 0668 | SIV nef | Recombinant SIV J5 nef. Produced in the Baculovirus expression system. Works well in immunoassays with CFAR Mabs: 3092, 3093 and 3094. |
| 0669 | SIV C8 nef | Recombinant SIV C8 nef-GST. Produced in the Baculovirus expression system. |
| 0670 | SIV mac 251 gp130 | This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp130/Anti-gp130 Mab-peroxidase capture ELISA. This protein activates simian T-Lymphocytes (CD4+,CD4+), in vitro, as measured by RNA synthesis during G0 to G1 |
| 0671 | HIV-1 MN gp41 | Produced as a fusion protein in an E.coli expression system. Truncated gp41 protein mol. Wt: 25kD.This protein binds to murine monoclonal antibodies of defined epitope specificity and HIV-1 converted human serum polyclonal antibodies in ELISA and Western |
| 0675 | HIV-1 nef | Recombinant HIV-1 nef aa3-190, produced in E.coli. Expressed as a fusion protein, B-galactosidase at N-terminus. |
| 0677 | HIV-2 gp36 [aa390-702] (E.coli) | HIV-2 env antigen (recombinant) a.a. 390 to a.a. 702 of the HIV-2
env region 34 kDa. Reacts strongly with human HIV positive serum. |
| 0678 | HIV-1 p24 (Pichia) | Recombinant p24 from HxB2 strain produced in Pichia pastoris (entire p24 protein, total 231 amino acids). |
| 0679 | HIV-2 gp36 | Recombinant ecto-domain of HIV-2 gp36 produced in Pichia
pastoris. Reacts with AIDS sera and human monoclonal antibodies
as determined by ELISA and Western blot. |
| 0680 | HIV-1 gp41(Pichia.) | Glycosylated recombinant ecto-domain of gp41, from HXB2 strain, amino acids 546-682, produced in Pichia pastoris (without the membrane spanning and cytoplasmic domains). |
| 0681 | SIV tat (E.coli) | Recombinant SIV GST-tat-Pk.His Produced in E.coli. Low endotoxin aliquots available. |
| 0683 | HIV-1 CN54 gp120 (Baculo.) | Chinese B/C recombinant. The env gene is predominantly subtype C except for a short region at the 5’ end. |
| 0684 | SIV J5 rev | Recombinant SIVmac Clone J5 rev protein is expressed as His tag-fusion protein in E.coli using expression vector pET24. |
| 0685 | SIV J5 tat | Recombinant TAT protein is expressed as His tag-fusion protein in E.coli using expression vector pET24. |
| 0686 | SIV J5 RT | Recombinant RT protein from SIVmac clone J5 protein is expressed as His tag-fusion protein in E.coli using expression vector pET24. |
| 0688 | SARS Spike S1 protein | S1 Subunit of SARS CoV. Protein is 100 Kda in size. This consists of a combination of the FC fusion (25 Kda) and the SARS S1 domain (70 Kda). |
| 0689 | HIV-1 IIIB p17 (E.coli) | Recombinant p17 with authentic N and C terminii. |
| 0691 | HIV-1 nef (Clade A) | Clade A recombinant nef-protein, expressed as His-tag fusion protein in E. Coli using expression vector pET24 and purified using Ni-agarose columns |
| 0692 | HIV-1 nef (Clade B) | Clade B recombinant Nef protein, expressed as a His-tag fusion protein in E. coli using expression vector pET24 and purified using Ni-agarose columns. |
| 0693 | HIV-1 nef (Clade C) | Clade C recombinant nef protein, expressed as His-tag fusion protein in E. coli using expression vector pET24 and purified using Ni-agarose columns. |
| 0694 | HIV-1 p17/24 (Clade B) | Clade B recombinant p17/24-B protein is expressed as His-tag fusion protein in E.coli using expression vector pET24 and purified using Talon Superflow metal affinity resin. |
| 0695 | HIV-1 p17/24 (Clade C) | Clade C recombinant p17/24-B protein, expressed as His-tag fusion protein in E.coli using expression vector pET24 and purified using Talon Superflow metal affinity resin. |
| 0698 | HIV-1 UG37 gp140 (CHO) | Recombinant protein from the HIV-1 clade A strain 92UG037. Terminating after 2F5 epitope, Accession No: AY494974 |
| 0699 | HIV-1 CN54 gp140 (CHO) | Recombinant gp140 envelope protein from the HIV-1 clade C/B' strain CN97001 (clone CN54); the envelope protein is of clade C origin, accession number AF286226, terminating at ALDSWKN. |
| 0703 | Overlapping peptides HIV-1 gag p17 | N-terminal cystine for conjugation. |
| 0704 | HIV-1 gag p15 | N-terminal cystine for conjugation. |
| 0706 | SIV gag p27 | SIV p27 (aa233-247). A possible T-cell epitope |
| 0707 | HIV-1 env gp41 | Conserved neutralisation epitope |
| 0708 | HIV-1 env gp41 | |
| 0709 | HIV-1 env gp120 | Peptide to the CD4 binding region. |
| 0710 | HIV-1 env gp120 | C-terminal of gp120 |
| 0711 | HIV-1 env gp41 | N-terminal of gp41 |
| 0712 | HIV-1 gag p24 | N-terminal of p24 |
| 0713 | HIV-1 gag p24 | LAI version of SF2 overlapping peptide number 18 |
| 0714 | SIV gag p26 | Set of overlapping 20mers covering entire SIV p26 region. Peptide 15, 16 and 18 have an additional N-terminal cysteine |
| 0715 | HIV-1 env gp120 V3 loop (MN) | |
| 0716 | HIV-1 gag p9 (p15) | Most hydrophobic region of p9. IIIB version of the SF2 overlapping peptide number 5 |
| 0717 | HIV-1 T-cell epitopes | |
| 0718 | HIV-1 gag T cell epitope | |
| 0719 | HIV-1 pol T-cell epitopes | Peptide to T-cell epitopes. |
| 0720 | HIV-1 pol T-cell epitopes | Peptide to T-cell epitopes. |
| 0721 | HIV-1 pol T-cell epitopes | Peptide to T-cell epitopes. |
| 0722 | HIV-1 pol T-cell epitopes | Peptide to T-cell epitopes. |
| 0723 | HIV-1 pol T-cell epitopes | Peptide to T-cell epitopes. |
| 0724 | HIV-1 pol T-cell epitopes | Peptide to T-cell epitopes. |
| 0725 | HIV-1 pol T-cell epitopes | Peptide to T-cell epitopes. |
| 0726 | HIV-1 pol T-cell epitopes | Peptide to T-cell epitopes. |
| 0727 | HIV-1 pol T-cell epitopes | Peptide to T-cell epitopes. |
| 0728 | HIV-1 T-cell epitopes | |
| 0729 | HIV-1 T-cell epitopes | |
| 0730 | HIV-1 nef T-cell peptide | |
| 0731 | HIV-1 nef T-cell peptide | |
| 0732 | HIV-1 T-cell epitopes | |
| 0733 | HIV-1 T-cell epitopes | |
| 0734 | HIV-1 T-cell epitopes | |
| 0735 | HIV-1 nef T-cell peptide | |
| 0738 | SIV env gp120 V3 loop | Region of SIV env that corresponds to the hypervariable V3 loop of HIV-1. This region in SIV is, however, relatively well conserved. |
| 0739 | SIV env gp120 C-terminal | SIV env gp120 C-terminal (aa497-516) . Available as a free peptide and conjugated to KLH. |
| 0740 | HIV-1 env gp120 (IIIB) | Overlapping series covering entire gp120 |
| 0741 | HIV-1 T-cell epitopes | peptides to a range of HIV-1 T-cell epitopes |
| 0743 | HIV-2 tat | |
| 0744 | HIV-2 tat | |
| 0745 | HIV-2 tat | |
| 0746 | SIV tat | SIV tat/rev (N and C-terminus). ETPLREQENSLESSN |
| 0747 | SIV tat | SIV tat/rev (N and C-terminus). ETPLREQENSLESSN |
| 0748 | SIV rev | SIV tat/rev (N and C-terminus). RSHTGEEELRRRLRL |
| 0749 | SIV rev | SIV tat/rev (N and C-terminus) . EALCDPTENSRSPQA |
| 0750 | HIV-2 rev | |
| 0751 | HIV-2 rev | |
| 0752 | HTLV-I rex | |
| 0753 | HTLV-I rex | |
| 0754 | HIV-1 pol integrase/endonuclease | Available in both an unconjugated form and conjugated to KLH |
| 0755 | HIV-1 pol integrase/endonuclease | Available in both an unconjugated form and conjugated to KLH |
| 0756 | HIV-1 pol integrase/endonuclease | Available in both an unconjugated form and conjugated to KLH |
| 0757 | HIV-1 pol integrase/endonuclease | Available in both an unconjugated form and conjugated to KLH |
| 0758 | FIV env gp120 | |
| 0759 | FIV env gp120 | |
| 0760 | FIV env gp41 | |
| 0761 | FIV orf 3 | |
| 0762 | HIV-1 env gp120 V3 loop | V3 peptide for African strain of HIV-1 from Zaire |
| 0763 | HIV-1 env gp120 V3 loop | V3 peptide for African strain of HIV-1 from Zaire |
| 0764 | HIV-1 env gp120 V3 loop | V3 peptide for African strain of HIV-1 from Zaire |
| 0765 | HIV-1 env gp120 V3 loop | V3 peptide for African strain of HIV-1 from Zaire |
| 0770 | HIV-1 env gp120 V3 loop | |
| 0771 | HIV-1 env gp120 V3 | Variant of Japanese HIV-1 GUN (770) |
| 0772 | Peptide substrate for HIV proteinase | Protected heptapeptide for use as a substrate for assaying proteinase activity and its inhibitors. |
| 0773 | Peptide substrate for HIV proteinase | Chromogenic substrate for HIV-1 proteinase |
| 0775 | SIV gag p17 | Peptide set homologous to the entire p17 of SIVmac251 (32H isolate), 20mers with 10 amino acid overlap. Based on consensus sequences derived by Drs N Almond and P Kitchin |
| 0776 | SIV gag p15 | Peptide set homologous to the entire p15 of SIVmac251 (32H isolate), 20mers with 10 amino acid overlap. Based on consensus sequences derived by Drs N Almond and P Kitchin |
| 0777 | SIV nef | Peptide set homologous to nef of SIVmac251 (32H isolate), 20mers with 10 amino acid overlap. Based on consensus sequences derived by Drs N Almond and P Kitchin |
| 0779 | HIV-1 tat | |
| 0780 | HIV-1 rev | |
| 0781 | COUP-TF | Cellular transcription factor that interacts with the LTR and influences transcription of the viral genome |
| 0782 | SIV env gp41 (Gnann) | Conserved immunoreactive epitope of gp41. Original peptide 5 from HIV-2 ROD has a serine in position 3 |
| 0783 | HIV-1 env gp41 | |
| 0784 | HIV-1 nef | Putative GTP binding site. |
| 0785 | HIV-2 nef | Putative GTP binding site |
| 0787 | HIV-1 env V3 loop (Ugandan loop) | Sequences partially conserved in serveral African isolates of HIV-1 |
| 0788 | HIV-1 gag p24 | Replacement for 702, it differs in that the peptides are 20mers and do not have additional C-terminal cysteines added. |
| 0789 | HIV-1 gag p17-3 variant | HIV-1 SF2 gag peptide p17-3 has been shown to be a CTL epitope in individuals with HLA-B8. These peptides represent strain variants of this region. |
| 0790 | HIV-1 tat | Peptides have been shown to bind to tar RNA and show specifcity for sense RNA |
| 0792 | HIV-1 env V3 loop | |
| 0793 | SIV env gp120 | Homologous to env gp120 (aa167-181). |
| 0794 | HIV-1 env gp120 peptide 18 (aa171-185) | This region from SF2 has soon to be a neutralising epitope recognised by HIV-1 antibody positive serum |
| 0795 | SIV env gp120 | Env peptide 18 has been shown to be a neutralising epitope recognised by patients sera. This set of peptides spans the equivalent region of SIV between the two cysteines. |
| 0796 | HIV-1 env V3 loop (RF) | Principle neutralising domain. |
| 0797 | HIV-1 env V3 loop (SF2) | Principle neutralising domain. |
| 0798 | SIVenv gp41 | Based on consensus sequences derived by Drs N Almond and P Kitchin |
| 0901 | Interleukin-2 | CTLL and similar cell lines should be subcultured 1:10 with medium supplemented with 1-5 IU/ml IL-2 every 3-4 days. T helper lines should be subcultured with medium supplemented with a similar concentration of IL-2 about every 10-14 days.
Recombinant DNA |
| 0902 | Interferon Gamma (Human) | Recombinant human interferon gamma diluted in PBS containing human serum albumin, 6mg/ml. Contains mannitol, sodium succinate and polysorbate 20 |
| 0903 | Inteferon Gamma (Murine) | Recombinant murine interferon gamma diluted in PBS containing human serum albumin, 6mg/ml. Contains TRIS-HCl |
| 0904 | TNF alpha (Human) | Recombinant TNF-alpha (Human) diluted in PBS containing human serum albumin, 6mg/ml. |
| 0905 | TNF Alpha (Murine) | Recombinant TNF-alpha (Murine) diluted in PBS containing human serum albumin, 6mg/ml. |
| 0952 | AZT (Zidovudine) | Pure AZT, for use as positive control in antivial assays. |
| 0956 | HIV-1 DNA PCR standards | A set of HIV-1 DNA standards for PCR consisting of coded samples containing from 0.1 -10,000 molecules of DNA per assay in carrier DNA. |
| 0961 | HMA genetic subtyping kit | Two aliquots each of purified plasmid DNA's containing envelope sequence subtype refrenceThe plasmids in this kit are for use in HMA only. |
| 0964 | HMA kit HIV-1 gag | The plasmids in this kit are for use in HMA only. |
| 0965 | OLA kit for NRTI | Kit for the detection of HIV-1 resistance mutations to NRTl. |
| 0966 | OLA kit for NNRTI | Kit for the detection of HIV-1 resistance mutations to NNRTI. |
| 0967 | OLA kit for Protease Inhibitors | Kit for the detection of HIV-1 resistance mutations to Protease Inhibitors. |
| 0968 | TAK779 (CCR5) | Small molecule, non-peptide CCR5 antagonist with potent and selective anti HIV-1 activity. |
| 0969 | Integrase Inhibitor | Potent inhibitor of the strand transfer reaction catalyzed by HIV-1 integrase. |
| 0970 | Nevirapine | Nevirapine is a non-nucleoside reverse transcriptase inhibitor of HIV-1. |
| 0971 | GM-CSF | Human Granulocyte monocyte colony growth factor produced in E.coli and purified via sequential chromatography. |
| 0972 | Indinavir Sulphate | Indinavir sulphate is a selective, competitive inhibitor of HIV-1 protease. |
| 0973 | PCS-RANTES | Amino-terminus modified RANTES. RANTES analogue inhibits entry of HIV-1 CCR5 tropic strains. |
| 0974 | AMD 3100 | CXCR4 Antagonist. A symmetrical bicyclam compound that antagonizes CXCL12 (SDF1) binding to CXCR4. |
| 0975 | Abacavir | Abacavir is a carbocyclic nucleoside analogue. |
| 0976 | Atazanavir | Atazanavir is an azapeptide HIV-1 protease inhibitor. |
| 0977 | Efavirenz | Efavirenz is a non-nucleoside reverse transcriptase inhibitor of HIV-1. |
| 0978 | Lopinavir | Lopinavir, is an inhibitor of the HIV-1 protease. |
| 0979 | Maraviroc | Maraviroc is an entry inhibitor. Specifically, maraviroc blocks the chemokine receptor CCR5. |
| 0980 | Ralregravir | Raltegravir is an HIV-1 integrase inhibitor. |
| 0981 | Tenofovir | Tenofovir is a cyclic nucleoside phosphonate analogue of adenosine monophosphate. |
| 0982 | Zidovudine | Zidovudine is a nucleoside analogue of the naturally occurring nucleoside, thymidine. |
| 0983 | Saquinavir | Saquinavir is an inhibitor of HIV protease. |
| 0984 | Trimeris/Roche T-20 Fusion Inhibitor | T-20 inhibitors target a sequence in the HIV gp41, preventing viral fusion. |
| 0985 | Emtricitabine [(-)FTC] | Emtricitabine, a nucleoside analogue of cytidine. |
| 0986 | Tenofovir Disoprxil Fumarate | Efavirenz is a non-nucleoside reverse transcriptase inhibitor. |
| 0987 | Nelfinavir Mesylate | Nelfinavir mesylate is an inhibitor of HIV-1 protease. |
| 0988 | Amprenavir | Amprenavir is an inhibitor of HIV-1 protease. |
| 0989 | Darunavir | Darunavir, also known as Prezista or TMC 114, is a nonpeptidic protease inhibitor. |
| 0990 | Etravirine | Etravirine, also known as Intelence or TMC125, is a NNRTI. |
| 0991 | Elvitegravir | An integrase inhibitor. Inhibition in-vivo can be boosted when combined with Ritonavir. |
| 0992 | Rilpivirine | NNRTI with higher potency, longer half-life and reduced side-effects compared with older NNRTIs. |
| 0993 | Ritinovir | Ritonavir is a peptidomimetic inhibitor of both HIV-1 and HIV-2 proteases. |
| 1000 | HIV-1 Saquinavir Resistant - Molecular Clone | HXB2 (48V) Proteinase mutation G→V at position 48. Derived by co-transfection of MT4 cells with PHXB 2 delta pro and PHXB2 proteinase coding region containing a single G→ V mutation at position 48. |
| 100000 | CFP10 IgG mAb ELISA kit | The Lionex CFP10 IgG antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgG antibodies against CFP10 in serum and plasma. |
| 100001 | CFP10 IgA mAb ELISA kit | The Lionex CFP10 IgA antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgA antibodies against CFP10 in serum and plasma. |
| 100002 | CFP10 IgM mAb ELISA kit | The Lionex CFP10 IgM antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgM antibodies against CFP10 in serum and plasma. |
| 100003 | e137, neutralising mAb against HCV E2 | Human recombinant antibody e137, binding to hepatitis C virus (HCV) E2 glycoprotein |
| 100004 | mAb66 (HIV-1neutralising) expressing plasmid | |
| 100005 | mAb66.6 (HIV-1 neutralising) expressing plasmid | |
| 100007 | Panel of Global HIV-1 Env Clones | A panel of 12 envelope clones designed to assess neutralization responses. These reference strains were chosen because they are representative of the global epidemic. |
| 100008 | TB recombinant protein MPT64 | Immunogenic protein MPT64 of M. tuberculosis, fuction unknown |
| 100028 | PSTS1 antigen | Phosphate transport protein of M. tuberculosis (PBP-1, 38 kDa antigen, PhoS, PhoS homologue) |
| 100029 | ELISA kit ESAT6 IgM | The LIONEX ESAT6 IgG antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgG antibodies against ESAT6 in serum and plasma. |
| 100030 | ELISA kit ESAT6 IgA | The LIONEX ESAT6 IgM antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgM antibodies against ESAT6 in serum and plasma. |
| 100031 | ELISA kit ESAT6 IgG | The LIONEX ESAT6 IgA antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgA antibodies against ESAT6 in serum and plasma. |
| 100032 | 85A antigen | FbpA, secreted antigen 85-A, antigen 85 complex A, Mycolyl transferase 85A, Fibronectin-binding protein A of M. tuberculosis |
| 100033 | PepMix HBV Ultra | HBV Core Protein, average coverage: 92.5%. 21peptides approx. 25ug/peptide/vial. |
| 100034 | PepMix ESAT-6 | esxA 6 kDa early secretory antigenic target ESAT-6.
21 peptides, 15meric, approx. 25ug/peptide/vial |
| 100035 | Adjuvant C | Recombinant Adjuvant C protein. |
| 100036 | M. tuberculosis 16 kDa (Rv2031c) | 14 kDa antigen, 16 kDa antigen, HSP16.3, acr, hspX of M. tuberculosis |
| 100037 | Mab to HIV-1 nef (2F2) | Mouse monoclonal antibody to HIV-1 Nef protein epitope mapped to amino acids 150-158 |
| 100038 | Mab to HIV-1nef (N5) | Mouse monoclonal antibody to HIV-1 Nef protein epitope mapped to amino acids 62-68 |
| 100039 | Mab to HIV-1 p24 (N17) | Mouse monoclonal antibody to HIV-1 p24 protein epitope mapped to C-terminus, a.a. 165- 231 |
| 100040 | Mab to HIV-1 p24 (N29) | Mouse monoclonal antibody to HIV-1 p24 protein epitope mapped to N-terminus, a.a. 1-104 |
| 100041 | Recombinent HIV-1 tat concensus C | HIV-1 recombinent tat concencus C protien |
| 100042 | Recombinent HIV-1 BaL tat | HIV-1 recombinent BaL tat protien |
| 100043 | HIV-1 (A1) EUR 0061 | Plasma from HIV-1 infected patient, SUBTYPE: A1 (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100044 | HIV-1 (F1) EUR0062 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100045 | HIV-1 (B) EUR0064 | Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100046 | HIV-1 (B) EUR0065 | Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3)
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100047 | HIV-1 (G) EUR0068 | Plasma from HIV-1 infected patient, SUBTYPE: G (PRT and V3)
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100048 | HIV-1 (F1) EUR0069 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (PRT and V3)
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100049 | HIV-1 (C) EUR0070 | Plasma from HIV-1 infected patient, SUBTYPE: C (PRT and V3)
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100050 | HIV-1 (C) EUR0071 | Plasma from HIV-1 infected patient, SUBTYPE: C (PRT and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100051 | HIV-1 (B) EUR0072 | Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100052 | HIV-1 (B) EUR0073 | Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3)
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.Plasma from HIV-1 infected patient, SUBTYPE:
See datasheet for P |
| 100053 | HIV-1 (F1) EUR0075 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (PRT and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100054 | HIV-1 (B) EUR0076 | Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100055 | HIV-1 (F1) EUR0077 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (PRT and V3)
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100056 | HIV-1 (B) EUR0078 | Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100057 | HIV-1 (C) EUR0079 | Plasma from HIV-1 infected patient, SUBTYPE: C (PRT and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100058 | HIV-1 (B) EUR0080 | Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100059 | HIV-1 (F1) EUR0081 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (PRT and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100060 | HIV-1 (CRF45_cpx: PRT, CRF02_AG: V3) EUR0082 | Plasma from HIV-1 infected patient, SUBTYPE: CRF45_cpx (PRT), CRF02_AG (V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100061 | HIV-1 (CRF45_cpx: PRT, CRF02_AG: V3) EUR0083 | Plasma from HIV-1 infected patient, SUBTYPE: CRF45_cpx (PRT), CRF02_AG (V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100062 | HIV-1 (B) EUR0084 | Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100063 | HIV-1 (CRF19_cpx ) EUR0040 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100064 | HIV-1 (CRF19_cpx ) EUR0041 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100065 | HIV-1 (B) EUR0043 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100066 | HIV-1 (B) EUR0044 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100067 | HIV-1 (B) EUR0045 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100068 | HIV-1 (B) EUR0046 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100069 | HIV-1 (URF 02_AG/A1 ) EUR0048 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100070 | HIV-1 (B) EUR0050 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100071 | HIV-1 (B) EUR0052 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100072 | HIV-1 (B) EUR0053 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resis |
| 100073 | HIV-1 gp160 clone subtype A1 in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample collected in Russia has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus |
| 100074 | HIV-1 gp160 clone subtype A1 in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample collected in Russia has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus |
| 100075 | HIV-1 gp160 clone subtype A1 in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample collected in Russia has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus |
| 100076 | HIV-1 gp160 clone subtype A1 in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample collected in Russia has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus |
| 100077 | HIV-1 gp160 clone subtype A1 in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample collected in Russia has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus |
| 100078 | HIV-1 gp160 clone subtype BG in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample collected in Spain has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100079 | HIV-1 gp160 clone subtype F1 in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100080 | HIV-1 gp160 clone subtype F1 in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100081 | HIV-1 gp160 clone subtype G in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100082 | HIV-1 gp160 clone subtype G in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100083 | HIV-1 gp160 clone subtype G in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100084 | HIV-1 gp160 clone subtype G in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100085 | HIV-1 gp160 clone subtype G in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100086 | HIV-1 gp160 clone subtype G in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100087 | HIV-1 gp160 clone subtype G in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100088 | HIV-1 gp160 clone subtype G in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100089 | HIV-1 gp160 clone subtype G in pcDNA3.1 | The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus. |
| 100091 | Mab to HIV-1 gp41 (m66.6) | Broadly neutralising anitbody, from an HIV-1-infected patient with 2F5-like serum Abs. This antibody binds to the D664KW666 core 2F5 epitope but use entirely different germ line V genes from 2F5 and that are significantly less divergent than 2F5 from thei |
| 100092 | MSCV (Puro)-HA-Flag-AU1-SAMHD1 WT | pMSC (purp) plasmid expressing codon optimised wild type human SAMHD1 protein |
| 100093 | MSCV (Puro)-HA-Flag-AU1-SAMHD1 VQ618AA | pMSC (purp) plasmid expressing codon optimised mutant human SAMHD1 protein VQ618AA |
| 100094 | MSCV (purp)-HA-Flag-AU1-SAMHD1 LF620AA | pMSC (purp) plasmid expressing codon optimised mutant human SAMHD1 protein LF620AA |
| 100095 | MSCV(puro)-HA-Flag-AU1-SAMHD1 T592A | pMSC (purp) plasmid expressing codon optimised mutant human SAMHD1 protein T592A |
| 100096 | PepMix M.Tb CFP-10 | M.Tb CFP-10, ESAT-6-like protein EsxB (P9WNK5). 23 peptides, 15meric; approx. 25 µg / peptide |
| 100097 | PepMix M.Tb TP10.4 | M.Tb TP10.4, ESAT-6-like protein EsxH (P9WNK3). 22 peptides, 15meric; approx. 25 µg / peptide |
| 100098 | PepMix M.Tb AG85B | M.Tb AG85B, Diacylglycerol acyltransferase/mycolyltransferase Ag85B (P9WQP1). 79 peptides, 15meric; approx. 25 µg / peptide. |
| 100099 | RepliTope Antigen Collection M.tb Ultra Microarray | Microarray with a comprehensive collection of 6388 overlapping, nonredundant 15-meric peptides from antigenic proteins of M.tb. This array was produced by carefully selecting 40 antigens of M.tb reference strain H37Rv supplemented by 354 homologous antige |
| 1001 | HIV-1 Saquinavir Resistant - Molecular Clone | HIV-1 Molecular Clone HXB2 with L→M mutation In proteinase at position 90. Derived by co-transfection of MT4 cells with PHXB 2 delta pro and PHXB2 proteinase coding region containing a single G→V mutation at position 90. |
| 100100 | Jtag Parental cell line | |
| 100101 | Jtag KO Serinc5/3 | |
| 100103 | pcDNA3.1-SERINC3-HA | SERINC3 human coding sequence with a C-terminal HA tag, cloned into pcDNA3.1 BS(-) between NotI and EcoRI restriction sites. pcDNA3.1 BS(-) (#100 104) is a derivative of pcDNA3.1(-) (Invitrogen) in which the NeoR was replaced with BsdR. Ampicilin resistan |
| 100104 | pcDNA3.1 BS(-) | pcDNA3.1 BS(-) is a derivative of pcDNA3.1(-) (Invitrogen) in which the NeoR was replaced with BsdR. Ampicilin resistant. |
| 100105 | pcDNA3.1-SERINC5-HA | SERINC5 human coding sequence with a C-terminal HA tag, cloned into pcDNA3.1 BS(-) between NotI and EcoRI restriction sites. pcDNA3.1 BS(-) (#100 104) is a derivative of pcDNA3.1(-) (Invitrogen) in which the NeoR was replaced with BsdR. Ampicilin resistan |
| 100106 | PBJ6-SERINC3-HA | SERINC3 human coding sequence with a C-terminal HA tag, cloned into PBJ6 between NotI and EcoRI restriction sites. PBJ6 is a derivative of PBJ5 in which the original SV40 early promoter fused to RU5 of HTLV-1 LTR was modified by removing the SV40 early pr |
| 100107 | PBJ6-SERINC5-HA | SERINC 5 human coding with a C-terminal HA tag, cloned into PBJ6 between NotI and EcoRI restriction sites.
PBJ6 is a derivative of PBJ5 in which the original SV40 early promoter fused to RU5 of HTLV-1 LTR was modified by removing the SV40 early promote |
| 100108 | PBJ6 | PBJ6 is a derivative of PBJ5 in which the original SV40 early promoter fused to RU5 of HTLV-1 LTR was modified by removing the SV40 early promoter and retaining only HTLV-1 RU5. Ampicilin resistant. |
| 100109 | peGFP-N1 | peGFP-N1 (Clontech) empty vector control. Kanamycin resistant. |
| 100110 | peGFP-N1-SERINC5 | SERINC5 human coding sequence fused at N-terminus of eGFP, cloned between NheI and EcoRI in peGFP-N1 (Clontech). Kanamycin resistant. |
| 100111 | peGFP-N1-SERINC3 | SERINC3 human coding sequence fused at N-terminus of eGFP, cloned between NheI and EcoRI in peGFP-N1 (Clontech). Kanamycin resistant. |
| 100112 | HIV-1 (B) EUR0056 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100113 | HIV-1 (F1) EUR0058 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100114 | HIV-1 (B) EUR0060 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100115 | HIV-1 (F1) EUR0062 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100116 | HIV-1 (B) EUR0065 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100117 | HIV-1 (A1) EUR0066 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100118 | HIV-1 (C) EUR0067 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100119 | HIV-1 (URF BG) EUR0068 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100120 | HIV-1 (URF F1_CRF14 BG) EUR0069 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100121 | HIV-1 (B) EUR0073 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 100133 | Hela HA-CPSF6-358 | HeLa cell line stably expressing N-terminal HA-tagged CPSF6 truncated at position 358. |
| 100134 | Hela Nup358 shRNA | HeLa cell line stably expressing Nup358 shRNA. |
| 100135 | CCR5-tropic NL4.3 (Ba-L Env) wt | Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env wild type |
| 100136 | CCR5-tropic NL4.3 (Ba-L Env) CA P90A | Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env containing the capsid P90A mutation |
| 100137 | CCR5-tropic NL4.3 (Ba-L Env) CA N74D | Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env containing the capsid N74D mutation |
| 100138 | CCR5-tropic NL4.3 (Ba-L Env) CA N57A | Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env containing the capsid N57A mutation |
| 100139 | CCR5-tropic NL4.3 (Ba-L Env) delta RT (D185E) | Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env containing the reverse transcriptase D185E mutation. |
| 100140 | CCR5-tropic NL4.3 (Ba-L Env) delta IN (D116N) | Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env containing the integrase D116N mutation |
| 100141 | Human CPSF6 expression vector | Plasmid expressing human CPSF6 |
| 100142 | pcDNA3.1 3xFLAG SIV Mnd2 Vpx | Vpx sequence from SIV Mnd2 (5440)cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI or XhoI site at 3’ end. The vector contains a 3xFLAG tag that is in-frame with the N-terminus of each Vpx gene. Ampicilin resistant. |
| 100143 | pcDNA3.1 3xFLAG SIV RCM Vpx | Vpx sequence from SIV RCM (NG411) cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI or XhoI site at 3’ end. The vector contains a 3xFLAG tag that is in-frame with the N-terminus of each Vpx gene. Ampicilin resistant. |
| 100144 | pcDNA3.1 3xFLAG SIV Syk Vpr | Vpr sequence from an SIVsyk provirus (Hirsch VM, Dapolito GA, Goldstein S, McClure H, Emau P, et al. (1993) A distinct African lentivirus from Sykes’ monkeys. J Virol 67: 1517–1528) cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI o |
| 100145 | pcDNA3.1 3xFLAG SIV Deb Vpr | Vpr sequence from SIV Deb (CM5) cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI or XhoI site at 3’ end. The vector contains a 3xFLAG tag that is in-frame with the N-terminus of each Vpr gene. Ampicilin resistant. |
| 100146 | pcDNA3.1 3xFLAG SIV Mus Vpr | Vpr sequence from SIV Mus (CM1239) cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI or XhoI site at 3’ end. The vector contains a 3xFLAG tag that is in-frame with the N-terminus of each Vpr gene. Ampicilin resistant. |
| 100147 | pcDNA3.1 3xFLAG SIV AGM Vpr | Vpr sequence from SIV AGM (Gri677) cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI or XhoI site at 3’ end. The vector contains a 3xFLAG tag that is in-frame with the N-terminus of each Vpr gene. Ampicilin resistant. |
| 100148 | Hela TRN-SR2 shRNA | HeLa cell line stably expressing TRN-SR2 shRNA. |
| 1002 | HIV-1 SAQR 90M | HIV-1 Molecular Clone HXB2 with G→V mutation at Position 48 and L→M mutation at position 90 of Proteinase. Derived by co-transfection of MT4 cells with PHXB2deltapro and PHXB2 proteinase coding region containing 2 mutations G→V at position 48, L→M at pos |
| 100224 | Mab to HIV-1 gp41 (m66) | Broadly neutralising anitbody, from an HIV-1-infected patient with 2F5-like serum Abs. This antibody binds to the D664KW666 core 2F5 epitope but use entirely different germ line V genes from 2F5 and that are significantly less divergent than 2F5 from thei |
| 1003 | HIV-1 Y115F | Derived from HXB2 by in vitro selection with 1592U89. RT mutation Y→F at position 115. Confers low-level resistance (two-fold) to carbocyclic nucleoside (1592U89) |
| 1004 | HIV-1 K65R | Derived from HXB2 by in vitro selection with 1592U89. RT mutation K→R at position 65. Confers low-level resistance (fourfold) to carbocyclic nucleoside (1592U89), increased cross- resistance to ddI, ddC & 3TC. |
| 1005 | HIV-1 Drug resistant L74V/M184V | Confers resistance (nine to ten-fold) to carbocyclic nucleoside (1592U89), increased cross- resistance to ddI, ddC & 3TC. |
| 1006 | HIV-1 Drug resistant K65R/M184V | Confers resistance (seven to eight-fold) to carbocyclic
nucleoside (1592U89), increased cross- resistance to ddI,
ddC & 3TC. |
| 1007 | HIV-1 Drug resistant K65R/L74V/M184V | Confers resistance (tenfold) to carbocyclic nucleoside (1592U89), increased cross- resistance to ddI, ddC & 3TC. |
| 1008 | HIV-1 Drug resistant I50V | Confers slight resistance (two to three-fold) to protease inhibitors VX-478 & VB-11, 328. |
| 1009 | HIV-1 Drug resistant 150V/M46I/I47V | Confers slight resistance (twenty fold) to protease inhibitors VX-478 & VB-11, 328. |
| 1010 | HIV-1 Drug resistant K103N | Confers resistance to a selection of non-nucleoside RT inhibitors. |
| 1011 | HIV-1 Drug resistant Y188H | Confers resistance to a selection of non-nucleoside RT inhibitors. |
| 1012 | HIV-1 Drug resistant Y188L | Confers resistance to a selection of non-nucleoside RT inhibitors. |
| 1013 | HIV-1 Drug resistant Y181C | Confers resistance to a selection of non-nucleoside RT inhibitors. |
| 1014 | HIV-1 Drug resistant G190A | Confers resistance to a selection of non-nucleoside RT inhibitors (Loviride & Nevirapine). |
| 1015 | HIV-1 Drug resistant V106A | Confers resistance to a large selection of non-nucleoside RT inhibitors. |
| 1016 | HIV-1 Drug resistant L100I | Confers resistance to a large selection of non-nucleoside RT inhibitors. |
| 1017 | SE9173 & SE9280 (Subtype J Isolates) | Sub-type J isolates, NSI. |
| 1018 | SIV SupT1AT-2TX | Aldrithiol-2-inactivated virus. Virus treated with Aldrithiol-2. Tested in proliferation assay vs PBLs. Unable to productively infect highly susceptable cells in vitro. 1018.1 = treated virus, 1018.2 = treated microvicles. See 'NOTE' on datasheet |
| 1020 | PH969 Cell Line | Simian T-cell Lymphotrophic virus cell line. Obtained from PBMC’s of an STLV-3 (formerly STLV-L) infected Erithrean Papio hamadryas (strain PH969). Cocultivated with blood lymphocytes from a seronegative baboon. |
| 1021 | PP1664 Cell Line | Stable IL-2 dependent Ag producing cell line. Simian T-cell Lymphotrophic virus cell line. Cell line of PBMC’s from an STLV-2 infected Pan paniscus, co-cultivated with human cord blood lymphocytes. |
| 1022 | Primary Isolates Djoubouti, Ethiopia | Isolated from seropositive individuals in Djibouti, Ethiopia. See datasheet for isolate numbers. |
| 1023 | Primary Isolates, Syria. | Isolated from seropositive individuals in Syria. See datasheet for isolate numbers. |
| 1024 | Primary Isolates, Egypt. | Isolated from seropositive individuals in Egypt. See datasheet for isolate numbers. |
| 1025 | Primary Isolates Belores. | Isolated from seropositive individuals in Belorus See datasheet for isolate numbers. |
| 1026 | Primary Isolates, China | Isolated from seropositive individuals in China. See datasheet for isolate numbers. |
| 1027 | Primary Isolates, India. | Isolated from seropositive individuals in India See datasheet for isolate numbers. |
| 1028 | Primary Isolates, Israel. | Isolated from seropositive individuals in Israel. See datasheet for isolate numbers. |
| 1029 | Primary Isolates, Kazachstan. | Isolated from seropositive individuals in Kazachstan. See datasheet for isolate numbers. |
| 1030 | Pirmary Isolates, Russia | Isolated from seropositive individuals in Russia. See datasheet for isolate numbers. |
| 1031 | Pirmary Isolates, Senegal. | Isolated from seropositive individuals in Senegal. See datasheet for isolate numbers. |
| 1032 | Primary isolates, Tanzania | Isolated from seropositive individuals from Tanzania. For known Genotype and Phenotype see datasheet. |
| 1033 | Primary Isolates, South Africa. | Isolated from seropositive individuals in South Africa. See datasheet for isolate numbers. |
| 1034 | X-421-2 (B/G CRF14) | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1035 | MP255 (F2) | MP255 has been placed in the subclade F2 |
| 1036 | MP535 (K) | MP535, previously placed in the subclade F3, has now been re-classified as subtype K. |
| 1037 | MP1213 (CRF02_AG) | A circulating recombinant form similar to the prototype AG recombinant virus IBNG. |
| 1038 | MP1307 (CRF11_CPX) | A circulating recombinant form with a complex mosaic structure involving subtypes A, G, J, and CRF-01_AE. |
| 1039 | USA Primary Isolates ENV subtype B. | Subtype B (gag and env determined) |
| 1040 | SIVsmE660 | Pathogenic, uncloned virus isolate derived from spleen cells. Replicates in primary macaque lymphocytes and macrophages. |
| 1041 | SHIV162P3 | Co-receptor specificity of SHIV162P3 is CCR5. Virus is transmissible in rhesus macaques by mucosal and parental routes of inoculation. |
| 1042 | VI191 | |
| 1043 | VI991 | |
| 1044 | VI997 | This sequence was isolated from a Belgian man who had sexual partners in the Democratic Republic of Congo. The virus was isolated 30/04/93. Accession Number AF190128. Full sequence can be seen at http://hiv-web.lanl.gov |
| 1047 | 96ZM651 (Subtype C) | One of very few full length characterised subtype C isolates. Isolated by co-culturing PBMCs from a seropositive individual from Zambia with PHA-stimulated PBMCs from a normal donor. The original virus has been amplified one additional time in PHA-stimula |
| 1048 | MN(P) | This is a low passage, PBMC-propagated isolate of the HIV-1 MN reference strain originally established by Drs Gallo and Popovic (102). It has not been grown in a T-cell line, only on human PBMCs |
| 1049 | DU174 | Infect 10x106 normal donor PBMCs, previously stimulated for three days with PHA. Exchange 50% of the medium every 3-4 days. Once each week, add 5 x 106 PHA-stimulated normal donor PBMCs. Freeze supernatant 10 days into the co-culture. Propagate in RPMI 16 |
| 1050 | CM244 | |
| 1051 | NP1525 | |
| 1052 | QH0692 | |
| 1053 | AC10 | |
| 1054 | HIV-2 CDC310319 | Primary isolate of HIV-2 subtype B propagated solely on primary
human PBMCs; will form syncytia in MT-2 cells. |
| 1055 | HIV-2 7312A | Phylogenetic analysis of the env and gag regions suggests that this
HIV-2 isolate is an A/B recombinant. |
| 1058 | KER2018 (00KE_KER2018) | Clade A. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists |
| 1059 | KNH1144 (00KE_KNH1144) | Clade A.This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists o |
| 1060 | BX08 (92FR_BX08) (BX08) | Clade B.This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists o |
| 1061 | PBL286(696) (02ET_14) | Clade C. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists |
| 1062 | PBL288(411) (02ET_288) | Clade C. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists |
| 1063 | TZBD9/11 (01TZ_911) | Clade C. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists |
| 1064 | J32228M4 (00UG_J32228M4) | Clade D. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists |
| 1065 | NKU3006 (00KE_NKU3006) | Clade D. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists |
| 1066 | CAM0002BBY (01CM_0002BBY) | CRF02_AG. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists |
| 1067 | CAM0013BBY (02CM_0013BBY) | CRF02_AG. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists |
| 1068 | CAM1970LE (02CM_1970LE) | CRF02_AG. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists |
| 1069 | ES X-1958 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1070 | ES X-1959 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1071 | ES X2149 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1072 | ES X-1980 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1073 | ES X-1936 ( C) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1074 | ES X-1998 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1075 | ES X-2102 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1076 | ES P-1261 (CRF02-AG) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1077 | ES P962 (G) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1078 | ES X-2210-3 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1079 | ES X-2363 - 2 ( C) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1080 | ES X-2118-2 ( C) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1081 | ES P1423 (CRF02-AG) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1082 | ES X2231 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1083 | ES X1870 (CRF14_BG) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1084 | ES X1628-2 (G) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1085 | ES X2425-2 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1086 | ES X2400-3 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1087 | Aldrithiol-2 treated MN ,CL.4 virus/microvesicles | Treatment of SIV or HIV-1 with Aldrithiol-2 has shown to inactivate the virus, as assessed by their inability to productively infect highly susceptible cells in vitro. Large doses of Aldrithiol-2 treated SIV (10mg) have been inoculated in monkeys and none |
| 1088 | SHIV KU-1 | Cellular fraction of CSF from a pig-tailed macaque that developed AIDS. A cell-free virus stock was amplified in PHA-stimulated rhesus macaque PBMCs. |
| 1089 | ES X-1608-8 (A1) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1090 | ES X-2110 (A1) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1091 | ES X-2456-2 (BG) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1092 | ES X-845-4 (F1) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1093 | ES X-1702-3 (C) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1094 | ES X-230-10 (CRF02_AG/A1) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1095 | ES X-1589-2 (CRF14_BG) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1096 | ES X-963-4 (DG) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1097 | ES X-772-8 (CRF14_BG) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1098 | ES X-2457-2 (BF) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1099 | ES P-2008 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1100 | ES P-1981-2 (G) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1101 | 99ZACM9 | Isolated from an HIV-1 infected female in South Africa in 1999. Patient
had cryptococcal meningitis and a CD4 count of 24 cells/µl at the time of virus isolation. HIV-1 subtype C R5X4 isolate that also uses alternate
coreceptors. Sequence information ca |
| 1102 | ES X-2510-2 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1103 | ES P-2021-3 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1104 | ES X-2432-2 (BF1) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1105 | ES X-1999-5 (G) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1106 | ES P-1751 (CRF02_AG/A3) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1107 | ES P-1942 (BF1) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1108 | ES X-2515-3 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1109 | ES X-2524-2 (CRF12_BF/B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE |
| 1110 | ES X-2634-2 (G) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e5.8
Obtained from an acute infection |
| 1111 | ES X-2574-2 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e4.9
Obtained from an acute infection |
| 1112 | ES X-2689-2 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5, X4 (SI); TCID50/ml=10e4.9
Obtained from a newly diagnosed patient |
| 1113 | ES P-2149-3 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e5.8
Obtained from an acute infection |
| 1114 | ES X-2556-3 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e5.8
Obtained from an acute infection |
| 1115 | ES X-2255-2 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e4.9
Obtained from a recent infection (2 months after seroconversion) |
| 1116 | ES P-2285-2 (B) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e4.9
Obtained from an acute infection |
| 1117 | ES X-2623-4 (BF1) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e4.9
Obtained from an newly diagnosed patient |
| 1118 | ES P2222-2 (CRF02_AG) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (SI); TCID50/ml=10e5.4
Obtained from an newly diagnosed patient |
| 1119 | ESR23 (A1) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
R5 (NSI); TCID50/ml=10e6
Obtained from chronic infection |
| 1120 | ES X5312 (CRF12_BF) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
R5 (NSI); TCID50/ml=10e6.6
Obtained from chronic infection |
| 1121 | ES X 874-9 (F) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
R5 and X4 (SI); TCID50/ml=106
Obtained from chronic infection |
| 1122 | 93IN905 | Subtype C isolate (CCR5). Isolated from seropositive individual in India. |
| 1123 | ESR772 (CRF20_BG) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
Isolate form a newly diagnosed pateint.
Subtype CRF20_BG, R5, (NSI); TDCI50/ml=10e5.2 |
| 1124 | ES R74 (CRF02_AG) | These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
Isolate form a newly diagnosed pateint.
Isolate is SI and CXCR4/CCR5 dependant. |
| 1125 | CRF04 | One of 4 patient samples (1125-1128). Subtype CRF04.
Original plasma was donated by Drs. Angelos Hatzakis and Dimitrios Paraskevis, National and Kapodistrian University of Athens, Greece.
Virus isolation was performed by Dr Mark Manak at SeraCare Lif |
| 1126 | CRF04 | One of 4 patient samples (1125-1128). Subtype CRF04.
Original plasma was donated by Drs. Angelos Hatzakis and Dimitrios Paraskevis, National and Kapodistrian University of Athens, Greece.
Virus isolation was performed by Dr Mark Manak at SeraCare Lif |
| 1127 | CRF04 | One of 4 patient samples (1125-1128). Subtype CRF04.
Original plasma was donated by Drs. Angelos Hatzakis and Dimitrios Paraskevis, National and Kapodistrian University of Athens, Greece.
Virus isolation was performed by Dr Mark Manak at SeraCare Lif |
| 1128 | CRF04 | One of 4 patient samples (1125-1128). Subtype CRF04.
Original plasma was donated by Drs. Angelos Hatzakis and Dimitrios Paraskevis, National and Kapodistrian University of Athens, Greece.
Virus isolation was performed by Dr Mark Manak at SeraCare Lif |
| 1129 | ES X-2730-2 (B) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
Subtype B, R5, X4 (SI);TCID50/ml=10e4.8 |
| 1130 | ES P-2196-2 (G) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
Subtype G, R5, X4 (SI); TDCI50/ml=10e6.8 |
| 1131 | ES X-2759-2 (BF) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. Subtype BF, R5, (NSI); TDCI50/ml=10e4.9 |
| 1132 | ES P-2420-3 (ADG) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. |
| 1133 | ES X-2757-2 (B) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. |
| 1134 | ES X-2160-2 (G) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. |
| 1135 | HIV-QH0692.42 | Envelope Plasmid: QH0692.42, Tier: 2, Clade: B, Country of origin: Trinidad, Fiebig Stage: V, Mode of Transmission: F-M, Accession number: AY835439 |
| 1136 | HIV-AC10.0.29 | Envelope Plasmid: AC10.0.29, Tier: 2, Clade: B, Country of origin: USA, Fiebig Stage: III, Mode of Transmission: M-M, Accession number: AY835446 |
| 1137 | HIV-SC422661.8 | Envelope Plasmid: SC422661.8, Tier: 2, Clade: B, Country of origin: Trinidad, Fiebig Stage: IV, Mode of Transmission: F-M, Accession number: AY835441 |
| 1138 | HIV-THRO4156.18 | Envelope Plasmid: THRO4156.18, Tier: 2, Clade: B, Country of origin: USA, Fiebig Stage: II, Mode of Transmission: M-M, Accession number: AY835448 |
| 1139 | HIV-TRO.11 | Envelope Plasmid: TRO.11, Tier: 2, Clade: B, Country of origin: Italy, Fiebig Stage: IIII, Mode of Transmission: M-M, Accession number: AY835445 |
| 1140 | HIV-CAP45.2.00.G37 | Envelope Plasmid: CAP45.2.00.G3, Tier: 2, Clade: C, Country of origin: S. Africa, Fiebig Stage: IV, Mode of Transmission: M-F, Accession number: DQ435682 |
| 1141 | HIV-Du422.1 | Envelope Plasmid: Du422.1, Tier: 2, Clade: C, Country of origin: S. Africa, Fiebig Stage: V, Mode of Transmission: M-F, Accession number: DQ411854 |
| 1142 | HIV-ZM53M.PB12 | Envelope Plasmid: ZM53M.PB12, Tier : 2, Clade: C, Country of origin: Zambia, Stage of infection: ≤VI, Mode of Transmission: F-M, Accession number: AY423984 |
| 1143 | HIV-CAP210.2.00.E8 | Envelope Plasmid: CAP210.2.00.E8, Tier : 2, Clade: C, Country of origin: South Africa, Stage of infection: IV, Mode of Transmission: M-F, Accession number: DQ435683 |
| 1144 | HIV-Q23.17 | Envelope Plasmid: Q23.17, Tier : 2, Clade: A, Country of origin: Kenya, Stage of infection: VI, Mode of Transmission: M-F, Accession number: AF004885 |
| 1145 | HIV-Q842.d12 | ENVELOPE PLASMID: Q842.d12
Tier : 2
Clade: A
Country of origin: Kenya
Stage of infection: Acute/Early
Mode of Transmission: M-F
Accession number: AF407160 |
| 1146 | HIV-Q769.d22 | ENVELOPE PLASMID: Q769.d22
Tier : 2
Clade: A
Country of origin: Kenya
Stage of infection: Acute/Early
Mode of Transmission: M-F
Accession number: AF407158 |
| 1147 | HIV-Q259.d2.17 | ENVELOPE PLASMID: Q259.d2.17
Tier : 2
Clade: A
Country of origin: Kenya
Stage of infection: Acute/Early
Mode of Transmission: M-F
Accession number: AF407152 |
| 1148 | HIV-427299.c12 | ENVELOPE PLASMID: 427299.c12
Tier : 2
Clade: CRF01_AE
Country of origin: Thailand
Fiebig Stage: I/II
Mode of Transmission: Hetero
Accession number: Pending |
| 1149 | HIV-816763.c02 | ENVELOPE PLASMID: 816763.c02
Tier : 2
Clade: CRF01_AE
Country of origin: Thailand
Fiebig Stage: I/II
Mode of Transmission: Hetero
Accession number: Pending |
| 1150 | HIV-CM246.c1 | ENVELOPE PLASMID: CM246.c1
Tier : 2
Clade: CRF01_AE
Country of origin: Thailand
Fiebig Stage: >VI
Mode of Transmission: Hetero
Accession number: Pending |
| 1151 | HIV-R3265.c06 | ENVELOPE PLASMID: R3265.c06
Tier : 2
Clade: CRF01_AE
Country of origin: Thailand
Fiebig Stage: >VI
Mode of Transmission: Hetero
Accession number: Pending |
| 1152 | HIV-Bal.26 | ENVELOPE PLASMID: Bal.26
Tier: 1
Clade: B
Country of origin: USA
Fiebig Stage: VI
Mode of Transmission:
Accession number: Pending |
| 1153 | HIV-TV1.21 | ENVELOPE PLASMID: TV1.21
Tier: 1
Clade: C
Country of origin: S. Africa
Fiebig Stage: VI
Mode of Transmission:
Accession number: Pending |
| 1154 | HIV-Bx08.16 | ENVELOPE PLASMID: Bx08.16
Tier: 1
Clade: B
Country of origin: France
Fiebig Stage: VI
Mode of Transmission: -
Accession number: GQ855765 |
| 1155 | HIV-SF162.LS | ENVELOPE PLASMID: SF162.LS
Tier: 1
Clade: B
Country of origin: USA
Fiebig Stage: VI
Mode of Transmission:
Accession number: EU123924 |
| 1156 | SIVmac239CS.23 | SIV gp160 clone for use as Env-pseudotyped virus |
| 1157 | SVA-MLV | MLV Env-pseudotyped virus for negative control in neutralizing antibody TZM-bl assay |
| 1158 | ES P-2468-2 (CRF02_AG/CRF06_cpx) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. |
| 1159 | ES P-2317-2 (B) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. |
| 1160 | SIVmac251 | Restricted to use by members of the European Vaccines and Microbicides Enterprise and for use within Europe. Only to be used in macaques. |
| 1161 | LAI-M184V (3TC-resistant) | Produced by electroporation of MT-2 cells with HIV-1 LAI proviral DNA encoding the M184V RT substitution. Highly cytopathic; replicates to high titers (>105 TCID50/ml). The virus is highly resistant to 3TC, with IC50 values >60 µM in HeLa-CD4/LacZ-1 cell |
| 1162 | ES P-2392-3 (CRF02_AG) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. NSI phenotype, CCR5 co-repector use. |
| 1163 | ES X-2733-2 (A1B) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
A unique recombinant form A1B genotype
NSI phenotype, CCR5 co-repector use. |
| 1164 | ESP 2391-3 (CFR02_AG) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. |
| 1165 | ES X2717-2 (B) | This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. |
| 1166 | SHIV-A | Clade A SHIV |
| 1167 | C-HIV-2 KAS | |
| 1168 | Primary Isolates, Ukraine | |
| 1169 | Primary Isolates, Ivory Coast | |
| 1170 | Primary Isolates, Barundi | |
| 1171 | ES X2546-2 (C) | Syncytium inducing phenotype (MT2): NSI
Coreceptor use: CCR5
Titration of infectivity (TCID50/ml): 10e4.6
Full-length genome: C
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbi |
| 1172 | ES X492-3 (CRF05_DF) | Syncytium inducing phenotype (MT2): NSI
Coreceptor use: CCR5
Titration of infectivity (TCID50/ml): 10e5.2
Full-length genome: CRF05_DF
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and |
| 1174 | P-2606-2 (B) | Syncytium inducing phenotype (MT2): NSI
Coreceptor use: R5
Titration of infectivity (TCID50/ml): 10e5.2
SUBTYPE: B
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterpri |
| 1175 | X-2432-5 (BF1) | Syncytium inducing phenotype (MT2): NSI
Coreceptor use: R5
Titration of infectivity (TCID50/ml): 10e5.4
SUBTYPE: BF1
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterpr |
| 1176 | X-2874-2 (F1) | Syncytium inducing phenotype (MT2): NSI
Coreceptor use: R5
Titration of infectivity (TCID50/ml): 10e5.2
SUBTYPE: F1
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterpr |
| 1177 | ES X-2899-2 (B) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use: R5
Titration of infectivity (TCID50/ml) : 10e5.2
Full-length genome : SUBTYPE B
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines |
| 1178 | ES X-2898-2 (F1) | Syncytium inducing phenotype (MT2) : SI
Coreceptor use: R5 and X4
Titration of infectivity (TCID50/ml) : 10e4.9
Full-length genome : F1
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and |
| 1179 | ES X-2834-2 (B) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use: R5
Titration of infectivity (TCID50/ml) : 10e5.6
Full-length genome : SUBTYPE B
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines |
| 1180 | ES X-2871-2 (F1) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use: R5
Titration of infectivity (TCID50/ml) : 10e4.9
Full-length genome : SUBTYPE F1
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccin |
| 1181 | ES X-2886-2 (B) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use:R5 and X4
Titration of infectivity (TCID50/ml) : 10e5.2
Full-length genome : SUBTYPE B
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vacc |
| 1182 | ES P-2593-2 (B) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use: R5
Titration of infectivity (TCID50/ml) : 10e4.6
Full-length genome : SUBTYPE B
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines |
| 1183 | ES X-2985-2 (B) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use: R5
Titration of infectivity (TCID50/ml) : 10e6.4
Full-length genome : SUBTYPE B
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines a |
| 1184 | ES X-2922-3 (F1) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use: R5
Titration of infectivity (TCID50/ml) : 10e4.2
Full-length genome : SUBTYPE F1
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccine |
| 1185 | ES X-2873-2 (F1) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use: CCR5, CXCR4 : R5
Titration of infectivity (TCID50/ml) : 10e5.6
Full-length genome : SUBTYPE F1
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence Euro |
| 1186 | ES P-2418-2 (B) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use : R5
Titration of infectivity (TCID50/ml) : 10e6.4
Full-length genome : SUBTYPE B
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines |
| 1187 | ES X-3097-2 (F1) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use : R5
Titration of infectivity (TCID50/ml) : 10e6.2
SUBTYPE: F1
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Ent |
| 1188 | ES X-3049-2 (BF) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use : R5
Titration of infectivity (TCID50/ml) : 10e6.8
SUBTYPE: BF (URF)
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbici |
| 1189 | ES X-3016-2 (F1) | Syncytium inducing phenotype (MT2) : -
Coreceptor use : R5
Titration of infectivity (TCID50/ml) : 10e5.6
SUBTYPE: F1
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enter |
| 1190 | ES X-3067-2 (BG) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use : R5
Titration of infectivity (TCID50/ml) : 10e6.8
SUBTYPE: BG (URF)
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbici |
| 1191 | ES X-3070-2 (F1) | Syncytium inducing phenotype (MT2) : NSI
Coreceptor use : R5 X4
Titration of infectivity (TCID50/ml) : 10e6.6
SUBTYPE: F1
This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides |
| 1192 | SHIV-1157ipEL-p, harvest day 9 | SHIV-1157ipEL-p is a tier 1 R5 clade C SHIV. It is a chimera of he "early" neutralization sensitive SHIV-1157ip envelope and the "late" engineered backbone of SHIV-1157ipd3N4, which was engineered to have extra NF-KB sites in the LTRs. The envelope gene w |
| 1193 | SHIV-1157ipEL-p, harvest day 11 | SHIV-1157ipEL-p is a tier 1 R5 clade C SHIV. It is a chimera of he "early" neutralization sensitive SHIV-1157ip envelope and the "late" engineered backbone of SHIV-1157ipd3N4, which was engineered to have extra NF-KB sites in the LTRs. The envelope gene w |
| 1194 | HIV-1 (CRF_02_AG/B) EUR001 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1195 | HIV-1 (B) EUR007 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1196 | HIV-1 (B) EUR008 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1197 | HIV-1 (F1) EUR010 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1198 | HIV-1 (C) EUR011 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1199 | HIV-1 (URF_BF1) EUR013 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1200 | HIV-1 (F1) EUR014 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1201 | HIV-1 (G) EUR016 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1202 | HIV-1 (B) EUR017 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1203 | HIV-1 (B) EUR023 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1204 | HIV-1 (B) EUR024 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1205 | HIV-1 (URF_02_AG/A1) EUR025 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1206 | HIV-1 (B) EUR026 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1207 | HIV-1 (B) EUR027 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1208 | HIV-1 (B) EUR028 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1209 | HIV-1 (URF_BF1) EUR029 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1210 | HIV-1 (CRF20_BG) EUR030 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1211 | HIV-1 (B) EUR031 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1212 | HIV-1 (URF_BF1) EUR032 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 1213 | HIV-1 (G) EUR033 SNF | Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 2002 | pCMV-rev | Expresses rev in mammalian cells.
A 722bp fragment from pCV-1 containing HIV-1 rev cDNA was obtained by Bsu361 digestion. This fragment was blunt end ligated into the BamH1 site of pCMV to generate the 4972 bp plasmid pCMV-rev |
| 2003 | pSV-rev | Expresses rev in mammalian cells.
Contains a cDNA copy of rev positioned between the SV40 late promoter and the rabbit -globin splice and poly-A adenylation signals. |
| 2004 | pCV1 | Derived from pCV, a 7 Kb mammalian expression vector containing hybrid regulatory sequences. The 1.8Kb insert encodes both rev and tat |
| 2005 | pT4B | Insert 3 Kb encoding the CD4 receptor of human T-Lymphocytes of which 1.5 Kb is the coding sequence. The cDNA insert has been cloned in eukaryotic expression systems to convert CD4- fibroblasts to the CD4+ phenotype. |
| 2006 | pNL4-3 | Derived from NY5 (5') and LAV (3') cloned directly from genomic DNA. Full length infection/replication competent chimeric DNA. Upon transfection pNL4-3 directs the production of infectious particles in mouse, monkey and mink cells as well as several non |
| 2007 | pSVIII gp160 clone 92UG975.10 | Derived from primary isolate Ugandan subtype G, 92UG975.10. HIV-1 gp160 gene produed by PCR of PBMC's |
| 2008 | pSVIII gp160 clone 92UG024.2 | Derived from primary isolate Ugandan subtype D/D (gag/env), 92UG024.2. HIV-1 gp160 gene produed by PCR of PBMC's |
| 2009 | pSVIII gp160 clones | Derived from primary isolate Rwanadan subtype A/A (gag/env), 92RW020.5. HIV-1 gp160 gene produed by PCR of PBMC's |
| 2010 | pSVIII gp160 clones | Derived from primary isolate Brazillian subtype B/F (gag/env), 93BR029.2. HIV-1 gp160 gene produed by PCR of PBMC's |
| 2011 | pEE14/tpa/HIV-1 IIIB env PR1-16 series | Contains IIIB (BH10) clone env fragments as detailed. When transfected into CHO or BHK cells directs the secreation of gp120/140 into ambient medium. |
| 2012 | pEE14/tpa/HIV-2 env ROD | Contains HIV-2 ROD env fragment (see 0298.1-2). Directs the secreation of env into the ambient media when transfected into CHO cells. |
| 2013 | pSR(alpha)Hcrm1 | Contains full length human CRM1 cDNA. |
| 2014 | Near Full length Clones of HIV-1 Primary Isolates | Set of 10 Near full-length clones, most of which were generated by long PCR technique. Reference clones were derived from non-subtype B isolates. Virus was derived from human PBMC cultures. |
| 2018 | pCCR Chemokine Receptor Exp.vectors | The inserts were derived from cDNAs encoding CCR-1, CCR-2B, CCR-3, CCR-4, CCR-5, or Fusin. Each cDNA was amplified from activated PBMC RNA using primers hybridizing to the 5’ and 3’ untranslated regions. CCR-1, CCR-2B, CCR-4, and CCR-5 inserts were obtai |
| 2019 | Rhesus CXCR4/CCR5 Exp .Vectors | These clones contain the rhesus CXCR4 or CCR5 coding regions cloned into the retroviral expression vector pBABE-puro. Expressed CCR5, and CXCR4 can be detected by FACS analysis. |
| 2020 | HIV-1 Protease Designer Gene | Coding sequences have been modified to utilise codons favoured by yeast and E. coli. Includes the N-terminal Met. The provided sequence of the designer Tat Gene was inserted between the Hindlll and EcoR1 sites of the pUC18 vector. Hindlll, BspM1, and Ncol |
| 2021 | HXB2 - env | Contains a 2897 bp 5’ Sacl 3’ Xhol HXB2 env fragment from HXB2gpt (env coding sequences are nt 6224-8794). HIV-1 gp 160 is expressed from an SV40 promoter. No other HIV gene products are expressed. Ampicillin-resistant vector. SV40 origin provides high l |
| 2022 | LTR-Luciferase plasmids HIV-1 A-G | The LTR region was PCR-amplified and the core enhancer-promoter region (position -147 to +63 relative to the transcription start site) was cloned in the pBlue 3’LTR-luciferase plasmid (2022.2)(Klaver B and Berkhout B, 1994) to replace the sequences of |
| 2025 | pGB8-46R | Near full length infectious clone. Transfection of HeLa or 293 T cells yields virus with tropism indistinguishable from the parental virus. Sequence analysis shows clone to be a non recombinant HIV-1 subtype B throughout its genome. Derived as half genome |
| 2027 | pEE14/tpa/UG37-08gp140REKR | |
| 2030 | vP1488 92BR025 gp160, subtype C | Cells infected with vp 1488 express HIV-1 Clade C gp160 which is properly processed and transported. |
| 2031 | vP1490 Vaccinia IIIB Rev | vp1490 infected cells express HIV-1IIIB Rev |
| 2032 | vPT135 92UG037 p55 subtype A vaccinia | vT135-infected cells express p55 gag precursor. Plasmid contains the vaccinia K1L gene and the HIV-192UG037.1 p55 (subtype A) gag gene under control of the vaccinia 40K promoter. |
| 2033 | vT139 92UG037.1 nef, Subtype A vaccinia | Cells infected with vT139 express HIV-1 92ug037.1 nef gene (subtype A) |
| 2034 | vT143 92UG037.1 pol, subtype A vaccinia | Cells infected with vT143 express HIV-192UG037.1 pol gene (subtype A). |
| 2035 | vT157 94UG114 gag, subtype D vaccinia | Cells infected with vT157 express HIV-1 94ug114.1 gag gene (subtype D) |
| 2036 | 94UG114 nef, subtype D vaccinia | Cells infected with vT158 express HIV-1 94ug114.1 nef gene (subtype D) |
| 2037 | 94UG114 env subtype D, vaccinia | Cells infected with vT173 express the HIV-1 94ug114.1 env gene (subtype D) |
| 2038 | vT183 92UG037 env, subtype A vaccinia | Cells infected with vT173 express the HIV-1 92ug037.1 env gene (subtype A) |
| 2039 | vT198R (92UG037 Env/Gag/Pol, Subtype A) | Cells infected with vT198 express HIV-1 92ug037.1 (subtype A) env-,gag-, and pol-encoded polypeptides. |
| 2040 | HIV-1 92UG001 (subtype D) full length I | Full length infectious clone from 92UG001 (subtype D). Produces dual trophic X4/R5 aggressive, syncytium inducing virus. |
| 2041 | pCRll gp160 clones | gp160 clones from US isolates. |
| 2042 | p96ZM651.8 | Near full length molecular clone of a subtype C isolate from Zambia. This genome encodes intact open reading frames for all nine HIV-1 genes. |
| 2043 | QH0692, clone 42 | Expresses functional env/rev and can be used to generate pseudotyped infectious virus for use in neutralization tests. A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMCs. Original virus was obtained |
| 2044 | AC10.0 clone 29 | Expresses functional env/rev and can be used to generate pseudotyped infectious virus for use in neutralization tests. A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMC. |
| 2045 | pCAAN5342 clone A2 | Expresses functional env/rev and can be used to generate pseudotyped infectious virus for use in neutralization tests. A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject infected with a cla |
| 2046 | Q23 ENV17 | Env clone was derived from PBMCs of an individual approximately one year following HIV-1 acquisition. It is a R5 subtype A virus from Kenya. This clone is useful for screening vaccine sera for neutralizing antibodies that can block transmitted subtype A v |
| 2047 | Q168 ENVa2 | This envelope clone was directly derived from PBMCs of an individual
one week after seroconversion. It is a R5 subtype A virus from Kenya.
This clone is useful for screening vaccine sera for neutralizing
antibodies that can block transmitted subtype A |
| 2048 | Q842 ENVd12 | This envelope clone was directly derived from an individual four weeks
after seroconversion. It is a R5 subtype A virus from Kenya. This clone is useful for screening vaccine sera for neutralizing antibodies that can
block transmitted subtype A viruses. |
| 2049 | Q769 ENVd22 | The envelope region of HIV-1 was amplified by PCR from PBMC DNA.
The PCR product was digested with Mlul/Notl, gel isolated and cloned
into Mlul/Notl digested pCI-neo. The coding region present is HIV-1
envelope gp160. Antibiotic resistance markers are |
| 2050 | Q259 ENVd2.17 | This envelope clone was directly derived from PBMCs of an individual
one week after seroconversion. It is a R5 subtype A virus from Kenya.
This clone is useful for screening vaccine sera for neutralizing
antibodies that can block transmitted subtype A |
| 2051 | Q461 ENVe2 | This envelope clone was directly derived from PBMCs of an individual
four weeks before seroconversion. It is a R5 subtype A virus from
Kenya. This clone is useful for screening vaccine sera for neutralizing
antibodies that can block transmitted subtype |
| 2052 | Du174.15 | |
| 2053 | CM244.ec1 | Env clones with inserts in the correct orientation screened for infectivity by co-transfection with an env deficient HIV-1 (SG3env) backbone in 293T cells |
| 2054 | MNP.ec3 | Env clones with inserts in the correct orientation screened for infectivity by cotransfection with an env deficient HIV-1 (SG3env) backbone in 293T cells |
| 2055 | VI 191 Plasmid clone | |
| 2056 | 6535, clone 3 (SVPB5) | PCR fragment containing full-length env and rev genes was derived
from the genomic DNA of infected PBMC. Original virus was obtained by PBMC co-culture. T |
| 2057 | PVO, clone 4 (SVPB11) | A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMC. Original virus was obtained by PBMC co-culture. |
| 2058 | TRO, clone 11 (SVPB12) | A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMC. Original virus was obtained by PBMC co-culture. |
| 2059 | pWITO4160 clone 33 (SVPB18) | A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject acutely infected with a clade B virus by reverse transcription and nested PCR amplification procedures. |
| 2060 | pTRJO4551 clone 58 (SVPB17) | A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject acutely infected with a clade B virus by reverse transcription and nested PCR amplification procedures. |
| 2061 | pRHPA4259 clone 7 (SVPB14) | A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject infected with a clade B virus by reverse transcription and nested PCR amplification procedures. |
| 2062 | pTHRO4156 clone 18 (SVPB15) | A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject infected with a clade B virus by reverse transcription and nested PCR amplification procedures. |
| 2063 | pREJO4541 clone 67 (SVPB16) | A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject acutely infected with a clade B virus by reverse transcription and nested PCR amplification. |
| 2064 | pSG3 delta Env | pSG3ΔENV was derived from pSG3.1 , by Spel partial digestion, Klenow filling of the 3’ recessed ends and religation. This introduced a four nucleotide insertion mutation (CTAG) in env and a translation stop codon after amino acid residue 142. |
| 2065 | SC422661, clone 8 (SVPB8) | A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject acutely infected with a clade B virus by reverse transcription and nested PCR amplification procedures. |
| 2066 | Std. Ref. Panel of Subtype B HIV-1 Env Clones | This reference panel was designed for use as Env-pseudotyped viruses to facilitate standardized Tier 2/3 assessments (Mascola JR. et al. J Virology 79(16):10103, 2005) of neutralizing antibody responses. |
| 2067 | pSVIII-92BR025.9 | Derived from a patient in Brazil. PCR-derived HIV-1 gp160 gene from primary PBMC culture was cloned into pSVIIIenv (Kpn). The primary isolate env gene was exchanged into the vector in place of the HXB2 env gene, and used in a single round CAT-based virus |
| 2068 | 92RW009-6 | The complete env gene (~2.6 kb) from the p92RW009.6 clone (NIH Cat No. 4006) was PCR amplified using primers containing a Eco RI (sense) respectively Not I (anti-sense) restriction recognition sequence site. Both sites were used for cloning after the Huma |
| 2069 | HIV-1 Subtype C Env Clones Reference Panel | This clade C reference panel was designed for use as Env-pseudotyped viruses to facilitate standardized Tier 2/3 assessments of HIV-1-specific neutralizing antibodies (Mascola JR. et al. J Virology 79(16):10103, 2005). When co-transfected with an env-dele |
| 2070 | pcDNA3.1 APOBEC-V5-6XHis | The cloning insert was obtained from Open Biosystems (Huntsville, AL). Insert for human APOBEC3G was cloned into mammalian expression vector pcDNA3 with a V5 epitope tag from SV5 paramyxovirus and a polyhistidine epitope at the C terminus. Plasmid DNA was |
| 2071 | HIV-1 SE8131-3 Clade A Clone | Full length clade A clone. Accession No: AF107771 in pCRII-TOPO vector. |
| 2072 | p93IN905 | Virtually full-length HIV-1 genome (lacks 74 bp in the LTR R-U5 region) was amplified from DNA obtained from co-cultured PBMCs infected with HIV-1 93IN905 (Catalog #1122).
The primers used were msf5 and msf12 (MO Salminen, et al.). The 9 kb product w |
| 2073 | pSVIII-93MW965.26 | Derived from a patient in Malawi. PCR-derived HIV-1 gp160 gene from PBMC culture was cloned into pSVIIIenv (Kpn). The primary isolate env gene was exchanged into the vector in place of the HXB2 env gene, and used in a single round CAT-based virus infecti |
| 2074 | HIV-1 clone TV1.29 | A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMC. T |
| 2075 | p1054.TC4.1499 | Env clones of transmitted and early founder HIV-1 subtype B in primary HIV-1 infection (RNA positive, Western blot negative). HIV-1 clade B molecular rev/env clones derived from patient plasma during acute HIV-1 infection.
The rev/env genes were PCR am |
| 2077 | pNL-845_4-Ren | Env clone of virus isolate X-845-4 clade F1 (1092), from a EUROPRISE panel of isolates. |
| 2078 | pNL-962-Ren | Env clone of virus isolate P-962 clade G (1077), from a EUROPRISE panel of isolates. |
| 2079 | pNL-1261-Ren | Env clone of virus isolate P-1261 clade CRF02_AG (1076), from a EUROPRISE panel of isolates. |
| 2080 | pNL-1423-Ren | Env clone of virus isolate P-1423 clade CRF02_AG (1081), from a EUROPRISE panel of isolates. |
| 2081 | pNL-1589_2-Ren | Env clone of virus isolate X-1589-2 clade CRF14_BG (1095), from a EUROPRISE panel of isolates. |
| 2082 | pNL-1608_8-Ren | Env clone of virus isolate X-1608-8 clade A1 (1089), from a EUROPRISE panel of isolates. |
| 2083 | pNL-1628_2 | Env clone of virus isolate X-1628-2 clade G (1084), from a EUROPRISE panel of isolates. |
| 2084 | pNL-1702-3 | Env clone of virus isolate X-1702-3 clade C (1093), an isolate from a EUROPRISE panel of isolates. |
| 2085 | pNL-1936-Ren | Env clone of virus isolate X-1936 clade C (1073), from a EUROPRISE panel of isolates. |
| 2086 | pNL-2118_2-Ren | Env clone of virus isolate X-2118-2 clade C (1080), from a EUROPRISE panel of isolates. |
| 2087 | pNL-2363_2-Ren | Env clone of virus isolate X-2363-2 clade C (1079), from a EUROPRISE panel of isolates. |
| 2088 | Panel of Paired Infant and Maternal Env Clones | A collection of HIV-1 envelope clones isolated from chronically infected women and their
infants who were infected with HIV-1 sometime between birth and 6 weeks post delivery.
These clones are useful for the study of paired maternal and infant viruses n |
| 2089 | Panel of HIV-1 Envelope Clones | Panel of HIV-1 envelope clones isolated from women who acquired HIV-1 sexually. The envelope sequence was cloned from PBMC DNA at 23-100 days post-infection, as described in Blish JV, 83: 7783-7788, 2009 and Long et al. ARHR 18: 567-576, 2002. The envelop |
| 2090 | p92NG083.2 | Near-full-length clone generated by long PCR technique and cloned into the MluI site of pTZ18Mlu1. Lacks less than 80 bp of LTR sequences. Ampicillin Resistant. |
| 2091 | p97CN001.12 | Genomic DNA was extracted from PBMC culture and used for PCR amplification. PCR products were cloned directly into vector pTZ18Mlu I at the Mlu I cloning site. This clone is ampicillin resistant. GenBank Accession #AF286226. Sequences in GenBank reflect d |
| 2092 | pNL-GFP-RRE(SA) | pNL-GFP-RRE was first constructed by complete deletion of all HIV ORFs of pNL4-3 by replacing the 8.1 kb BssHII-BlpI fragment of the HIV-1 genomes with an insert containing the GFP ORF and the HIV-1 Rev-responsive element (RRE) including the HIV-1 sequenc |
| 2093 | DuoFluo (R7GEmC) | This HIV-1 construct contains two distinct fluorescent proteins under control of independent promotors. EGFP has been inserted in place of nef and is expressed through LTR activation. An EF1a-mCherry transcriptional unit was inserted between EGFP and the |
| 2110 | vBD3 (89.6gp160) | Cells infected with vBD3 express env glycoprotein from the dual trophic HIV-1 primary isolate 89.6, which uses both CXCR4 and CCR5, and well as a number of other chemokine co-receptors for entry. The gp160 is expressed on the surface of infected cells, an |
| 2111 | vNEF2 (NL4-3) (vTFnef) | The HIV-1 nef ORF was isolated from the plasmid pNLXho, a pNL432 derivative. A BamHl fragment was blunt end ligated to pSCll (from Dr. Bernard Moss) and cleaved with SmaI to produce the plasmid pTFnef. This clone contains the nef coding sequence under tr |
| 2112 | vP1218 rvHIV-1 nef (MN) ABI | Contains the HIV-1MN nef gene. The vaccinia virus 13L early/intermediate promoter is cloned upstream of the nef coding sequences. Cells infected with vP1218 express HIV-1MN Nef |
| 2114 | Baculovirus HIV-1 HXBC2gp120 | Baculovirus expressing HIV-1 HXB2 gp120 with FLAG
tail - EFGGDYKDD-DDKGG |
| 2115 | Baculovirus HIV-1 Bal gp120 Flag Tailed | Baculovirus expressing HIV-1 HXB2 gp120 with FLAG tail - EFGGDYKDD-DDKGG |
| 2116 | C2, HIV-1 env gene cassetting system | Based on infectious clone NL4-3.C2 env chimearas retain glycoprotein determined phenotype of their parent viruses. |
| 2117 | pcDNA3-DC-SIGN | DC-SIGN is a C-type lectin, which efficiently binds and transmits HIV-1, HIV-2 and SIV to receptor positive cells. This clone can be used for DC-SIGN expression in mammalian cells.
DC-SIGN cDNA was amplified from human dendritic cells and cloned between |
| 2118 | pcDNA3-DC-SIGNR | DC-SIGNRelated is a C-type lectin that binds ICAM-3 and HIV gp120 and transmits HIV-1, HIV-2 and SIV to receptor cells in the liver and lymph nodes.This clone can be used for DC-SIGN expression in mammalian cells. |
| 2119 | HIV-1 p89.6 plasmid | Full length infectious molecular clone, full 9.7KB provirus with intact LTR's. |
| 2120 | pSHIV-KB9 5' plasmid | The KB9 5' construct contains the HindIII-SphI fragment (nt 215-6706) of SIVmac239 in pBS(+) (Stratagene). The insert size is 6.5 kb (total plasmid size is 9.5 kb). Asynthetic polylinker was introduced between the vector EcoRI site and the SIVmac239 cellu |
| 2121 | pSHIV KB9 3' plasmid | The KB9 3' construct encodes the HIV-1 portions of the chimeric virus. Vector is pSL1180 (Pharmacia). |
| 2122 | pSHIV-89.6 5' plasmid | The KB9 5' construct contains the HindIII-SphI fragment (nt 215-6706) of SIVmac239 in pBS(+) (Stratagene). The insert size is 6.5 kb (total plasmid size is 9.5 kb). A synthetic polylinker was introduced between the vector EcoRI site and the SIVmac239 cell |
| 2123 | pSHIV 89.6 3' plasmid | The SHIV-89.6 3' construct encodes the HIV-1 portions of the chimeric virus, cloned into the pBluescript II KS(+) vector (Stratagene). The insert size is 5.9 kb, and the plasmid size is 8.9 kb. |
| 2124 | vT183 | The HIV-192UG037.1 env gene was modified to introduce silent mutations to remove two internal T5NT sequences encoding vaccinia virus early transcription termination sequences. A plasmid containing the vaccinia K1L gene and the modified env gene under cont |
| 2125 | pCAGGS SF162 gp160 | Co-transfection of 293T cells with NL4-3 env plasmid yields an HIV-1
pseudotype virus that is R5-tropic and susceptible to neutralization by
multiple antibodies. |
| 2126 | SV-A-MLV-env | Contains the amphotropic murine leukemia virus env gene (nt. 5407-
7846) linked to the MLV LTR. The plasmid also contains the SV40 origin. Ampicillin resistant. Co-transfection of COS cells with SV-A-MLV-env and HIV-gpt yields an HIV/MLV (amphotropic) ps |
| 2127 | HIV-1 pSVIII 92UG021.16 | Approximate plasmid size 8290bp |
| 2128 | pNL4-3.Luc.R-E- | Firefly luciferase gene was inserted into the pNL4-3 nef gene. Two frameshifts (5′ Env and Vpr aa 26) render this clone Env- and Vpr-. |
| 2129 | rVVgp120Bx08 | Vaccinia virus (Western Reserve) recombinant for the codon-optimised gp120 gene from HIV-1(Bx08) expressing gp120 protein in (VERO) cell culture supernatant. |
| 2130 | pNL-Env-Ren (Clades A,B,C,D&E) | The env gene (complete gp160) of 10 viruses representative of the five primary clades A to E1 was amplified by PCR from viral RNA using specific primers, digested with XbaI and NotI and inserted in the same sites in the pNL-lacZ/env-Ren2 with the resultin |
| 2132 | pZM96gp140 | |
| 3002 | SIV gp41 (KK15) | Suitable for ELISA, immunoblotting , RIPA and IF |
| 3004 | SIV p17 (KK59) | Suitable for ELISA and immunoblotting |
| 3005 | SIV p27 (KK64) | Suitable for ELISA and immunoblotting |
| 3006 | SIV p27(KK64) | Suitable for ELISA and immunoblotting |
| 3007 | Feline class II MHC | Specific to Feline Class II MHC. IgG1 |
| 3008 | Feline CD8 | Specific to Feline CD8. |
| 3010 | Feline CD4 | Specific to Feline CD4. IgG1 |
| 3012 | HIV-1 LAI gp120 (4G10) | Reacts in ELISA with V3 loop peptide (734) and with purified gp160(LAI). Reacts in immunoblot with gp120(LAI) and IFA with infected cells. Inhibits syncitium formation, RT activity and p24 production in vitro (100% inhibition over 20 days) |
| 3013 | HIV-1 LAI gp120 (5F7) | Reacts in ELISA with V3 loop peptide (734) and with purified gp160(LAI). Reacts in immunoblot with gp120(LAI) and IFA with infected cells. Inhibits syncitium formation, RT activity and p24 production in vitro (partial and retardation over 20 days) |
| 3014 | HIV-1 LAI gp120 (7D8) | Inhibits syncitium formation, RT activity and p24 production in vitro.
Reacts in ELISA with V3 loop peptide ADP737. Inhibits syncytium formation, RT activity and p24 production in vitro (retardation over 20 days) |
| 3015 | CD4 | Does not inhibit binding of gp120 or virus to CD4, but blocks infection and syncitium formation by a number of isolates. |
| 3016 | HIV-1 gp120 (Human) | Blocks CD4 binding. Neutralises a wide range of strains IIIB, Z84, MN and SA3. Reacts in ELISA/Immunoblot with at least 2 strains of HIV-1 |
| 3018 | HIV-1 RT | Epitope mapped to aa 193-284. Can be used in ELISA and IF assays |
| 3019 | HIV-1 RT | Reacts with p66/p51. Can be used in ELISA/IF assays |
| 3020 | HIV-1 RT | Reacts with p66. Can be used in ELISA and IF assays |
| 3021 | HIV-1 tat | Reacts with HIV-1 tat in ELISA and Immunoblot. Epitope mapped to aa 1-20. |
| 3022 | HIV-1 tat | Reacts with HIV-1 tat in ELISA and Immunoblot. |
| 3023 | HIV-1 MN gp120 (Human) 257-D IV | Reacts in ELISA/RIPA. Neutralises MN and SF2 but not IIIB |
| 3024 | HIV-1 MN gp120 (Human) 268-D IV | Reacts in ELISA/RIPA. Neutralises MN and SF2 but not IIIB |
| 3025 | HIV-1 IIIB gp120 (V3) | Neutralises IIIB. Immunoblots/reacts in ELISA with IIIB |
| 3026 | HIV-1 nef | Recognises an epitope at the n-terminus of nef, possibly only including the last 6 aa. Suitable in ELISA's and Western blots. It recognises nef from a wide range of strains. |
| 3028 | HIV-1 gp120 (2D7-V4) | Reacts in ELISA, Immunoblot and IF |
| 3029 | HIV-2 gp105 | Mapped to C1 |
| 3030 | HIV-2 gp105 | Mapped to C1 |
| 3031 | HIV-2 gp105 | Mapped to C-terminus |
| 3032 | HIV-2 gp105 | Mapped to C2 |
| 3033 | HIV-2 gp105 | Mapped to C2 |
| 3035 | HIV-1 gp120 | Neutralises HXB10 clone of HIV-1 IIIB but not HXB2 or IIIB itself. Suitable for ELISA. |
| 3036 | HIV-1 gp120 | Virion binding and neutralisation of HIV-1IIB only in the presence of sCD4
Suitable for ELISA and RIA |
| 3037 | HIV-1 gp120 | Neutralises IIIB. suitable for ELISA and RIA |
| 3038 | HIV-1 gp120 | Neutralises IIIB. suitable for ELISA and RIA |
| 3039 | HIV-1 gp120 | Virion binding and neutralisation of HIV-1IIB only in the presence of sCD4
Suitable for ELISA and RIA |
| 3040 | HIV-1 gp120 | Vition binding only in the presence of sCD4. Does not neutralise IIIB. Suitable for ELISA and RIA. |
| 3041 | HIV-1 gp120 | Neutralises HXB10 clone of HIV-1 IIIB, but not HXB2 or IIIB itself. Binds to virion. Antibody binding to gp120 is inhibited by sCD4.Antibody does not inhibit sCD4 binding to gp120. Suitable for ELISA and RIA. |
| 3042 | SIV gp160/120 (KK66) | Suitable for ELISA, immunoblotting , RIPA and IF. Reacts with peptide 774.13 |
| 3043 | SIV gp160/gp120 (KK18) | Suitable for ELISA, immunoblotting , RIPA and IF. Reacts with peptide 774.1 |
| 3044 | SIVgp160/gp32 (KK41) | Suitable for ELISA, immunoblotting , RIPA and IF. Reacts with peptide 798.10 |
| 3045 | SIV gp120 (KK9) | Suitable for ELISA, immunoblotting , RIPA and IF. Neutralises SIVmac251 at a titre of 1:1920 |
| 3046 | HIV-1 IIIB gp120 (IIIB-V3-01) | Bind to non-glycosylated denatured IIIB in ELISA, but does not neutralise IIIB, MN, SF2 or RF, or react with cell-surface gp120 expressed IIIB infected Molt-3 cells. |
| 3047 | HIV-1 IIIB gp120 (IIIB-V3-13/IIIB-V3-34) | Exhibits strong tpe-specific neutralisation of IIIB and medium to weak neutralisation of SF2, NY5, MFc and two primary isolates. Reacts with native IIIB and SF2 gp120 and denatured IIIB, SF2 and SK gp120. |
| 3048 | HIV-1 IIIB gp120 (IIIB-V3-21) | Does not neutralise HIV-1 |
| 3049 | HIV-1 gp160/120 | Binds weakly to denatured gp120. Binding enhanced by the persence of non-ionic detergent. |
| 3051 | HIV-1 gp160/120 | Binds weakly to denatured, but not native gp120. |
| 3053 | p50 subunit of NF-kB | Recognises a linear epitope either very close to, or including, the nuclear localisation signal of the p50 protein. |
| 3055 | HIV-1 gp120 (GP68) | Human mab suitable for use in ELISA/IRMA, RIPA and IF. Neutralises a wide range of HIV-1 strains |
| 3056 | HIV-1 gp120 (Human) | Suitable for use in ELISA/IRMA, RIPA, IF, Western blotting and virus neutralisation |
| 3057 | HIV-1 p17 (Human) | Does not recognise linear peptides. Reacts in ELISA/Western blot. Inhibition of syncitia formation in C8166 cell line. Shown to be HIV-1 negative by PCR |
| 3058 | HIV-1 rev | Suitable for ELISA , Western blot and IF |
| 3060 | HIV-1 rev | Suitable for ELISA, western blot and IF |
| 3061 | SIV p27 (KK60) | Reacts in ELISA, Western blot and RIPA. High titre antibody produced in technomouse. |
| 3063 | HIV-1 gp41 (2F5) | Human recombinant mab produced in CHO cells. Neutralises a broad variety of laboratory strains and Primary isolates. |
| 3064 | HIV-1 gp120 (2G12) | Human mab neutralises HIV-1 IIIB, RF and a broad variety of primary isolates. |
| 3065 | HIV-1 IIIB gp120 (Human) b12 | Obtained as a Fab by selection against gp120 IIIB of an antibody phage display library prepared from bone marrow of a asymptomatic HIV-1 seropositive donor. Was then expressed as a whole antibody in CHO cells in tissue culture. Neutralises field isolates |
| 3066 | SV5-Pk tag | May be used for the affinity purification of the SIV-Pk fusion protein from bacterial expression vectors 282 and 283. |
| 3067 | HIV-1 BRU nef | Cross reactivity measured by immunoperoxidase staining. Also reacts in ELISA and western blot. |
| 3068 | HIV-1 JR-CSF nef | 3 mAbs specific to different epitopes of nef. |
| 3069 | HIV-1 IIIB tat | As IgM is difficult to purify Mab 8.2 (2069.2) is an enriched fraction from mouse Ascitis (in PBS + 0.1% NaN3). Therefore it is composed of some other proteins which do not cause problems with the antibody specificity. Since IgM is around 0.5mg/ml we a |
| 3070 | HIV-1 IIIB rev | 3 mAbs to different epitopes of rev. |
| 3071 | SIV nef | 5 mAbs to different epitopes of SIV nef |
| 3072 | SIV rev | 4 mAbs to different epitopes of SIV rev |
| 3074 | HIV-1 gp120 (V2) | Neutralises molecular clones HXB10 and HXB2. Binds to cell surface expressed oligomeric gp120. Suitable for ELISA. |
| 3075 | HIV-1 gp120 (V2) | Crossv reacts with RF. Binds to cell surface expressed oligomeric gp120. Suitable for ELISA. |
| 3076 | HIV-1 gp120 (C1) | Binds to rec. gp120 by ELISA. Cross reacts with IIIB, MN and RF. |
| 3077 | HIV-1 gp120 (V2) | Neutalises HXB10. Binds to cell surface expressed oligomeric gp120. Binds to rec. gp120 by ELISA. |
| 3078 | HIV-1 gp120 (17b) | Human mab neutralises a wide range of isolates, reacts in ELISA and Immunoblot. |
| 3079 | HIV-1 gp120 (48D) | Human mab neutralises a wide range of isolates, reacts in ELISA and Immunoblot. |
| 3080 | FIV env | Recognises several FIV isolates |
| 3081 | FIV env | FIV-petaluma specific |
| 3082 | FIV env | FIV-petaluma specific |
| 3083 | HIV-2 gp105 | HIV-2 env C1 aa43-54. Positive in ELISA, IF and western blot |
| 3084 | HIV-2 gp105 | HIV-2 env V1 aa125-133. Positive in ELISA, and IF |
| 3085 | HIV-2 gp105 | HIV-2 env V2 aa140-148. Positive in ELISA, IF and western blot |
| 3086 | HIV-2 gp105 | HIV-2 env V2 aa149-154. Positive in ELISA, IF and western blot. Neutralises virus infectivity. |
| 3087 | HIV-2 gp105 | HIV-2 env conformational dependant not V1, V2 nor V3. Positive in ELISA |
| 3088 | HIV-2 gp105 | HIV-2 env conformational dependant not V1,V2 nor V3. Positive in ELISA, IF and neutralises virus. |
| 3089 | HIV-2 gp105 | HIV-2 env conformational dependant not V1, V2 nor V3. Positive in ELISA |
| 3090 | HIV-2 gp105 | HIV-2 ROD V3 aa304-311. Positive in ELISA, neutralises virus infectivity |
| 3091 | HIV-2 gp105 | HIV-2 ROD V3 aa306-311. Positive in ELISA and western blot |
| 3092 | SIV nef (KK75) | Positive in westernblot, FACScan, reacts with 777.7. Suitable for Immunohistochemistry (formalin-fixed, parafin embedded tissue). |
| 3093 | SIV nef (KK77) | Positive in western blot, RIPA, FACScan, reacts with 777.8 |
| 3094 | SIV nef (KK80) | Positive in western blot, RIPA, FACScan |
| 3095 | HIV-1 W61D (TH1) | Isolate specific. Reacts with 3095. |
| 3096 | HIV-1 W61D (TH3) | Clade specific. reacts with 7035.14 |
| 3097 | HIV-1 W61D (TH8) | Braodly cross reactive. |
| 3098 | HIV-1 W61D (KK86) | Broadly cross reactine. Reacts with 7035.42 and 7035.14 |
| 3100 | CCR3 | Good neutralising ability, works well in immunoassays. |
| 3101 | CXCR4 | Works well in FACS assay. Partial antagonist of SDF-1 |
| 3102 | RANTES | Works well in ELISA, westernblot, cell staining and Immuno precipitation |
| 3103 | RANTES | Works well in ELISA, westernblot and cell staining
Negative for immunoprecipitation. |
| 3104 | RANTES | Works well in ELISA, western blot and immunoprecipitation
Positive for immunoprecipitation. |
| 3105 | RANTES | Works well in ELISA, western blot and immunoprecipitation. Positive for immunoprecipitation. |
| 3106 | HIV-1 nef | Works well in ELISA |
| 3107 | HIV-1 nef | Works well in ELISA |
| 3108 | HIV-1 nef | Works well in RIPA and ELISA |
| 3109 | HIV-1 nef | Works well in ELISA |
| 3110 | CCR2 | Specificity to aa24-38 of the human CCR2. IgG2α |
| 3111 | CCR2 | Specificity to aa24-38 of the human CCR2. IgG2α |
| 3112 | CCR5 | Specificity to aa13-28 of the human CCR5. IgM |
| 3113 | CCR5 | Specificity to aa13-28 of the human CCR5. IgM |
| 3114 | CCR5 | Specificity to aa13-28 of the human CCR5 receptor |
| 3115 | HIV-1 gp120 (F105) | Reacts with a discontinuous or conformational, gp120 epitope. Binds to gp120 on the surface of IIIB, SF2, MN, RF, and CC-infected cells. Neutralises SF2, IIIB, and MN infection at concentrations ranging from 140 ng/ml to 10µg/ml. |
| 3116 | HIV-1 Vif (TG001) | Raised in mice immunised with purified HIV-1 Vif protein derived from E-coli . Recognises Vif in ELISA, Western blot, and RIPA assays. Maps to the C-terminal region (aa 176-192). |
| 3117 | HIV-1 env (CA1) | Specific to HIV-1 env subtype A. |
| 3118 | HIV-1 env (CA8) | Sub-type A & D specific (92/UG/029, 92/UG/035 & rec IIIB gp120), works in ELISA. |
| 3119 | HIV-1 env (CA13) | HIV-1 env sub-type, broadly cross-reactive. |
| 3200 | SIV nef (J5) KK70 | Monoclonal antibody to SIV nef (J5) |
| 3201 | SIV nef (J5 and C8) KK71 | Monoclonal antibody to SIV nef (J5 and C8). Positive in Western blot, RIPA, FACSCAN (SIV J5/C8) |
| 3202 | HIV-1 W61D gp120 | 7 mAbs to regions V2, V3, C4 and V5/C5 of HIV-1 W61D gp120 |
| 3203 | HIV-1 W61D gp120 (68/77a) | Conformational dependent epitope (V1V2V3 dependent) preferentially exposed on gp160 |
| 3204 | HIV-1 W61D gp120 (68/91) | Conformational dependent epitope (V1V2V3 independent) preferentially exposed on gp160. |
| 3205 | HIV-1 W61D gp120 (68/92) | Conformational dependent epitope preferentially exposed on
gp160. |
| 3206 | HIV-1 env gp120 (63/10) | Linear epitope to C1. Recognises peptide 740.8 |
| 3207 | HIV-1 env gp120 (63/45a, 69a, 84c, 85a, & 91a) | Linear epitope in C1 |
| 3208 | HIV-1 env gp120 (63/49) | Conformational dependent epitope within V1. |
| 3209 | HIV-1 env gp120 (63/11b) | Conformational dependent epitope within V1V2 |
| 3210 | HIV-1 env gp120 (63/42) | Conformational dependent epitope within C1 |
| 3211 | HIV-1 env gp120 (63/45b) | Conformational dependent epitope within V2 |
| 3214 | CCR5 | Specific to aa13-28 of the human CCR5. IgM |
| 3215 | HIV-1 vif (Tg002) | Recognises Vif in ELISA and RIPA assays (not reactive in Western blots). Maps to the N-terminal region (aa 34-47) |
| 3218 | HIV-1 gp120 (697D) | The epitope spans the region 164-194 of gp120HXB2 and is primarily conformation-dependent with weak reactivity for a linear region between aa 161-180(1). This epitope is common to 75% of clade B primary isolates (2). SincemAb 697-D reacts sporadically wit |
| 3219 | HIV-1 gp120 (447-52D) | The antibody neutralises laboratory strains1,2 and clinical isolates3 which contain the GPGR sequence at the apex of the V3 loop. This monoclonal binds to virus-infected cells4, cross-reacts with V3 peptides derived from isolates of various clades5, and |
| 3220 | HIV-1 CD4 | This mAb recognizes a discontinuous epitope on gp 120 and its binding depends on the tertiary protein structure and intact carbohydrates (1). The epitope,though infrequently detected, is expressed on cells infected with various clades (2). MAb 654-D bloc |
| 3221 | HIV-1 gp120 (670D) | Core epitope localised to region aa 503-509 of rgp 120LAI based on binding to overlapping C-terminus peptides. MAb 670-D binds to the surface of cells infected with majority of viruses tested from clades A-E (1) and reacts with intact virions from clade |
| 3222 | HIV-1 gp41(50-69D) | |
| 3223 | HIV-1 gp41 (98-6D) | Reactivity was tested with recombinant proteins
(Microgenetics). gp41specificity 644-663 |
| 3224 | HIV-1 p24 | Obtained from EBV-immortalised peripheral blood Mononuclear cells from HIV-seropositive individuals.This antibody is anti-p24, and reacts with HIV lysate In ELISA. It reacts with the p55 core precursor as well as p24 and several intermediates as determin |
| 3225 | DC-SIGN (DC28) | This is a murine lgG2 generated from a mouse immunised with a thioredoxin fusion protein containing the entire DC-SIGN ectodomain. Works by Western blot and FACS analysis. Also works well for immunoperoxidase staining of tissue sections. Directed agai |
| 3226 | RAID 54 67a 2k anti HIV-2 gp105 | |
| 3227 | RAID 54 3b 1a anti HIV-2 gp105 | |
| 3228 | RAID 54 77.o.w 12f anti HIV-2 gp105 | |
| 3229 | RAID 54 64 4a anti HIV-2 gp105 | |
| 3230 | RAID 54 34a 4e anti HIV-2 gp105 | |
| 3237 | DC-SIGN (DC6) | Anti DC-SIGN specific monoclonal antibody, reacts against an epitope at the C-terminus included within KKSAASCSRDEEQFLSPAPATPNPPPA. Balb/c mice were immunised intradermally 4 times weekly with 100g of bacterial ectodomain of hu-DC-SIGN. Four days followi |
| 3239 | HIV-1 gp41 (4E10) | Recombinant human monoclonal antibody to HIV-1gp41 epitope NWFDIT. IgG1 (kappa). |
| 3240 | TriMab (2F5, 2G12 & b12) | Consists of equal concentrations of Mabs 2F5, 2G12 and b12 diluted to 1mg/ml in PBS (333μg/ml of each antibody)). The individual monoclonal antibodies are also available separately see 3063 2F5, 3064 2G12, and 3065 b12. |
| 3241 | HIV-1 tat | |
| 3242 | HIV-1 tat | mAb to C-terminal peptide of tat |
| 3243 | HIV-1 p24 | 5 antibodies to various epitopes of p24 (see datasheet) Reacts in ELISA, WB, IHC, IF, RIP with HIV-1 native p24 as well as rp24 expressed in bacteria & Cos-7 cells. |
| 3245 | HIV-1 97CN54 gp140 (N03B11) | Binds env from 2 geographically distant clade C isolates but not env from other clades |
| 3246 | HIV-1 CN54 gp140 (subtype C) | Competition group
MH9 = 1
MH10 = 2
MH13 = 4 |
| 3248 | SIV tat | Recognises recombinant SIV tat in Elisa |
| 3249 | CXCR4 | Monoclonal antibody to N-terminal of CXCR4 |
| 3250 | CD4 region of gp120 | Binds to CD4 region of gp120 |
| 3251 | HIV-1 gp120 (P4/D10) | Mediates highly efficient antibody-dependent cellular cytotoxicity and virus neutralisation. The reactivity was located to a major neutralising region on gp120 (aa304-323). |
| 3252 | tat (N-terminal) | mAb to N-terminal peptide of tat |
| 3253 | tat (N-terminal) | mAb to N-terminal peptide of tat |
| 3254 | tat | mAb to tat |
| 3255 | tat | mAb to tat |
| 3256 | tat | mAb to tat |
| 3257 | HIV-1 gp120 (P3B2) | Antibody to the HIV V1 region (mAB: IgG1 kappa, chimera protein A/G binding, used immunogen SF162 ΔV2 gp140/V1 gp120, Elisa 0.5 mg/ml). |
| 3258 | HIV-1 gp41 (P4A3) | Antibody to the HIV gp41 (mAB: IgG2a kappa, chimera protein A/G binding, used immunogen SF162 gp140/gp41, Elisa 0.5 mg/ml). |
| 3259 | HIV-1 gp41 | Antibody to the HIV-1 gp41 region (mAB: IgG1 kappa, chimera protein A/G binding, used immunogen SF162 gp140/SF162 gp41, Elisa 0.5 mg/ml). |
| 3260 | HIV-1 gp120 (P1H6G11) | Antibody to the HIV-1 gp41 region (mAb: IgG1 kappa, chimera protein A/G binding, used immunogen SF162 gp140/SF162 gp41, Elisa 0.5 mg/ml. |
| 3261 | Murine Human APOBEC3G | High affinity murine Anti-Human APOBEC3G (CEM15) mAb. Binds to native and recombinant human CEM15 in ELISA and Western ELISA. |
| 3262 | Murine Anti-Human TRIM5 Alpha | High affinity murine Anti-Human TRIM5a mAb. Binds to native and recombinant human TRIM5 in ELISA and Western ELISA, cross reactive with RhTrim 5 Alpha as determined by ELISA and Immunofluoresence assays. |
| 3263 | HIV-1 env V3 loop region (P3E1F3) | Antibody to the HIV env V3 loop region (mAB: IgG2a kappa, chimera protein A/G binding, used immunogen SF162 gp140/V3 gp120. SNF shows strong binding to 7012.2 and 7041 V3 peptides (100ng/well) at a dilution of 1:1000. |
| 3277 | HIV-1 anti-idiotypic antibody to 2G12 (M1G1) | Murine monoclonal non-inhibiting, anti-idiotypic antibody to HIV-1 antibody 2G12 |
| 3278 | HIV-1 gp41 (3D6) | Human monoclonal antibody to HIV-1 gp41 epitope GCSGKLICTTAVPW. |
| 3279 | HIV p24 | Human Monoclonal antibody to HIV-1 p24 |
| 3280 | HIV-1 p24 | Murine Monoclonal antibody to HIV-1 p24 epitope GATPQDLNTML |
| 3281 | HIV-1 gp41 (5F3) | Recombinant human monoclonal antibody to HIV-1 gp41 epitope AAGSTMGAASMTLTVQARQ |
| 3282 | HIV-1 gp41 (4B3) | Human Monoclonal antibody to HIV-1 gp41 epitope GCSGKLICTTAVPW |
| 3283 | SIV gp160/gp120 (KK17) | Raised in mice primed with a SIVmac251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaraldehyde-fixed SIVmac11/88 from C8166 cells. Reacts with the SIV env region (aa 8-303). Reacts in WB with gp160/gp120; also reactive in RIPA and surface fl |
| 3284 | SIV env (KK42) | Raised in mice primed with a SIVmac251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaraldehyde-fixed SIVmac11/88 from C8166 cells. Reacts with the SIV V3 region (aa 321-340). Reacts in WB with gp160/gp120; also reactive in RIPA and surface f |
| 3285 | HIV-1 V3 (2191) | Isolated PBMCs taken from a HIV-1 Subtype B infected patient from the USA. Produced by Epstein-Barr virus transformed peripheral blood mononuclear cells producing V3 specific antibodies fused with heteromyeloma SHM-D33, and the resulting hybridoma was clo |
| 3286 | HIV-1 V3 (2219) | Isolated PBMCs taken from a HIV-1 Subtype B infected patient from the USA. Produced by Epstein-Barr virus transformed peripheral blood mononuclear cells producing V3 specific antibodies fused with heteromyeloma SHM-D33, and the resulting hybridoma was clo |
| 3287 | HIV-1 V3 (3869) | Isolated PBMCs taken from a HIV-1 (subtype unknown) infected patient from Cameroon. Produced by Epstein-Barr virus transformed peripheral blood mononuclear cells producing V3 specific antibodies fused with heteromyeloma SHM-D33, and the resulting hybridom |
| 3288 | HIV-1 IIIb gp41 (246-D) | Reacts in ELISA with a gp41 peptide spanning aa 579-613 of gp160. mAb 246-D binds to overlapping hexapeptides which identified its core epitope as qqLLGIwg (aa 591-598) which is located in the immunodominant region (cluster I) of gp41, just upstream from |
| 3289 | HIV-1 gp120 (VRC03) | HIV-1 envelope monoclonal antibody directed towards the CD4-binding site of HIV-1 gp120. Purified by protein A sepharose column chromatography. Broadly neutralizing HIV-1 antibody; active against all major subtypes. No cross-reactivity against host self o |
| 3290 | Mouse Anti-Human CD195 (2D7/CCR5) | Raised against CCR5 transfectants. Recognizes the second extracellular domain of CCR5. Works well in flow cytometry and immunohistochemistry. Also works in immunoprecipitation of transfected cells, but reacts poorly in WB assays. The antibody completely b |
| 3291 | HIV-1 gp120 MAb (VRC01) | HIV-1 envelope monoclonal antibody directed towards the CD4-binding site of HIV-1 gp120. Purified by protein A sepharose column chromatography.
Broadly neutralizing HIV-1 antibody; active against all major subtypes. No cross-reactivity against host self |
| 3292 | HIV 1 V3 Monoclonal Antibody (3074) | This antibody was developed from an HIV-1 infected individual. It binds by ELISA to V3 peptides derived from Clade A, B and C viruses and neutralizes viruses from various clades. |
| 3293 | HIV-1 Env mab PG16 | Epitope targeted might be preferentially expressed on HIV Env.
Broad and potent anti-HIV1 cross-clade neutralization.
No poly-reactivity against variety of structurally dissimilar antigens. |
| 3294 | HIV-1 Env mab PG9 | Epitope targeted might be preferentially expressed on HIV Env.
Broad and potent anti-HIV1 cross-clade neutralization.
No poly-reactivity against variety of structurally dissimilar antigens. |
| 3295 | Mouse anti-human α4-β7 integrin (Act-1) | This antibody stains approximately 50% of NK cells, 30-40% of CD4+ and CD8+ T cells and 15-30% B cells by flow cytometry. It reacts with an unique epitope of alpha4beta7 integrin such that it does not block the binding of commercially available alpha 4 in |
| 3296 | Anti-Human CD4 FITC conjugated (11/210) | |
| 3297 | Mab to SIVmac251 gp41 (KK15) | |
| 3299 | mAb to SIVmac251 gp120 (KK65) | SIV env gp120. Maps to V1 region. Suitable for ELISA. |
| 3300 | HIV-1 gp41 (F240) | Human antibody to gp41, specificity to epitope RYLKDQQLLGIWG |
| 3301 | HIV-1 gp41 (Z13e1) | Recombinent human monloclonal antibody to epitope WASLWNWFDITN of HIV-1 gp41 |
| 3302 | mAb to SIVmac251gp120 | |
| 4001 | Antiserum to IL8 | |
| 4002 | Antiserum to MIP-1 alpha | |
| 4003 | Antiserum to RANTES | |
| 4004 | Antiserum to GRO alpha | |
| 4005 | Antiserum to MCP-1 | |
| 4006 | Antiserum to SIVmac tat | Reacts in ELISA 1:3000 and Western blot 1:1600. (See datasheet for potential false positives) |
| 4007 | Antiserum tp SIVmac nef | Reacts in ELISA 1:1600 and Western blot 1:400. (See datasheet for potential false positives) |
| 4008 | Antiserum to SIVmac vpx | Reacts in ELISA 1:1600 and Western blot 1:800. (See datasheet for potential false positives) |
| 4009 | Antiserum to SIVmac RT | Reacts in ELISA 1:6000 and Western blot 1:3000. (See datasheet for potential false positives) |
| 4010 | Antiserum to SIVmac Proteinase | Reacts in ELISA 1:1600 and Western blot 1:800. (See datasheet for potential false positives) |
| 4011 | Sheep anti CXCR4 | |
| 4012 | Sheep anti CCR5 | Raised against 7039 LESTR (Fusin) Human Chemokine Co-receptor peptide and 7040 CC-CKR-5 Human B-Chemokine receptor. |
| 4013 | HIV-1 NL4-3 Vpr Antiserum | Raised against synthetic NL4-3 Vpr peptide corresponding to amino acids 2-22. Detects full length Vpr protein at 1:100 in Western blots, immunoprecipitation, and immunofluorescence, and at 1:2000 in ELISA. Cross-reactivity with SIV Vpr has not been asses |
| 4014 | Antiserum to simian CCR5 | |
| 4015 | Antisera to C-CCKR-5 | |
| 4016 | Antisera to CXCR4 | |
| 4017 | Rabbit anti CCR5 | |
| 4018 | Rabbit anti CCR5 | |
| 4019 | Rabbit anti CCR3 | |
| 4020 | Rabbit anti CCR5 | |
| 4021 | Antiserum to p50 | |
| 4024 | Antisera to SARS S1 Protein | Rabbits were immunised with the S1 subunit of SCoV. SCoV protein was expressed using recombinant baculoviruses as a fusin with Fc and purified on Protein A sepherose column. Due to this expression the serum may contain some anti-insect cell and anti-human |
| 4026 | Anti-Sera to HIV-1 gp41 (aa 662-667) | |
| 4027 | Anti-sera to HIV-1 UG37gp140 | Sheep inoculated initally with 150ug of UG37gp140 with GSK Adjuvant AS01B, then boosted 3 times with 50ug UG37gp140 in the same adjuvant. |
| 4028 | Anti-srea to HIV-1 UG37gp140 | Sheep inoculated initally with 150ug of UG37gp140 with Freunds complete Adjuvant, then boosted 3 times with 50ug UG37gp140 with Incomplete Freunds Adjuvant. |
| 4029 | Anti-sera to HIV-1 CN54gp140 | Sheep inoculated initally with 150ug of CN54gp140 with GSK Adjuvant AS01B, then boosted 3 times with 50ug CN54gp140 in the same adjuvant. |
| 4030 | Anti-sera to HIV-1 CN54gp140 | Sheep inoculated initally with 150ug of CN54gp140 with Freunds complete Adjuvant, then boosted 3 times with 50ug CN54gp140 with Incomplete Freunds Adjuvant. |
| 5000 | HOS CXCR4 cell line | CXCR4 cDNA was subcloned into the retroviral vector pBABE-puro. Amphotrophic virus stocks were prepared by co-transfecting 293T cells with the resulting pBABE-puro construct, a VSV-G envelope expression vector, and pSV-gag-pol.-env-. Supernatants were us |
| 50000 | HIV-1(G) EUR037 | Plasma from HIV-1 infected patient, SUBTYPE: G (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50001 | HIV-1 (A1) EUR038 | Plasma from HIV-1 infected patient, SUBTYPE: A1 (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50002 | HIV-1 (B) EUR039 | Plasma from HIV-1 infected patient, SUBTYPE: B (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50003 | HIV-1 (CRF19_cpx) EUR040 | Plasma from HIV-1 infected patient, SUBTYPE: CRF19_cpx (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50004 | HIV-1 (CRF19_cpx) EUR041 | Plasma from HIV-1 infected patient, SUBTYPE: CRF19_cpx (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50005 | HIV-1 (A1) EUR042 | Plasma from HIV-1 infected patient, SUBTYPE: A1 (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50006 | HIV-1 (B) EUR043 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50007 | HIV-1 (B) EUR044 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50008 | HIV-1 (B) EUR045 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50009 | HIV-1 (B) EUR046 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 5001 | HOS CCR5 | CCR5 cDNA was subcloned into the retroviral vector pBABE-puro. Amphotrophic virus stocks were prepared by co-transfecting 293T cells with the resulting pBABE-puro construct, a VSV-G envelope expression vector, and pSV-gag-pol.-env-. Supernatants were use |
| 50010 | HIV-1 (F1) EUR047 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50011 | HIV-1 (CRF02_AG) EUR048 | Plasma from HIV-1 infected patient, SUBTYPE: CRF02_AG (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50012 | HIV-1 (URF CRF02_AG/B) EUR049 | Plasma from HIV-1 infected patient, SUBTYPE: URF CRF02_AG/B (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50013 | HIV-1 (B) EUR050 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50014 | HIV-1 (F1) EUR051 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50015 | HIV-1 (B) EUR052 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG)
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50016 | HIV-1 (B) EUR053 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG)
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50017 | HIV-1 (F1) EUR054 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (pol and V3)
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50018 | HIV-1 (A1) EUR055 | Plasma from HIV-1 infected patient, SUBTYPE: A1 (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50019 | HIV-1 (B) EUR056 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 5002 | CHO-UG21 Cell Line | Stable CHO cell line secreting D-clade oligomeric gp140 (gp120 + external domain of gp41) into ambient medium. Cleavage site between gp120/41 retained. N-terminal signal sequence of gp replaced by that of tissue plasminogen activator (tpa) - cleaved from |
| 50020 | HIV-1 (CRF02_AG) EUR057 | Plasma from HIV-1 infected patient, SUBTYPE: CRF02_AG (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50021 | HIV-1 (F1) EUR058 | Plasma from HIV-1 infected patient, SUBTYPE: F1 (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50022 | HIV-1 (A1) EUR059 | Plasma from HIV-1 infected patient, SUBTYPE: A1 (pol and V3).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 50023 | HIV-1 (B) EUR060 | Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG).
See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers. |
| 5003 | UG37-CHO cell line | Stable CHO cell line secreting A-clade oligomeric gp140 (gp120 + external domain of gp41) into ambient medium. Cleavage site between gp120/41 retained. N-terminal signal sequence of gp replaced by that of tissue plasminogen activator (tpa) - cleaved from |
| 5004 | BR29-CHO Cell Line | Stable CHO cell line secreting F-clade oligomeric gp140 (gp120 + external domain of gp41) into ambient medium. Cleavage site between gp120/41 retained. N-terminal signal sequence of gp replaced by that of tissue plasminogen activator (tpa) – cleaved from |
| 5005 | CHO-MVP510 #12#2 | Stable CHO cell line secreting O-clade
oligomeric gp140 (gp120 + external domain of
gp41) into ambient medium. Cleavage site
between gp120/41 retained. N-terminal signal
sequence of gp replaced by that of tissue plasminogen activator (tpa) – cleaved f |
| 5006 | BR25gp140 cell line | |
| 5007 | CEM.NKR-CCR5-Luc | Express Luciferase activity after transactivation of the HIV-2 LTR. Suitable for infection with primary HIV isolates, for neutralisation and drug sensitivity assays. |
| 5008 | SF9 Serum free medica adapted cells | Cloned isolate derived from the parental Spodoptera frugiperda IPLB-Sf-21 cell line. The cells can be grown both in suspension and as monolayer. |
| 5009 | MAGI-CCR5 | This is an indicator cell line susceptible to both macrophage-tropic and T-cell line adapted HIV-1 viruses. Also these cells are susceptible to SIV infection. |
| 5010 | 1G5/LTR - Luciferase cells | 1G5 is a Jurkat derivative containing a stably integrated HIV-LTR-luciferase construct. Cells were selected for low basal liciferase activity, HIV infectability, high responsiveness to tat expression, and high responsiveness to T-cell activation signals. |
| 5011 | TZM-bl cells | The TZM-bl indicator cell line enables simple and quantitative analysis of HIV using either -gal or luciferase as a reporter. It is maximally sensitive to HIV infection by including DEAE-dextran in the infection medium. The -gal and luciferase genes a |
| 5012 | B-THP-1 | Suspension cell line. Doubling time of approximately 20 hours.
Lymphocytic.
PCR analysis reveals this line is Epstein Barr Virus (EBV) positive.
Used as the parental line in deriving B-THP-1/DC-SIGN cells (5013) Negative control line used in DC-SIGN |
| 5013 | B-THP-1/DC SIGN | Suspension cell line. Doubling time of approximately 20 hours.
Lymphocytic.
BTHP-1 parental cells were transduced with the MLV vector MX-DC-SIGN and FACS sorted as a population for high levels of DC-SIGN expression. The MX-DCSIGN vector encodes no drug- |
| 5014 | H9 | Clone derived from HUT78 cell line. Widely used for the propagation of HIV. |
| 5014 | CN54 gp140 | Stablely transfected CHO-K1 cells with pEE14 vector containing CN54gp140 gene. Cells produce CN54 gp140 protein expressed into media. MSX selection must be maintained throughout culturing. |
| 5016 | 293RT/17 (DM) | The 293T/17 cell line is a derivative of the 293T (293tsA1609neo) cell line. 293T is a highly transfectable derivative of the 293 cell line into which the temperature sensitive gene for SV40 T-antigen was inserted. 293T cells were cloned and the clones te |
| 5017 | Neg Con for proliferation assay | The freeze dried stabilised proliferation standard. This material is
intended for use as an internal flow cytometry control for detection of proliferation via CFSE staining and validation of techniques. |
| 5018 | Pos Control for proliferation assay | The freeze dried stabilised proliferation standard. This material is intended for use as an internal flow cytometry control for detection of proliferation via CFSE staining and validation of techniques |
| 5019 | Negative Control for ICS Assay | The freeze dried stabilised cytokine standard. This material is intended for use as an internal flow cytometry control for detection of intracellular cytokines and validation of techniques. |
| 5021 | U87.CD4 CXCR4/CCR5 | Cell lines with chimeric cell surface receptor CXCR4/CCR5. (See datasheet for diagrammatic representation of transition of cell surface receptor from CXCR4 to CCR5.) |
| 5022 | Neg con for ICS assay | The freeze dried stabilised cytokine standard. This material is intended for use as an internal flow cytometry control for detection of intracellular cytokines and validation of techniques. |
| 5024 | IFN-gamma Pos Con, ELISPOT | |
| 5025 | Positive Control for ELISPOT (Optimised) | |
| 5026 | FITC CD4+ Control Cells (Working Std.) | |
| 5027 | FITC Untouched CD4+ Cells | his material is intended for use as a flow cytometry control and for validation of techniques. Each vial contains a CD4 positive sub-population of human PBMC, pre-labelled with a FITC conjugated anti-CD4. The population is >90% pure. |
| 5028 | TZM bl/Fc[gamma]RI | This is a derivative of the TZM-bl cell line, engineered by lentiviral transduction to stably express human FcγRI on the surface. The parent TZM-bl cell line is an engineered HeLa cell clone that expresses human CD4, CCR5 and CXCR4 and contains HIV-1 Tat- |
| 5029 | TZM-Bl/Fc[gamma]RIIa | This is a derivative of the TZM-bl cell line, engineered by lentiviral transduction to stably express human FcγRIIa on the surface. The parent TZM-bl cell line is an engineered HeLa cell clone that expresses human CD4, CCR5 and CXCR4 and contains HIV-1 Ta |
| 5030 | TZM-bl/ Fc[gamma]RIIb | This is a derivative of the TZM-bl cell line, engineered by lentiviral transduction to stably express human FcγRIIb on the surface. The parent TZM-bl cell line is an engineered HeLa cell clone that expresses human CD4, CCR5 and CXCR4 and contains HIV-1 Ta |
| 5031 | TZM-bl/ Fc[gamma]RIIIa | This is a derivative of the TZM-bl cell line, engineered by lentiviral transduction to stably express human FcγRIIIa on the surface. The parent TZM-bl cell line is an engineered HeLa cell clone that expresses human CD4, CCR5 and CXCR4 and contains HIV-1 T |
| 5032 | C8166-45 | Human umbilical cord blood lymphocytes. CR-M2 cells were banded on Percol gradients to obtain cells with increased production of HTLV-I. The resulting CR II contain the poorly infectious HTLV-ICR virus. Morphology is T-lymphoid; indistinguishable from nor |
| 5033 | CMMT-CD4-LTR-β-Gal (sMAGI) | CMMT (a rhesus macaque mammary tumor line) infected with the amphotropic retroviral vector LT4SN to express human CD4. Stably transfected with a plasmid containing the HIV-1 LTR fused to the ß-galactosidase gene. This indicator cell line allows rapid quan |
| 5035 | Anti CD4 FITC labelled PBMC (SS-319) | |
| 5036 | Anti CD4 FITC conjugated (11/210) | |
| 5037 | Anti CD4 FITC labelled PBMC (SS320) | |
| 5038 | Rev-CEM | CEM-SS cells were infected with a Lentivirus pNL-GFP-RRE(SA), [cat# 11466]. Clones were isolated and selected for HIV-dependent GFP expression.
Scientists at for-profit institutions or who intend commercial use these cells must contact Dr. Sally Hu, at |
| 5039 | MOLT-4/CCR5 | CCR5 expression plasmid was transfected into MOLT-4 cells. Stable transfectants were selected in culture medium containing G418 (1mg/ml). The expression of CCR5 on their surface was analyzed by laser flow cytometry. MOLT-4/CCR5 highly susceptible to R5 HI |
| 6000 | Human Soluble CD4 (CHO) | Full length extracellular domain of human CD4 (aa 1-370) produced in a mammalian (CHO) expression system. Reactive with HIV-1 gp120 and anti-CD4 monoclonal and polyclonal antibodies. It’s glycosylation pattern is identical to that of the natural human pro |
| 6001 | Human APOBEC3G (Baculo.) | Binds HIV-1 vif as determined by ELISA and Western Blot, and complexes with native vif in HIV infected cells. Protein also binds to anti CEM15 murine monoclonal antibodies as determined by Elisa and Western Elisa assays. Produced in the Baculo Expression |
| 6002 | Human TRIM5 alpha (Baculo.) | Full Length hTRIM5 alpha produced in the Baculovirus Expression System. |
| 6003 | HIV-1 MN gp160 | Gene cloned from T-cell-tropic HIV-1 MN strain and the full length recombinant envelope gp160 glycoprotein produced in the Baculovirus Expression System.
This protein is purified by immuno-affinity chromatography to >95% purity as determined by SDS-PAGE |
| 6004 | HIV-1 BR29 gp140 | Terminates after 2F5 epitope
Accession No: AY494969 |
| 6005 | HIV-1 gp41 subtype O | E.coli derived recombinant protein . Protein contains the HIV type O immunodominant regions from gp41. |
| 6006 | HIV-1 UG21 gp140 (Clade D) | Terminates after 2F5 epitope
Accession No: U27399 |
| 6007 | HIV-1BaL gp120 | HIV-1 env gp120 prepared from an expression construct in HEK-293 cells. Positive reactivity on Western Blot using rabbit antibody to HIV-1 gp120. Binds to CD4. |
| 6008 | HIV-2 Protease | Recombinant HIV-2 Protease produced in E.Coli. |
| 6009 | HIV-2 gp32 | Contains the HIV-2 immunodominant regions from env gp32 |
| 6010 | p17/24 (Han2) | Recombinent p17/14 protein from HIV-1 (Han-s isolate) expressed as a His-tag fusion protein produced in E.coli using vector pET24 and purified using Ni-columns. |
| 6011 | LAI gp120 | Recombinant HIV-1 g120 (LAI) protein. |
| 6012 | HIV-1 p24 (Clade A) | Clade A recombinant p24. |
| 6013 | p55 Clade C (delta p6) | Contains proteins p17 (matrix), p24 (capsid), p2 (spacer peptide), p7 (nucleocapsid), p1 (spacer peptide). Protein p6 is missing. Not myristoylated at N-end.
MW: 49697 Da, 445 amino acids
Sequence: UniProt Q75001 form isolate ETH2220 |
| 6014 | HIV-1 Rev (Wild Type) | The rev cDNA from pCV-1 (NIH Cat #303) was amplified using PCR and cloned into the expression vector pOTS Nco1 (SmithKline Beecham). This plasmid was transformed into E. coli N5151 and thermally induced. The crude Rev was re-suspended in Buffer A (50 mM T |
| 6015 | HIV-1 gp120 (CN54) | C-terminal 6x His tagged HIV-1 gp120 protein (aa24-518) of CN54. Genebank: AX149771 |
| 6016 | HIV-1 IIIB gp120 (CHO) | This protein binds to murine monoclonal antibodies of defined epitope specificity and human serum polyclonal antibodies in ELISA and Western ELISA. This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti- |
| 6017 | HIV-1 Bal tat | Full length (101 amino acids) Recombinant HIV-1 Bal tat produced in the E. coli Expression System.
This protein binds to murine monoclonal antibodies of defined epitope specificity and rabbit and human serum polyclonal antibodies in ELISA and Western ELI |
| 6018 | HCV soluble E2 (H77) | Soluble E2 (sE2), extracellular domain of genotype 1a (H77strain, AF009606) HCV/E2 (aa 384-715), includes a HIS-tag. |
| 7001 | SIV env gp120 | SIV env gp120 (aa411-425) from SIVmac251 (32H) |
| 7002 | SIV env gp120 | SIV env gp120 (aa411-425) from SIVmac251. |
| 7003 | SIV env gp41 | SIV env gp41 (aa114-127) from SIVmac251. |
| 7004 | HIV-1 tat | 7004.1 is an extension of 790.1 with 5 extra residues at the N-terminus.7004.2 is truncated 10 amino acids short of the end exon 1 of tat. |
| 7005 | HIV-1 tat | peptide containing the second exon of tat. Has a proline at position 77. |
| 7006 | HIV-1 p17 B8 restricted CTL epitope | CTL epitope |
| 7007 | HIV-1 pol CTL epitope | CTL epitopes. A2 restricted |
| 7008 | HIV-1 pol CTL epitope | CTL epitopes. B8 restricted |
| 7011 | SIV env gp120 V1 | Two variants from the hypervariable V1 region of SIV gp120, aa121-146. |
| 7012 | HIV-1 env V3 consensus peptide | |
| 7013 | FIV gag and env (Glasgow 8) | Predictive T-cell epitopes and residues conforming to the DR1 binding motif. |
| 7014 | HIV-1 IIIB nef | Peptides from the N' and C' terminal regions of nef |
| 7015 | HIV-1 gag NCp7 | Contains deletions of residues 15-29 and 35-57. Reported to facilitate the annealing of retroviral RNA in vitro |
| 7016 | HIV-1 env consensus group B gp120 | 3 overlapping peptides which closely represent V2 neutralisation epitopes. |
| 7017 | HIV-1 env gp120 V3 (Uganda) | |
| 7018 | HIV-1 env gp120 V3 (Uganda) | |
| 7019 | HIV-1 env V3 loop (MN) | Full length V3 loop |
| 7021 | HIV-1 env gp120 V3 loop | |
| 7022 | HIV-1 gp41epitope | Conserved immunodominant region of gp41. |
| 7024 | HIV-1 env gp120 V3 (Brazilian) | Symetric and asymetric V3 peptides based on Brazilian HIV sequences provided by Drs G Castro and M Schechter. |
| 7025 | HIV-1 env gp120 V3 (Brazilian) | Symetric and asymetric V3 peptides based on Brazilian HIV sequences provided by Drs G Castro and M Schechter. |
| 7026 | HIV-1 env gp120 V3 (Brazilian) | Symetric and asymetric V3 peptides based on Brazilian HIV sequences provided by Drs G Castro and M Schechter. |
| 7027 | HIV-1 p17 A2 restricted CTL epitope | A2 restricted CTL epitope |
| 7028 | HIV-1 env V3 group O | env V3 genotype O sequences |
| 7029 | HIV-1 env V3 consensus groups | env V3 consensus sequences |
| 7030 | HIV-1 env V3 consensus groups | |
| 7031 | FIV env-gag | 7031.1 contains residues from all 3 regions linked by proline residues.Regions may be involved in CTL responses. |
| 7033 | SIV C8 nef | For analysis of escape mutants. |
| 7034 | HIV-1 env gp120 | Reported to be a B-cell epitope. Contains the region VEINCTR which shares sequential homology with the apoptosis mediating antigen Fas |
| 7035 | HIV-1 env gp120 (Overlapping peptides) | Overlapping series covering entire gp120. |
| 7037 | HIV-1 env gp41 | Contains highly conserved ELDKWAS sequence |
| 7039 | Human CXCR4 | |
| 7040 | Human CCR5 | N-terminal extracellular domain of CCR5 (aa1-33) |
| 7042 | Human CCR5 Domain2 | |
| 7043 | Human CCR5 Domain 3 | |
| 7044 | Human CCR5 Domain 4 | |
| 7045 | Simian CCR5 (Cynomolgus) | |
| 7046 | HIV-1 p24 (Subtype A) | Overlapping 20-mers spanning the subtype A consensus sequence. 7046.4 and 7046.22 are identical to 788.4 and 788.22 and have therefore not been re-made |
| 7047 | Human CCR3 Domain 1 | |
| 7048 | Simian CCR1 (Cynomolgus) | |
| 7049 | Simian CCR3 (Cynomolgus) | |
| 7050 | CMV US28 (CCR1 related) | US28 is a protein encoded by the CMV open reading frame which shows a striking homology with CCR1. Thought to assist HIV infection in cells previously infected with CMV |
| 7051 | Simian CXCR4 (Cynomolgus) | |
| 7052 | HIV-1 p17 Clade A | Overlapping series HIV-1 subtype A peptide p17 |
| 7053 | HIV-1 gp120 Subtype C V3 | |
| 7054 | HIV-1 gp41 Subtype C | |
| 7055 | HIV-2 env V3 Indian subtype A consensus | Represents V3 Loop of HIV-2 subtype A consensus |
| 7056 | HIV-1 gp41 Subtype A consensus | |
| 7057 | SIV J5 tat | |
| 7058 | SIV J5 rev | Overlapping series of peptides representing SIV J5 rev |
| 7059 | HTLV-I env | |
| 7060 | HTLV-II env | |
| 7061 | HTLV-I env5 | |
| 7062 | HTLV-II env20 | |
| 7063 | HTLV-I GAG-1a | |
| 7064 | HIV-1 Protease Inhibitor | |
| 7065 | HIV-1 Protease Inhibitor | |
| 7066 | SIV gag | Overlapping series of peptides representing SIV gag. |
| 7067 | SIV nef 15mer | Overlapping series of peptides representing SIV nef. |
| 7068 | SIV rev (15-mer) | Overlapping series of peptides representing SIV rev |
| 7069 | SIV tat | Overlapping series of peptides representing SIV tat |
| 7070 | SIV gag (9-mer) | Overlapping series of peptides representing SIV gag (aa22-505) |
| 7071 | SIV nef (9-mer) | Overlapping series of peptides representing SIV J5 nef |
| 7072 | SIV rev | Overlapping series of peptides representing SIV rev (aa7-77) |
| 7073 | SIV tat | Overlapping series of peptides representing SIV tat |
| 7074 | HIV-1 BRU Nef | HIV-1 Nef set. Mostly 20mers with 10 amino acid overlap (7074.20 is a 15mer).
Sequence is based on GenBank Accession Number # K02013 |
| 7075 | Human HLA Sequence gp120 C5 | |
| 7076 | HIV-1 tat indian subtype C consensus | |
| 7077 | HIV-Nef HLA Multimer Reagents (Tetramers) | |
| 7078 | T-cell epitope peptide set (3 peptides) | Highly conserved T-cell epitopes in subtype B and other subtypes. Identified by their predicted binding to MHC class II DR molecules. |
| 7079 | CD4 T cell epitope peptide set | Highly conserved T-cell epitopes in subtype B and other subtypes. Identified by their predicted binding to MHC class II DR molecules |
| 7080 | HIV-1 gag Subtype B/C CN54 | Derived from Chinese Isolate 97CN001 which is a C/B recombinant. |
| 7081 | HIV-1 Nef Clade C/B CN54 | CN54 is derived from the Chinese Isolate 97CN001, which is a C/B recombinant. |
| 7082 | HIV-1 env Predicted CMI epitopes | Predicted epitopes for use in ELISPOT, tetramer assays and for intracellular cytokine assays |
| 7083 | HIV-1 Gag | Predicted epitopes for use in ELISPOT, tetrameric assays and for intracellular cytokine assays |
| 7084 | HIV-1 tat | |
| 7085 | HIV-1 Rev | |
| 7086 | HIV-1 Nef | |
| 7087 | 9mer Peptide to HIV-1 Proteinase | |
| 7088 | 9mer peptides to HIV-1 Pol RT | Predicted epitope for use in ELISPOT, tetrameric assays and intracellular cytokine assays. |
| 7089 | HIV-1 Env -2 consensus | |
| 7090 | HIV-1 Gag Consensus | Supplied as trifluoroacetate salts |
| 7091 | HIV-1 RT Consensus Clade C | Supplied as trifluoroacetate salts |
| 7092 | HIV-1 nef Clade C | Supplied as trifluoroacetate salts |
| 7093 | HIV-1tat Clade C | Supplied as trifluoroacetae salts |
| 7094 | HIV-1 Clade C rev | Supplied as trifluoroacetate salts |
| 7099 | FEC peptide pool | Cytomegalovirus, Epstein Barr and Influenza peptides. The FEC pool is useful for QC of ELISPOT, CTL and Intracellular cytokine assays. The FEC pool stimunlates release of IFNg. ELISPOT, CD8+ T cells in individuals with defined HLA types. |
| 7102 | HIV-1 (Bru) nef | This product is supplied as a triflouroacetate salt |
| 7103 | HIV-1 (BH10) tat | This product is supplied as a triflouroacetate salt |
| 7104 | 96ZM651 env gp160 (subtype C) | |
| 7106 | HIV-1 Bru CTL Epitopes | |
| 7107 | FEC 13 | FEC peptide 13 missing from the original FEC peptide pool (ARP7099) |
| 7108 | HIV-1 clade C tat | |
| 7109 | HIV-1 nef clade C | |
| 7110 | HIV-1 nef S.African Clade C | |
| 7111 | HIV-1 Concensus B Gag | Series of peptides comprising the Subtype B Gag region. Most of the peptides are 15 amino acids in length, with 11-amino acid overlaps between sequential peptides. Most peptides are >80% pure. Peptides that are difficult to solubilize can almost always be |
| 7112 | SHIV SF162P3 env | Series of peptides comprising the SHIV SF162P3 Env region. Most of the peptides are 15 amino acids in length, with 11-amino acid overlaps between sequential peptides. There are 7 peptides with 12-amino acid overlaps. Most peptides are >80% pure. Peptides |
| 7113 | HIV-1 MN env | Series of peptides comprising the MN Env region. Most of the peptides are 15 amino acids in length, with 11-amino acid overlaps between sequential peptides. Most peptides are >80% pure. Peptides that are difficult to solubilize can almost always be dissol |
| 7114 | HIV-1 Gag | |
| 7115 | HIV-1 Consensus C Gag | Series of peptides comprising the Subtype C Gag region. Most of the peptides are 15 amino acids in length, with 11-amino acid overlaps between sequential peptides. Most peptides are >80% pure. Peptides that are difficult to solubilize can almost always be |
| 7116 | 96ZM651.8 Gag | Series of peptides comprising the HIV-1 subtype C (96ZM651.8) Gag region. Most of the peptides are 20 amino acids in length, with 10-amino acid overlaps between sequential peptides. Most peptides are >80% pure. Peptides that are difficult to solubilize ca |
| 7117 | SHIV sf33 env gp120 | |
| 7119 | HIV-1 Protease | This product is supplied as a triflouroacetate salt |
| 7120 | SIVmac 239 Gag | Series of peptides comprising the SIVmac239 Gag region. Most of the peptides are 15 amino
acids in length, with 11-amino acid overlaps between sequential peptides. Most peptides are
>80% pure. Peptides that are difficult to solubilize can almost always |
| 7121 | HIV-1 Env Potenial T-cell Epitopes | This peptide panel is designed to permit expression of the most frequent potential T cell epitopes (PTE) embedded in the sequences of circulating HIV-1 strains of HIV-1 worldwide. The peptides are 15 a.a. in
length and contain naturally occurring 9 a.a. |
| 7122 | HIV-1 Pol Poteinial T-cell Epitopes | This peptide panel is designed to permit expression of the most frequent potential T cell epitopes (PTE) embedded in the sequences of circulating HIV-1 strains of HIV-1 worldwide. The peptides are 15 a.a. in length and contain naturally occurring 9 a.a. s |
| 7123 | HIV-1 Nef Potenial T-Cell Epitopes | This peptide panel is designed to permit expression of the most frequent potential T cell epitopes (PTE) embedded in the sequences of circulating HIV-1 strains of HIV-1 worldwide. The peptides are 15 a.a. in length and contain naturally occurring 9 a.a. s |
| 7124 | HIV-1 Gag Potenial T-Cell Epitopes | Suggested pooling protocol for T cell assays: The peptides are used in pools of up to 160 peptides. Resuspend the peptides at 20mg/ml in 100% DMSO, then pool them into subpools of 40 peptides and add water for 400ug/ml (per peptide) in 80% DMSO/20% H2O. F |
| 7125 | SIVmac 239 tat (15 mers) | Series of peptides comprising the SIVmac239 Tat region. Most of the peptides are 15 amino acids in length, with 11-amino acid overlaps between sequential peptides. Most peptides are >80% pure. Peptides that are difficult to solubilize can almost always be |
| 7126 | SIVmac239 nef | Peptide set homologous to nef of SIVmac239. 15mers |
| 7127 | HIV-1 Group M Consensus Gag Peptides Set | Series of 129 peptides comprising the Group M Consensus Gag region. Most of the peptides are 15 amino acids in length, with 11-amino acid overlaps between sequential peptides. Most peptides are >80% pure. Peptides that are difficult to solubilize can almo |
| 7128 | HIV-1 MPER (662-684) peptide | The conserved membrane-proximal external region (MPER) of HIV-1 gp41 is a target of the broadly neutralizing human monoclonal antibodies, 2F5 and 4E10. The gp41 MPER peptide overlaps with T-20, and is recognized in ELISA by both 2F5 and 4E10. |
| 7129 | PepMix HIV (NEF) Ultra | HIV-1 NEF, average coverage: 51%, 150 peptides, 15meric; approx. 25 µg / peptide. All sequences are based on the HIV sequence database form the Los Alamos National Laboratory. |
| 7130 | PepMix HIV (GAG) Ultra | HIV-1 GAG, average coverage: 57.8%. 150 peptides, 15meric; approx. 25 µg / peptide. |
| 7131 | RepliTope Antigen Collection HIV Ultra Microarray | Immunogenic regions of HIV-1 Proteome as reported by LANL. The coverage of the library for all sequences in the respective alignment is for ENV 57%, GAG 72%, NEF 62% and TAT46%. |
| 7132 | RepliTope Antigen Collection HBV Ultra Microarray | Microarray combining overlapping peptide scans through 53 annotated proteomes of HBV and covers strains from genotypes A1, A2, A3, B, B/C, B1, B2, C, D, E, F1, F2, G and H. This extensive collection consists of 4782 15mer peptides on one microarray. |
| BLA97001 | BL/97/001 | |
| BLA97002 | BL/97/002 | |
| BLA97003 | BL/97/003 | |
| BLA97004 | BL/97/004 | |
| BLA97005 | BL/97/005 | |
| BLA97006 | BL/97/006 | |
| BRA97001 | BR/97/001 | |
| BRA97002 | BR/97/002 | |
| BRA97003 | BR/97/003 | |
| BRA98004 | BR/98/004 | |
| BRA98005 | BR/98/005 | |
| BRA98006 | BR/98/006 | |
| BRA98007 | BR/98/007 | |
| BRA98008 | BR/98/008 | |
| BRA98009 | BR/98/009 | |
| CNA97001 | CN/97/001 | |
| CNA98002 | CN/98/002 | |
| CNA98003 | CN/98/003 | |
| CNA98004 | CN/98/004 | |
| CNA98005 | CN/98/005 | |
| CNA98006 | CN/98/006 | |
| CNA98007 | CN/98/007 | |
| CNA98008 | CN/98/008 | |
| CNA98009 | CN/98/009 | |
| CNA99010 | CN/99/010 | |
| CNA99011 | CN/99/011 | |
| CNA99012 | CN/99/012 | |
| INA97001 | IN/97/001 | |
| INA97002 | IN/97/002 | |
| INA97003 | IN/97/003 | |
| INA97004 | IN/97/004 | |
| INA97005 | IN/97/005 | |
| INA97008 | IN/97/008 | |
| INA97009 | IN/97/009 | |
| INA98006 | IN/98/006 | |
| INA98007 | IN/98/007 | |
| INA98010 | IN/98/010 | |
| INA98012 | IN/98/012 | |
| INA98013 | IN/98/013 | |
| INA98014 | IN/98/014 | |
| INA98015 | IN/98/015 | |
| INA98016 | IN/98/016 | |
| INA98017 | IN/98/017 | |
| INA98018 | IN/98/018 | |
| INA98019 | IN/98/019 | |
| INA98020 | IN/98/020 | |
| INA98021 | IN/98/021 | |
| INA98022 | IN/98/022 | |
| INA98023 | IN/98/023 | |
| INA98024 | IN/98/024 | |
| INA98025 | IN/98/025 | |
| INA98026 | IN/98/026 | |
| ISA98001 | IS/98/001 | |
| ISA98002 | IS/98/002 | |
| ISA98003 | IS/98/003 | |
| ISA99004 | IS/99/004 | |
| ISA99005 | IS/99/005 | |
| ISA99006 | IS/99/006 | |
| ISA99007 | IS/99/007 | |
| ISA99008 | IS/99/008 | |
| ISA99009 | IS/99/009 | |
| KSA98001 | KS/98/001 | |
| KSA98002 | KS/98/002 | |
| KSA98003 | KS/98/003 | |
| KSA98004 | KS/98/004 | |
| KSA98005 | KS/98/005 | |
| MAL0600 | Malaria CSP1-pf Antigen | Synthetic malaria parasite CSP 1 pf DNA sequence expressed in E. coli. This protein binds to murine monoclonal antibodies – structural epitopes, rabbit polyclonal antibodies and to malaria parasite converted human sera as determined by ELISA and Western |
| RUA98001 | RU/98/001 | |
| RUA98002 | RU/98/002 | |
| RUA98003 | RU/98/003 | |
| RUA98004 | RU/98/004 | |
| RUA98005 | RU/98/005 | |
| RUA98006 | RU/98/006 | |
| RUA98007 | RU/98/007 | |
| RUA98008 | RU/98/008 | |
| RUA98009 | RU/98/009 | |
| RUA98010 | RU/98/010 | |
| RUA99011 | RU/99/011 | |
| RUA99012 | RU/99/012 | |
| RUA99013 | RU/99/013 | |
| RUA99014 | RU/99/014 | |
| RUA99015 | RU/99/015 | |
| RUA99016 | RU/99/016 | |
| RUA99025 | RU/99/025 | |
| RUA99026 | RU/99/026 | |
| RUA99027 | RU/99/027 | |
| RUA99028 | RU/99/028 | |
| TB0600 | ESAT-6 | M. Tuberculosis ESAT-6 Antigen produced in the E. Coli expression system. This ESAT-6 protein reacts with human TB serum in ELISA and Western ELISA. |
| TB0601 | CFP-10 | M. Tuberculosis (virulent strain specific) CFP-10 antigen produced in the E. coli expression system. This CFP-10 protein reacts with human TB serum in ELISA and Western ELISA. Suitable for diagnostic applications. |
| TB0602 | BCG LAM (Lipoarabinomannan) | M. bovis BCG Lipoarabinomannan (LAM). |
| TB0603 | BCG LM (Lipomannan) | M. bovis BCG Lipomannan (LM). |
| TB0604 | BCG PIM (Phosphatidylinositol mannoside) | M. bovis BCG Phosphatidylinositol mannosides (PIM) |
| TB0605 | MTB LAM (Lipoarabinomannan) | M. tuberculosis H37Rv Lipoarabinomannan (LAM) |
| TB0606 | MTB LM (Lipomannan) | M. tuberculosis H37Rv Lipomannan (LM) |
| TB0607 | MTB PIM (Phosphatidylinositol mannoside) | M. tuberculosis H37Rv Phosphatidylinositol mannosides (PIM) |
| TZA97001 | TZ/97/001 | |
| TZA97002 | TZ/97/002 | |
| TZA97003 | TZ/97/003 | |
| TZA97004 | TZ/97/004 | |
| TZA97005 | TZ/97/005 | |
| TZA97006 | TZ/97/006 | |
| TZA97007 | TZ/97/007 | |
| TZA97008 | TZ/97/008 | |
| TZA97009 | TZ/97/009 | |
| TZA98010 | TZ/98/010 | |
| TZA98011 | TZ/98/011 | |
| TZA98012 | TZ/98/012 | |
| TZA98013 | TZ/98/013 | |
| TZA98014 | TZ/98/014 | |
| TZA98015 | TZ/98/015 | |
| TZA98016 | TZ/98/016 | |
| TZA98017 | TZ/98/017 | |
| UGA99001 | UG/99/001 | |
| UGA99002 | UG/99/002 | |
| UGA99003 | UG/99/003 | |
| UGA99004 | UG/99/004 | |
| UGA99005 | UG/99/005 | |
| UGA99006 | UG/99/006 | |
| UGA99007 | UG/99/007 | |
| UGA99008 | UG/99/008 | |
| UGA99009 | UG/99/009 | |
| UGA99010 | UG/99/010 | |
| UGA99011 | UG/99/011 | |
| UGA99012 | UG/99/012 | |
| UGA99013 | UG/99/013 | |
| UGA99014 | UG/99/014 | |
| URA97001 | UR/97/001 | |
| URA97002 | UR/97/002 | |
| URA97003 | UR/97/003 | |
| URA97004 | UR/97/004 | |
| URA97005 | UR/97/005 | |
| URA97006 | UR/97/006 | |
| URA97007 | UR/97/007 | |
| URA97008 | UR/97/008 | |
| URA97009 | UR/97/009 | |
| URA97010 | UR/97/010 | |
| URA97011 | UR/97/011 | |
| ZAA97001 | ZA/97/001 | |
| ZAA97002 | ZA/97/002 | |
| ZAA97003 | ZA/97/003 | |
| ZAA97004 | ZA/97/004 | |
| ZAA97005 | ZA/97/005 | |
| ZAA97006 | ZA/97/006 | |
| ZAA97007 | ZA/97/007 | |
| ZAA97008 | ZA/97/008 | |
| ZAA97009 | ZA/97/009 | |
| ZAA97010 | ZA/97/010 | |
| ZAA97011 | ZA/97/011 | |
| ZAA97012 | ZA/97/012 | |
| ZAA97013 | ZA/97/013 | |